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Abstract 
 
Pathogenesis of juvenile idiopathic arthritis (JIA) is linked to the IL-23/IL-17 axis. 
This is of particular interest as new biological drugs targeting this pathway have 
been developed and may prove a useful treatment. Increased IL-17+CD4+ T 
cells have been reported in the joints of patients with JIA, but less is known 
about IL-17 production from other cell types. Innate lymphoid cells (ILC) bridge 
innate and adaptive immune systems and are sub-divided into 3 types (1,2 and 
3), which mirror CD4+T- cell subsets. This thesis aimed to investigate T cell and 
ILC contribution to the disease phenotype in the joints of patients with JIA.  
 
Using a combination of flow cytometry techniques along with multiplex cytokine 
analysis, qPCR and culture assays this study has assessed the immune 
phenotype of patients with JIA. Significant enrichments of IL-17A+ CD4+, CD8 
and γδ T cells were observed in the synovial fluid of patients compared to 
blood, which correlated with disease severity. In parallel, a significant difference 
was seen between relative proportions and functionality of ILC subpopulations 
in the synovial fluid of patients compared to blood. IL17+ILC3 and IL-22+ILC3 
were significantly enriched at the inflamed site. These two ILC3 populations 
were negatively correlated suggesting interplay between the two groups. 
Additionally, IL-17+ILC3 were associated with more severe disease. Further 
exploration of immune cells found a significant enrichment of myeloid DC 
(mDC), which strongly correlated with IL-22+ILC3 at the inflamed site. It was 
shown that synovial mDC produce retinoic acid which may contribute to 
skewing of ILC populations.  
 
These data suggest a strong IL-17A signature in JIA patients, which extends 
beyond the T cell compartment. Therefore, therapies targeting the IL-17/IL-23 
axis could also attenuate ILC populations within the inflamed joint. Finally, these 
data suggest that IL22+ILC3 populations are induced by mDC and may be 
protective in disease.  
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1.1 Juvenile Idiopathic Arthritis  
 
1.1.1 Definition of Juvenile Idiopathic Arthritis (JIA) 
 
Juvenile idiopathic arthritis (JIA) is a term for a group of conditions, which 
together represent the most common rheumatic disease of childhood (Ravelli 
and Martini, 2007). JIA is defined by arthritis of unknown cause, etiology in one 
or more joints, which onsets before the age of 16 and persists for at least 6 
weeks. JIA covers a heterogeneous group of diseases, which can be divided 
into distinct subsets based on clinical manifestations Table 1.1 denotes the 
classification criteria and clinical presentations for JIA subtypes. (Petty et al., 
2004)  
 
1.1.1.1 Classification of Enthesitis Related Arthritis (ERA JIA) 
 
While many subtypes of JIA have been well investigated, the pathogenesis of 
ERA JIA is still illusive. The initial focus of this thesis will be to define 
pathogenic immune responses in the ERA JIA subtype. ERA JIA occurs more 
frequently in males than in females with a ratio of 6-7:1, with onset most 
commonly in adolescence. ERA JIA has a close genetic association with the 
HLA-B27 allele. The strength of this association increases with age of onset 
(Murray et al., 1999). ERA JIA can be broadly divided into two subtypes with 
differential prognosis according to HLA-B27 status and age of onset (Berntson 
et al., 2008). Early onset ERA JIA tends to present with less severe, peripheral 
arthritis. This type of ERA JIA has a lower rate of the HLA-B27 allele, and 
usually responds well to treatment. More severe ERA JIA tends to onset during 
adolescence and has higher incidence of HLA-B27. This phenotype has a poor 
prognosis frequently resulting in the involvement of axial and sacroiliac joints. 
This second phenotype is more similar to the well-recognised adult condition, 
known as ankylosing spondylitis (AS) or spondyloarthropathy (SpA) (Fisher et 
al., 2011, Corinne Fisher, 2012).  
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1.1.2 Pathogenesis of JIA 
 
1.1.2.1 Genetic associations 
 
There is some evidence for a genetic contribution to JIA pathogenesis, which is 
highlighted by familial aggregation of the disease (Prahalad et al., 2000, 
Prahalad et al., 2004, Prahalad et al., 2010). The strongest genetic factors 
affecting JIA are associated with alleles within the MHC region, and the allele 
associations differ according to JIA subtype(Edmonds et al., 1974, Thomson et 
al., 2002). Most of the JIA subtypes defined above are primarily associated with 
MHC class II alleles. In particular, HLA-DR alleles have been heavily 
implicated(Thomson et al., 2002, Zeggini et al., 2002, Hinks et al., 2016). Of 
these, HLA-DRB1*, HLA-DRB1*1101 and HLA-DRB1*1301 are associated with 
oligo-JIA; HLA-DRB1*801 and HLA-DRB1*0401 are linked to poly-JIA(Donn et 
al., 1995). Indeed these findings have been confirmed in immunoCHiP studies 
where the primary genetic association was HLA-DRB1, and in particular HLA-
DRB1 alleles which share a histidine amino acid at position 13, which was 
shown to contribute 50% of HLA-associated variance (Hinks et al., 2016). 
Within the MHC class I loci, HLA-B27 has been shown to be strongly associated 
with ERA JIA (Hinks et al., 2016). The putative roles for HLA-B27 in ERA JIA 
pathogenesis will be discussed further in section 1.1.2.3.1. 
 
Outside of the MHC loci, several polymorphisms in genes associated with 
cytokines have also been described. A significant link between intronic +851 
TNFα SNP and oligo-JIA has been reported (Zeggini et al., 2002). A putative 
role for the IL-23/IL-17 axis has been described in JIA, and a rs1004819 
polymorphism in the IL-23R gene has been shown to be protective in poly-JIA 
(Emami et al., 2016). Additionally, SNPs in the IL-6 gene have been reported 
(Crawley et al., 1999)and are associated with systemic-JIA. Specifically, the 
174G/C polymorphism in the IL-6 gene is associated with systemic JIA 
susceptibility (Fishman et al., 1998, Ogilvie et al., 2003). Mutations in the IL-10 
gene have also been described in oligo-JIA patients, which result in impaired IL-
10 production (Crawley et al., 1999). Finally, polymorphisms in genes 
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associated with T cell function including PTPN22, which is involved in T cell 
activation, have also been described and support a role for T cells in disease 
pathogenesis(Hinks et al., 2005). These targeted studies have been 
subsequently validated using the immunoCHiP platform where 14 non-HLA loci, 
including PTPN22, PTPN2, IL-2RA and STAT4, were identified as significantly 
associated with JIA susceptibility at genome wide level (Hinks et al., 2013). 
 
1.1.2.2 Immunopathology of JIA 
 
During inflammatory arthritis, including JIA, the synovia of patients are infiltrated 
by immune cells and become engorged. Many studies have been conducted 
investigating the immune cells at the site of inflammation in order to determine 
the mechanism of pathogenesis. These studies have focused predominantly on 
oligo-JIA and poly-JIA subtypes, which will be discussed in this section. The 
immune pathogenesis of ERA JIA will be considered independently in section 
1.1.2.3.  
 
Several members of the innate system have been identified as abnormal in JIA.  
High levels of the S100 protein myeloid reactive protein (MRP)8/14 have been 
detected in the joints of patients with active arthritis, which alludes to monocyte 
and neutrophil involvement in disease pathogenesis (Frosch et al., 2009). 
Indeed, synovial monocytes, though similar in absolute number, are functionally 
different in the joint, where they are highly activated (Hunter et al., 2010). In 
addition to MRP8/14, synovial monocytes from JIA patients have been shown to 
secrete numerous inflammatory cytokines including IL-6, IL-1β and TNFα as 
well as IFNγ (Saxena et al., 2005, Hunter et al., 2010) .Furthermore, the hypoxic 
conditions of the JIA synovia has been shown to induce CCL20 secretion from 
monocytes, a chemokine known to be significant for the recruitment of immune 
cells to the site of inflammation (Bosco et al., 2008). Several gene families 
linked to IL-8 and IFNγ have been identified as differentially expressed in JIA 
patients compared to healthy control blood, supporting a role for neutrophils in 
disease pathogenesis. Expression of these genes remained abnormal even 
during disease remission (Jarvis et al., 2006). Although relatively poorly 
 23 
investigated, myeloid dendritic cells (mDC) have been identified in increased 
frequency in the inflamed joints of JIA patients, where they mediate disease via 
the secretion of receptor activator of NFκB (RANK)(Varsani et al., 2003, 
Smolewska et al., 2008, Tabarkiewicz et al., 2011). Binding of the ligand 
(RANKL) to RANK results in osteoclast formation and bone degradation. 
Interestingly, hypoxia is shown to induce triggering receptor expressed on 
myeloid cells 1 (TREM-1) expression on monocyte derived DC, and the 
induction of proinflammatory signature. This finding has been confirmed in 
synovial mDC from JIA patients supporting a highly inflammatory and potentially 
pathogenic role for these cells at the inflamed site(Bosco et al., 2011). 
 
The strong HLA-associations highlight the significance of T cells in JIA, given 
the central role of MHC molecules in antigen presentation to T cells. Due to the 
previously defined association of oligo-JIA and poly-JIA to MHC class II alleles, 
it is unsurprising that research to date has focused on CD4 T cell populations. 
Indeed, CD3 T cells are usually the most abundant cell type within the synovial 
fluid mononuclear cells, and are typically highly activated memory cells 
(Silverman et al., 1993, Wedderburn et al., 2000a, Chiesa et al., 2004).  
Investigation into T cell subtypes at the inflamed site has identified Th1 and 
Th17 cell expansions at the inflamed site, which are likely to have been 
preferentially recruited via the respective expression of CCR5, CXCR3 and 
CCR6(Wedderburn et al., 2000a, Nistala et al., 2008a). Although, IFNγ 
blockade does not yield beneficial outcomes in murine models of inflammatory 
arthritis, it is possible that Th1 cells contribute to pathogenesis via the 
production of TNFα, which is routinely, and successfully used for treatment of 
JIA(Lovell et al., 2000, Brasted et al., 2005). Highlighting a role for IL-17 in JIA 
pathogenesis, Th17 cells and IL-17 are both increased in the synovial fluid and 
are associated with worse disease outcomes (Nistala et al., 2008a, Agarwal et 
al., 2008b).  Significant Th17 plasticity has been reported at the inflamed site in 
JIA, where synovial IL-12 is shown to drive the conversion of Th17 cells towards 
IFNγ and GM-CSF producing phenotypes (de Jager et al., 2007, Nistala et al., 
2010a, Piper et al., 2014a). Interestingly, one study investigating the clonality of 
synovial T cells in JIA observed significant oligoclonality in T cell subsets, which 
varied according to JIA subtype. Significant CD4 T cell clonality was seen in 
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oligo-JIA, supporting the hypothesis that disease pathogenesis may be, at least 
in part, antigen driven (Wedderburn et al., 2001). Although CD8 cells are not 
frequently studied in oligo- and poly-JIA subtypes, an expansion of CD8 T cells 
has been reported, and an inverted CD4:CD8 ratio is associated with more 
severe disease(Hunter et al., 2010).  
 
In addition to effector T cells, regulatory T cells (Treg) are also enriched within 
the synovial fluid of JIA patients compared to the patients’ blood, although lower 
frequencies are reported in more severe subtypes of the disease (de Kleer et 
al., 2004, Nistala et al., 2008a). There is still some debate over the functionality 
of Treg at the inflamed site. In vitro studies have demonstrated equal 
suppressive capacity of synovial Treg compared to Treg isolated from 
peripheral blood(Wehrens et al., 2011). However, neither synovial nor 
peripheral blood Treg are able to inhibit proliferation of effector T cells from the 
synovial fluid (Wehrens et al., 2011). More recent studies in JIA have identified 
a population of Treg that express high levels of CD25 but reduced expression of 
FOXP3. Further analysis demonstrated robust suppressive activity and TSDR 
demethylation in these FOXP3low cells(Bending et al., 2014). Additionally, there 
was significant TCR repertoire overlap between FOXP3 positive and FOXP3 
negative CD25 expressing populations(Bending et al., 2015). Together these 
studies suggest uncoupling of FOXP3 with the TSDR, and functional FOXP3 
negative Treg cells may exist in inflamed sites.    
 
In contrast to their traditional role in controlling aberrant inflammation, there is 
growing evidence that Treg at the inflamed site may in fact exacerbate 
inflammation. A population of Treg with effector functions has recently been 
identified at the inflamed site, characterised by CD161 expression(Pesenacker 
et al., 2013, Duurland et al., 2017a). Additionally, abnormal Treg responses and 
significant repertoire sharing across patients has been reported in JIA, 
suggesting that antigen recognition by Treg could also play a role in disease 
pathogenesis(Henderson et al., 2016). 
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1.1.2.3 Pathogenesis of ERA JIA 
 
1.1.2.3.1 HLA-B27 mediated immunopathology of ERA JIA 
 
As previously alluded to, the MHC Class l HLA-B27 allele is the strongest 
genetic factor associated with ERA JIA and presence of this allele is linked to 
more severe disease and axial joint involvement (Fisher et al., 2011, Corinne 
Fisher, 2012).  The exact role of HLA-B27 in disease pathogenesis is still 
unclear, although several hypotheses have been proposed and investigated in 
adult spondyloarthropathies and animal models of disease.  
 
One putative mechanism for HLA-B27-mediated ERA JIA is the presentation of 
arthritogenic peptides to CD8 T cells via MHC class I. ERA is also associated 
with polymorphisms in the gene for endoplasmic reticulum aminopeptidase 
(ERAP1), an enzyme involved in the optimisation of peptides for MHC 
presentation, which gives weight to this hypothesis(Saric et al., 2002, Hinks et 
al., 2011). However, HLA-B27 transgenic rat models of disease have 
discredited this theory, as rats continued to develop disease in the absence of 
CD8 T cells(May et al., 2003, Taurog et al., 2009).  
 
A second hypothesis for HLA-B27 focuses on HLA-B27 protein misfolding within 
the endoplasmic reticulum (ER) (Mear et al., 1999). This misfolding has been 
shown in rat models and myeloid derived DC to invoke ER stress, which results 
in the up regulation of IL-23 in response to lipopolysaccharides (LPS)(DeLay et 
al., 2009, Goodall et al., 2010). This enhanced IL-23 production could in part 
explain the expanded Th17 populations reported in the inflamed site of SpA 
patients, as IL-23 is known to be significant for Th17 differentiation and function 
(Shen et al., 2009, Jansen et al., 2015, Bowness et al., 2011). However, again, 
doubt has now been cast over this putative mechanism of pathogenesis for 
HLA-B27. A recent study failed to identify evidence of deregulated unfolded 
protein response–associated genes in the inflamed gut in adult AS, but instead 
implicated autophagy (Ciccia et al., 2014a).  
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The final hypothesis proposes a direct role for HLA-B27 in disease 
pathogenesis, and more specifically in directing Th17-type immune responses. 
Free HLA-B27 heavy chains have been shown to form disulphide-bonded 
homodimers, which are expressed both intracellularly and/or on the cell surface 
(Allen et al., 1999, Kollnberger et al., 2004, Colbert et al., 2014). Although 
expression of these homodimers have not been examined in ERA JIA, their 
expression has been observed on PBMC in adult AS(Tsai et al., 2002, Raine et 
al., 2006, Payeli et al., 2012). In addition, it has been shown that these heavy 
chain homodimers can be directly recognised by killer-immunoglobulin-like 
receptors (KIRs) expressed on NK cells and CD4 T cells (Kollnberger et al., 
2002, Kollnberger et al., 2007, Cauli et al., 2013). Subsequent investigations 
demonstrated increased expression of KIR3DL2 on CD4 T cells from PBMC 
taken from HLA-B27-positive healthy controls and AS patients. These KIR3DL2 
expressing CD4+T cells produced IL-17 following stimulation, and expressed 
the Th17 master transcription factor RORC(Bowness et al., 2011, Ridley et al., 
2016). Interestingly, silencing of ERAP1 has been shown to down regulate 
expression of HLA-B27 heavy chain homodimers and suppress Th17 responses 
in vitro (Chen et al., 2016). 
 
1.1.2.3.2 Immune pathology of ERA JIA 
 
Investigation of ERA JIA pathogenesis to date has been limited, and has 
focused predominantly on innate immune cell involvement. Microarray analysis 
of unsorted PBMC and SFMC from ERA JIA patients has identified 
overexpression of genes related to antigen presentation and scavenger function 
in cells from the joint compared to ERA JIA blood (Myles et al., 2012). Other 
studies have shown that monocyte-derived pro- inflammatory molecules such 
as the S100 protein MRP8/14 are elevated in the synovial fluid of ERA JIA 
patients and the expression of toll like receptors (TLR) 2 and 4 is increased on 
peripheral blood and synovial fluid monocytes in ERA JIA patients (Saxena et 
al., 2005, Myles and Aggarwal, 2011, Rahman et al., 2014). To date there has 
been no analyses of the recently defined innate lymphoid cells (ILC), their 
phenotype or relative abundance in the joints of patients with ERA JIA: although 
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given their potential for inflammatory cytokine production this area certainly 
warrants investigation. 
 
Very few studies have been conducted investigating T cell involvement in ERA 
JIA pathogenesis. One study analysed T cell receptor clonality in ERA JIA 
compared to oligo-JIA and found that the oligoclonality, was more marked in 
CD8 cells in ERA JIA patients. This is intriguing given the link to a class I MHC 
allele, HLA- B27 (Wedderburn et al., 2001). An initial study has suggested Th17 
cell enrichment in the synovial fluid mononuclear cells of ERA JIA patients in an 
Indian cohort (Mahendra et al., 2009). More recent reports have also 
demonstrated expanded IL-17 producing NK and γδ T cell populations within 
the peripheral blood from ERA JIA patients(Gaur et al., 2015).  
 
The involvement of IL-17-producing cells in ERA JIA could have important 
implications for the treatment of this subtype of JIA as several new therapies 
targeting the IL-17/IL-23 axis have been developed. These treatments include 
blockade of IL-17 by drugs such as Secukinumab, of IL-23 (e.g. by the drug 
Guselkumab), and of the common p40 subunit, which is shared by IL-12 and IL-
23, which is blocked by drugs such as Ustekinumab.  
 
1.1.2.3.3 Pathogenesis of adult spondyloarthropathies 
 
Similarly to ERA JIA, adult AS is characterized by enthesitis and axial joint 
involvement and shares strong genetic associations with the HLA-B27 allele 
and ERAP1(Schlosstein et al., 1973, Newport et al., 2007, Chen et al., 2014b). 
In fact, ERA JIA is, by some, considered to be young onset AS. The 
pathogenesis of AS has been extensively examined and may provide clues to 
direct investigation of ERA JIA. Over 40 AS-associated genes have been 
identified in genome wide association studies (GWAS)(Cortes et al., 2013). Of 
note, AS has been linked to the IL-23/IL-17 axis in both genetic and immune 
analyses. Polymorphisms in genes associated with IL-23 and IL-6 (two 
cytokines known to be important for the differentiation of Th17 cells from naïve 
CD4 T cells) receptor signalling have been shown to be associated with disease 
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susceptibility in AS (Newport et al., 2007, Zhou et al., 2007, McGeachy et al., 
2009, Cortes et al., 2013)  
 
Translating results from genome wide association studies (GWAS) to immune 
mechanisms, the IL-23/IL-17 axis has been further implicated in pathogenesis in 
both human AS and murine models. There is significant evidence of an 
expanded Th17 population in the peripheral blood from AS patients(Shen et al., 
2009, Bowness et al., 2011, Jansen et al., 2015). Additionally, IL-17+ γδ T cells, 
CD8 MAIT cells, and ILC have also been identified in the peripheral blood, 
synovial fluid and ilium from patients(Kenna et al., 2012, Ciccia et al., 2015, 
Gracey et al., 2016). Additionally, murine models of AS suggest entheseal 
inflammation in may be attributed to with IL-23 activated tissue resident T cells, 
although this is yet to be confirmed in human disease(Sherlock et al., 2012). 
 
1.1.3 Current strategies for the treatment of JIA 
 
The aim of treatment of JIA is to achieve complete control of the disease whilst 
preventing long-term side effects of therapy (Ravelli and Martini, 2007). The 
Juvenile Arthritis Disease Activity Score (JADAS) is a clinical tool used for 
assessing disease severity in JIA patients and takes into consideration 
biological measures of disease (active and tender joint counts and erythrocyte 
sedimentation rate (ESR), as well as more the more holistic physician and 
parent’s global assessments (Consolaro et al., 2009, Wu et al., 2016).  
 
Treatment for JIA varies on a patient-by-patient basis, and according to JIA 
subtype, however similar approaches are often implemented. In addition to 
physiotherapy and occupational therapy, a plethora of drugs are deployed.  
Non-steroidal anti-inflammatory drugs (NSAIDs), most commonly Naproxen, are 
usually the first line of treatment. Patients often also receive intra-articular 
injections of corticosteroid. During this procedure, corticosteroid is injected into 
the inflamed joints, and excess synovial fluid is aspirated. If these first line 
treatments fail, patients may enter into more aggressive treatment programs, 
such as systemic corticosteroids or disease modifying anti-rheumatic drugs 
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(DMARDs), such as methotrexate (MTX) (Ruperto et al., 2004). These 
treatments are effective in approximately 50% of cases. Unresponsive patients 
may then be considered for biological treatments. The most common of these 
are anti-TNFα agents, Etanercept (recombinant soluble TNF-R –Ig fusion 
protein) or one of the monoclonal antibodies to TNFα Infliximab or Adalimumab, 
which are generally well tolerated, and result in significant improvements in 
many patients(Lovell et al., 2006). However, systemic JIA-patients do not 
generally respond well to these agents, and anti-IL-6 receptor, Tocilizumab; or 
recombinant IL-1 receptor antagonist, Anakinra, are more effective for the 
treatment of this subtype(Klein and Horneff, 2009).  
 
More recently, biological treatments targeting the IL-23/IL-17 axis have been 
developed and appear effective for the treatment of adult arthropathies. 
Secukinumab, which targets IL-17A, and Ustekinumab, which targets the p40-
shared subunit between IL-23 and IL-12, are shown to be effective for the 
treatment of adult ankylosing spondylistis in clinical trials(Baeten et al., 2013, 
Poddubnyy et al., 2014). These treatments are yet to be trialled in JIA, although 
a clinical trail for Secukinumab in JIA is currently being established.   
 
The response to treatment in JIA is, in most studies, measured according to the 
American College of Rheumatology (ACR) criteria(Giannini et al., 1997). 
Treatment is deemed successful when patients achieve at least 70% 
improvement in 3 out of the 6 core outcome variables, with no more than one 
getting 30 % worse or more, defined as patients reaching ACR70 or above. 
Unfortunately, remission is only achieved in a minority of patients, and therefore 
improved treatment strategies are required.  
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1.2 The immune System  
 
The immune system can be broadly divided into innate and adaptive arms, 
which together provide protection and host defence against exogenous 
(pathogens) and endogenous (e.g. apoptotic cells) noxious stimuli.  Despite 
differential functions, there is significant overlap and cross talk between the 
innate and adaptive immune systems, both in initiating immune responses and 
in ensuring regulation of inflammation and maintaining immune homeostasis.  
 
The innate immune system in conjunction with the epithelia forms the first-line 
of response to invading pathogens. Innate cells are short lived and act non-
specifically to commensals and pathogens. Innate leukocytes such as 
monocytes, dendritic cells (DC) and natural killer (NK) cells are poised to 
respond and are activated upon recognition of preserved microbe-associated 
molecules (MAMPS) via pattern recognition receptors (PRR)(Medzhitov and 
Janeway, 2002, Janeway and Medzhitov, 2002). Following their activation these 
cells will lyse or phagocytose foreign and infected cells. Microbial antigens are 
then presented by professional antigen presenting cells (APC), via the major 
histocompatibility complex (MHC) I or II, to members of the adaptive immune 
system. In addition, innate immune cells produce a plethora of inflammatory 
mediators such as cytokines and chemokines that recruit other cells to the sites 
of inflammation and are pivotal in directing the magnitude and outcome of the 
adaptive immune response.  
 
In contrast to their innate counterparts, cells of the adaptive immune system are 
slower to respond, are highly specific and develop memory, such that they are 
able to respond more quickly and with higher affinity upon second and repeat 
exposure to the same microbe. T- and B-lymphocytes are components and 
responsible for adaptive immune responses. These cells detect antigens 
presented by APC via interaction with their highly specific T cell and B cell 
receptors (TCR/BCR). Once activated, these lymphocytes respond by the 
production of further inflammatory mediators, by killing of infected cells and by 
the production of antibodies(Abbas, 2011).  
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1.2.1 Innate immunity 
 
The innate immune system acts as the first line of response against infection, 
but in certain conditions such as in genetically susceptible individuals, innate 
immunity may also contribute to aberrant inflammation and autoimmunity.   As 
innate lymphoid cells and myeloid dendritic cells were major cell-types 
investigated in this thesis, it is appropriate to describe their known structure and 
function in greater detail.  
 
1.2.1.1 Innate Lymphoid Cells 
 
Innate lymphoid cells (ILC) are a recently discovered population of lymphocytes. 
As the name suggests, ILC contribute to innate immunity. NK cells were the first 
ILC population to be discovered and could be considered to be analogous to 
cytotoxic CD8 T cells, mediating inflammation by inducing death of infected 
cells. Lymphoid tissue inducer cells (LTi) also fall under the ILC umbrella, and 
play a pivotal role in the formation and maintenance of lymphoid tissues 
(Mebius et al., 1997, Hazenberg and Spits, 2014a).   Non-cytotoxic “helper” ILC 
populations, which are identified by the expression of the IL-7 receptor alpha 
chain (CD127) and can be broadly divided into 3 major subsets (ILC1, ILC2 and 
ILC3)(Spits et al., 2013). These subpopulations, in some respects mirror CD4 
helper T (Th) cell subsets (Th1, Th2 and Th17/Th22), based on their cytokine 
and transcription factor profiles (Walker et al., 2013, Hazenberg and Spits, 
2014b). T cell immunity will be discussed in more detail in section 1.2.2.1. 
Unlike their respective T cell counterparts, ILC lack RAG-rearranged genes for 
antigen receptors. Instead, ILC are acutely sensitive to their local environment 
and, following cytokine stimulation, become potent cytokine producers 
(Hoorweg et al., 2012). Since their discovery, ILC subsets have been implicated 
in the early stages of pathogenesis of a multitude of diseases, as well as being 
important mediators of repair and homeostasis. To date, very little has been 
reported about the role of ILC in arthritis (Hazenberg and Spits, 2014b). ILC 
subtypes are depicted in Figure 1.1. 
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1.2.1.1.1 ILC development 
 
Investigations into the development of ILC populations are largely restricted to 
murine studies. In this context, it has been shown that ILC, both NK cells and 
non-cytotoxic ILC, originate from common lymphoid precursors (CLP). ILC 
subpopulation progenitors can be subdivided into alpha-lymphoid progenitors 
(α-LP) and early innate lymphoid progenitor (EILP). However, more specific 
committed helper ILC progenitors (CHILP) have been identified, which lack the 
potential to develop into NK cells. Subsequent helper ILC development from 
these progenitor cells is dependent on expression of the transcription factors 
thymocyte selection–associated high- mobility group box (TOX), nuclear factor 
interleukin 3 regulated (NILF3), T-cell factor 1 (TCF1) and nuclear repressor Id2 
(Cherrier et al., 2012, Constantinides et al., 2014, Yu et al., 2014, Yang et al., 
2015, Scoville et al., 2016). Non-cytotoxic ILC are dependent on IL-7 for their 
development and typically express the alpha chain of the IL-7 receptor (CD127). 
Subsequent differentiation of ILC into their respective subsets is reliant on their 
cytokine environment. While this part of the differentiation process is less well 
defined, it is likely that the same factors are involves as for late stage T cell 
differentiation into their effector states (Vosshenrich and Di Santo, 
2013)(Hazenberg and Spits, 2014).  
 
The process of ILC development in humans is poorly defined; understanding is 
currently limited to ILC1 and ILC3 subpopulations. It is known that, similar to 
mice, human helper ILC arise from CHILP, and the transcription factor 
promyelocytic leukaemia zinc finger (PLZF) can additionally be used to identify 
ILC1 precursors (Constantinides et al., 2015). By contrast, ILC3 may develop 
from RORC+ CD34+ hematopoietic stem cells under stimulation with stem cell 
factor (SCF), IL-7 and IL-15 (Montaldo et al., 2014). Furthermore, there is now 
evidence for a role of retinoic acid and ligands of the aryl hydrocarbon receptor 
(AhR) in promoting ILC3 development from early committed precursors(Lee et 
al., 2011, van de Pavert et al., 2014). Further investigation of ILC differentiation 
in human cells needs to be clarified; analysis of ILC repopulation after stem cell 
transplantation may provide useful insight.  
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1.2.1.1.2 Non-cytotoxic ILC subpopulations (CD127+) 
 
CD127+ ILC comprises a heterogeneous population of cells defined by 
lymphoid morphology paired with the absence of rearranged antigen receptors 
and other surface molecules associated with previously identified lineages (T 
cells, B cells, monocytes, DC, stem cells, eosinophils, or mast cells).  To date, 
ILC can be divided into 3 subsets (ILC1, ILC2 and ILC3), which share cytokine 
and transcription factor signatures with Th subsets (Th1, Th2, Th17 
respectively). ILC are thought to be predominantly tissue resident cells, where 
they mediate both inflammation and tissue repair via the production of 
cytokines, in response to the local milieu. CD127+ ILC help maintain mucosal 
homeostasis by providing anti-microbial immunity (Scandella et al., 2008, Cella 
et al., 2009, Sonnenberg et al., 2012).  It is however becoming clear that when 
dysregulated, ILC may also promote damage and contribute to disease 
pathogenesis such as in inflammatory bowel disease and arthritis (Hazenberg 
and Spits, 2014a).   
 
1.2.1.1.2.1 Group 1 Innate Lymphoid Cells (ILC1) 
 
ILC1 have been identified in several organs including the gut and the lungs and 
play an important role in immunity against intracellular pathogens. Murine 
models have identified a protective role for ILC1 against parasite infection by 
inducing recruitment of myeloid cells to the site of infection, and against 
bacterial infection, where ILC1-secreted IFNγ protects the epithelial barrier by 
promoting release of glycoproteins, which form a protective mucus(Klose et al., 
2014). Additionally, ILC1 have been implicated in the pathogenesis of human 
autoimmunity and are significantly expanded in colons of Crohn’s 
patients(Bernink et al., 2013b). In addition, ILC1-like cells have also been 
identified in the synovial fluid from patients with rheumatoid arthritis and 
ankylosing spondylitis (Dalbeth and Callan, 2002, Leijten et al., 2015, 
Yeremenko et al., 2015). 
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Two predominant populations of ILC1 have been described, which diverge 
according to expression of CD127 as well as differential expression of T-box 
expressed in T cells (Tbet) and Eomesodermin (Eomes) transcription factors. 
Similarly to Th1 cells, the master transcription factor of CD127+ILC1 is Tbet. 
There is significant functional overlap between CD127+ILC1 and NK cell 
populations. However CD127+ILC1 lack expression of Eomes, a transcription 
factor, which is therefore useful when discriminating between these two 
subsets. Following activation and stimulation with IL-12 and IL-18, ILC1 rapidly 
produce IFNγ as well as TNFα (Fuchs et al., 2013).  
 
Interestingly, human ILC1, expressing CXCR3 and Tbet without Eomes, have 
been shown to express several T cell associated markers intracellularly, 
including CD3 (Roan et al., 2016b). Further supporting a close association 
between ILC1 and T cell subsets, single cell RNA-seq of ILC1 (identified as 
lineage- CD127+CRTH2−CD117−NKp44−), isolated from healthy human 
tonsils, has shown that ILC1 express transcripts for T cell associated genes 
encoding for CD5 and CD6 (Bjorklund et al., 2016). Unlike some other ILC 
subsets, ILC1 do not express MHC class II molecules and are therefore 
incapable of antigen presentation to T cells; their major contribution instead is 
via IFNγ mediated inflammation.  
 
1.2.1.1.2.2 Group 2 Innate Lymphoid Cells (ILC2) 
 
ILC2, initially named nuocytes, mirror Th2 cells, are regulated by GATA- binding 
factor 3 (GATA3) and can be identified by expression of the prostaglandin D2 
receptor, CRTH2. Similar to Th2 cells, ILC2 are involved in the responses 
against extracellular pathogens(Mjosberg et al., 2011b). ILC2 are potent 
producers of IL-4, IL-5 and IL-13 in response to stimulation with IL-25, IL-33 and 
thymic stromal lymphopoietin (TSLP), which are commonly released during 
tissue damage and allergic reaction (Hazenberg and Spits, 2014a).  
 
ILC2 are the most prevalent ILC subtype in healthy blood, although they are 
also implicated in the allergic response and protection against helminth 
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infections(Hazenberg and Spits, 2014a).  Several studies have shown an 
important role for these cells in promoting airway hyper reactivity in asthmatic 
models, where they are major contributors to the total IL-5 and IL-13 production 
(Fort et al., 2001, Lund et al., 2013, Drake and Kita, 2014). In fact these studies 
have shown that ILC2 produce increased IL-5 and IL-13 compared to their T cell 
counterparts in this context, demonstrating their pivotal role in allergic 
responses, which has shifted the focus in this area away from T cells(Halim et 
al., 2012, Bartemes et al., 2012).  
 
ILC2 are known to interact with, and direct the function of, cells of the adaptive 
immune system. IL-5, IL-6 and IL-13 are readily produced by ILC2 and may 
mediate the activation of naïve T cells, or the production of IgA responses from 
B cells (Halim et al., 2014, Drake et al., 2016). In addition to production of 
cytokines, ILC2 may also function as antigen presenting cells. A number of 
studies have identifies expression of MHC class II and co-stimulatory 
molecules, CD80 and CD86, on the surface of ILC2, suggesting that these cells 
may activate T cell responses via antigen presentation (Oliphant et al., 2014). 
 
1.2.1.1.2.3 Group 3 Innate Lymphoid Cells (ILC3)  
 
ILC3 require retinoic acid-related orphan nuclear receptor C (RORC) for their 
development and function, and include non-cytotoxic ILC3 as well as tissue 
inducer cells (LTi)(Luci et al., 2009). For the purpose of this thesis, only 
CD127+ILC3, non-cytotoxic, populations will be discussed. ILC3 produce Th17 
type cytokines, including IL-17, IL-22 and GM-CSF, in response to stimulation 
with IL-23 and IL-1β.  ILC3 can be further divided into 2 groups with differential 
cytokine and transcription factor profiles. These two distinct populations can 
been distinguished according to expression of natural cytotoxicity receptor 
(NCR) NKp44 (Spits et al., 2013). 
 
 
 
 36 
1.2.1.1.2.3.1 NCR-ILC3 
 
NCR-ILC3, and more specifically, HLA-DR+ NCR-ILC3 are potent producers of 
IL-17, and are instrumental for the containment of commensals in the gut 
(Sonnenberg et al., 2012, Hoorweg et al., 2012, Bjorklund et al., 2016). 
Additionally, mouse models show that MHC class II-expressing NCR-ILC3 
mediate commensal tolerance via antigen presentation to, and killing of, 
commensal reactive CD4 T cells (Hepworth et al., 2013). Although this role for 
NCR-ILC3 has not yet been confirmed in humans, this population is decreased 
in the colon of paediatric IBD patients, suggesting comparability to mouse 
models (Hepworth et al., 2015).  
 
Conversely, NCR-ILC3 have been described in the gut of experimental models 
of colitis, as well as human Crohn’s patients where they are believed to 
contribute to disease via the production of IL-17A (Geremia et al., 2011) 
Perhaps unsurprisingly, in addition to ILC1, NCR-ILC3 have been identified as 
the predominant ILC subtype in the inflamed synovia of AS patients 
(Yeremenko et al., 2015, Ciccia et al., 2015).  
 
1.2.1.1.2.3.2 NCR+ILC3 
 
NCR+ILC3 typically produce reduced IL-17 compared to NCR-ILC3, but are 
instead potent producers of IL-22 (Taube et al., 2011). This ILC3 subpopulation 
is somewhat parallel to proposed Th22 cells in humans. NCR+ILC3 are most 
prevalent in the healthy gut where they are play an important role in gut 
homeostasis and wound healing, by regulation of IL-17 production via AHR, and 
by direct interaction of IL-22 with epithelial cells (Cella et al., 2009, Hepworth et 
al., 2013, Qiu et al., 2013). In addition, murine NCR+ILC3 have recently been 
shown to produce GM-CSF in a model of inflammatory bowel disease. In this 
context, they mediate Treg responses via the GM-CSF-dependent induction of 
retinoic acid from myeloid cells (Mortha et al., 2014). On the other hand 
NCR+ILC3 may also contribute to inflammation via the production of 
inflammatory cytokines including IL-17 and TNFα. It is suggested that the 
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mechanism of activation impacts the inflammatory program of NCR+ILC3. While 
cytokine stimulation largely results in the production of IL-22 and GM-CSF, 
engagement of NKp44 on the cell surface induces a pro-inflammatory signature 
and aberrant TNFα and IL-2 (Glatzer et al., 2013). 
 
ILC have not been previously investigated in JIA, although NCR+ILC3 have 
been reported in the skin, blood and synovial fluid from patients with adult 
psoriatic arthritis where they were associated with more severe disease 
(Teunissen et al., 2014b, Leijten et al., 2015). Additionally, an enrichment of 
NCR+ILC3 have been detected in the blood, synovial fluid and ilium of adult 
ankylosing spondylitis (AS) patients (Ciccia et al., 2012, Ciccia et al., 2015). 
 
Figure 1.1 Schematic showing ILC subtypes and disease associations. 
 
1.2.1.1.3 ILC plasticity 
 
Adding complexity to this population of cells, there is now significant evidence, 
in both human and mouse systems, that there is substantial plasticity between 
ILC subpopulations. This plasticity allows ILC groups to switch phenotype 
(Bernink et al., 2013b, Klose et al., 2014). Skewing of human ILC1 to ILC3 has 
been clearly shown under the influence of IL-23 and IL-1β (Bernink et al., 2015). 
It is additionally clear that this plasticity is reversible and under the influence of 
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IL-12, ILC3 populations are able to up regulate expression of Tbet and initiate 
production of IFNγ, essentially transitioning back into ILC1 (Bernink et al., 
2013b). One example of this in a disease setting is the depletion of intestinal 
mucosal NCR+ILC3 in Crohn’s disease patients, which is likely to be a result of 
IL-12 dependent switching to ILC1. Other mediators of ILC switching include: 
retinoic acid, which causes switching towards IL-22 producing ILC subsets 
(Bernink et al., 2015).  In the presence of IL-23 and IL1β, NCR-ILC3 can 
transdifferentiate into NCR+ILC3. There is even increasing evidence to support 
ILC2 plasticity, whereby IL-4 induces ILC2 differentiation and IL-12 and IL-1β 
induces switching towards an ILC1 phenotype (Silver et al., 2016b). Intriguingly, 
while stimulation with IL-23 causes IL-17 and IL-22 production from ILC3 
populations, extended exposure can promote a more pathogenic phenotype and 
IFNγ production (Mielke et al., 2013, Bernink et al., 2013b). Together these 
reports highlight the sensitivity and versatility of CD127+ILC and their ability to 
readily adapt to their inflammatory environment. 
 
 
Figure 1.2 Schematic showing ILC differentiation and plasticity. 
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1.2.1.2 Myeloid dendritic cells 
 
Myeloid dendritic cells (mDC) are a bone marrow derived population, which 
form an essential arm of the innate immune system and function as APC, 
characteristically identified by the expression of CD11c and CD13 in the 
absence of CD14. mDC can be further divided into two groups according to the 
expression of BDCA1 (CD1c) and BDCA3 (CD141) respectively(Dzionek et al., 
2000). The primary function of mDC is antigen uptake and subsequent 
presentation to T cells in secondary lymphoid tissues.  
 
Immature mDC are typically localized in peripheral tissues and have high 
endocytic capacity, but a low capacity for T cell activation. As APCs, mDC 
continuously sample and internalize antigens, employing a combination of 
micropinocytosis, macropinocytosis and phagocytosis. While micro- and macro-
pinocytosis do not require antigen recognition, phagocytosis relies on the 
identification of foreign antigens by MAMPs such as Toll-like receptors and 
other microbial sensors on the cell surface (reviewed in (Cella et al., 1997)).   
 
Internalised antigens are degraded within lysosomes and the constituent 
peptides are subsequently loaded into MHC class II molecules and presented 
on the cell surface to MHC-class II-restricted CD4 T cells. Additionally, 
intracellular pathogens, and phagocytosed material that has escaped 
lysosomes and moved into the cytosol, do not escape processing by mDC. 
These antigens are processed in a pathway known as “cross presentation”. 
During cross presentation, antigens are degraded within the proteasome and 
loaded onto MHC class I molecules. In this way mDC may also interact with and 
activate CD8 T cells, which are MHC-class I-restricted (Norbury et al., 1995, 
Reis e Sousa and Germain, 1995).  
 
Upon activation by antigen uptake, or from local cytokines, including TNFα and 
IL-1, mDC mature and their function transitions from antigen capture, to antigen 
presentation. At this time, the cells upregulate expression of chemokine 
receptor, CCR7, as well as several co-stimulatory molecules, such as CD80 and 
CD86, and migrate towards the T cell zones of local lymph nodes and 
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secondary lymphoid tissues. The CCR7 receptor allows migration of cells 
towards these lymphoid tissues (reviewed in (Forster et al., 2008)). Here, they 
may present processed peptides to circulating naïve T cells via their MHC 
molecules and high expression of co stimulatory molecules such as CD80 and 
CD86, required to activate naïve T cells. In parallel, mDC also secrete a 
plethora of cytokines. The combination of cytokines secreted, combined with 
antigen presentation, works to drive clonal expansion of T cells and direct the 
nature of the immune response elicited (reviewed in (Cella et al., 1997)). In 
addition to their role in antigen presentation, mDC and their cytokines have 
been implicated in promoting inflammation and autoimmunity. Of particular note, 
mDC are implicated in the pathogenesis of HLA-B27 mediated disease, via 
aberrant production of IL-1β and IL-23, supporting pathogenic Th17 responses 
(Goodall et al., 2010).  
 
Interestingly, tolerogenic mDC have now been described (Coombes et al., 2007, 
Xia et al., 2008), although these cells have not been investigated in JIA. Rather 
than exacerbating inflammation, these cells are important for the control of 
aberrant immune responses and the maintenance of immune homeostasis. Of 
particular interest in the context of this thesis is a population of mucosal mDC 
defined by expression of integrin αE (CD103), which is encoded by 
ITGAE(Kilshaw, 1999). CD103+mDC are major producers of retinoic acid (RA) 
in the gut under homeostatic conditions and are important for the induction of 
lymphocytes with gut homing properties (Iwata et al., 2004, Johansson-Lindbom 
et al., 2005, Coombes et al., 2007, Jaensson et al., 2008). Compared to 
CD103-mDC, CD103+mDC express high levels of retinal dehydrogenase 
enzymes, which are essential catalysts for the conversion of vitamin A to active 
RA(Coombes et al., 2007, Hall et al., 2011). RA subsequently acts in an 
autocrine positive feedback mechanism to further enhance RALDH expression 
and augment RA catalysis(Molenaar et al., 2011). RA is an important immune 
mediator and has been shown to impact the development and stability of T cell 
lineages(Hall et al., 2011). Of note, RA, in combination with TGFβ, is shown to 
stimulate the differentiation of regulatory T cells(Benson et al., 2007, Mucida et 
al., 2007, Xiao et al., 2008). Meanwhile, high dose RA inhibits the development 
of pathogenic Th17 responses(Mucida et al., 2007, Xiao et al., 2008). More 
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recently, as mentioned above, RA has also been shown to augment ILC 
skewing and support the development of IL-22-producing NCR+ILC3(Bernink et 
al., 2015). 
 
1.2.2 Adaptive immunity 
 
Members of the adaptive immune system are defined by expression of highly 
specific, RAG-recombined antigen recognition receptors. The adaptive 
response can be divided into T- and B- lymphocytes, both of which are able to 
develop memory and thus respond quickly and efficiently to repeated antigen 
exposure.  As T cell responses were investigated in detail in this thesis, B cell 
function is not discussed further.  
 
1.2.2.1 T cells 
 
Two main populations of T cells exist, defined by the chains that constitute the 
heterodimeric TCRs that they express. αβ T cells (CD4+ and CD8+) represent 
the majority of T cells in human blood and express TCRs made up of an alpha-
chain and beta-chain, while γδ T cells represent the minority of T cells within the 
blood, and express TCR constituted of a gamma-chain and delta-chain(Marrack 
and Kappler, 1986, Brenner et al., 1986). T cells, similarly to ILC, are derived 
from common lymphoid progenitor cells; which arise from hematopoietic stem 
cells in the bone marrow and subsequently migrate to the thymus. Within the 
thymus, these committed progenitor cells (thymocytes) which lack CD4 and 
CD8 expression, differentiate into CD4+ and CD8+ and γδ T cell subsets via 
several stages of positive and negative selection. In order to generate TCR 
specificity and diversity, TCR genes undergo RAG-dependent recombination of 
the variable (V), diversity (D) and joining (J) gene regions (Tonegawa et al., 
1981). While V(D)J rearrangement results in enhanced diversity, the most 
significant contribution to TCR diversity arises from the addition or removal of 
nucleotides at the junctions between V and D and J segments, which is known 
as junctional diversity. After successfully undergoing selection, naïve T cells will 
finally migrate out of the thymus and into the periphery where they may 
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differentiate further and perform their effector functions, which vary according to 
T cell subtype. 
 
1.2.2.1.1 CD4 T cell subsets 
 
CD4 T cells, commonly called T helper (Th) cells, comprises a heterogeneous T 
cell population whose main effector functions aid in guiding the immune 
response via antigen recognition and cytokine production. Th1 and Th2 were 
first to be identified as distinct populations, with divergent signature cytokines 
and effector functions (Mosmann et al., 1986). Since then, many other Th 
subsets have been reported and can be distinguished according to their 
cytokine and transcription factor profiles (Harrington et al., 2005, Crotty, 2014, 
Kaplan et al., 2015).  Differentiation of CD4 T cells into their Th subtype is 
directed by antigen recognition and the local cytokine milieu. This thesis will 
focus predominantly on Th1, Th17 and regulatory CD4 T cells (Treg) and 
therefore only these populations will be discussed further in this introduction. 
 
1.2.2.1.1.1 Th1 
 
Th1 cells are important for immunity to intracellular bacteria, and are heavily 
implicated in autoimmunity. Th1 cells are regulated by the master transcription 
factor Tbet and readily produce IFNγ, IL-2 and TNFα upon activation (Mosmann 
et al., 1986, Szabo et al., 2000). Th1 differentiation is driven by IL-12, which 
signals via the STAT4 pathway(Bacon et al., 1995). IFNγ production is induced 
by activation by IL-12 in combination with IL-18 or, to a lesser extent, IL-1β 
(Tominaga et al., 2000). Additionally, IFNγ secreted by Th1 cells operates in a 
positive feedback mechanism to further enhance production of IFNγ, whereby 
STAT1 is activated resulting in increased transcription of Tbet, which induces 
increased expression of IFNγ and expression of the inducible chain of the IL-12 
receptor (Lighvani et al., 2001). In parallel, ligation of CD40 ligand on Th1 cells 
with CD40 on the surface of macrophages and DC results in increased IL-12 
secretion by APCs and exacerbates inflammation. In addition to their cytokine 
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profile, Th1 cells can also be characterized by expression of chemokine 
receptors CXCR3 and CCR5 on their surface (Loetscher et al., 1998, Bonecchi 
et al., 1998).  
 
1.2.2.1.1.2 Th17 
 
Th17 cells are most abundant in mucosal sites, where they offer protection 
against extracellular bacterial and fungal infections. Defined by production of IL-
17 (A and F) and regulated by expression of the transcription factor, RORC, 
Th17 cells were first described in murine models of autoimmunity (Ivanov et al., 
2006). In this context, Th17 cells were shown to be critical for the onset of 
experimental autoimmune encephomyelitis, and have since been implicated in 
the pathogenesis of a plethora of inflammatory diseases including mouse and 
human arthritis and diabetes (Langrish et al., 2005, Spreafico et al., 2016).  
 
In mice, Th17 differentiation is driven by various combinations of; IL-23 (which 
shares a common subunit, (p40) with IL-12) with: IL-6, transforming growth 
factor β (TGFβ) and IL-1β. There are conflicting reports on the factors, which 
drive Th17 differentiation in humans. While some studies have suggested a 
cocktail of IL-6 and IL-1β is sufficient; other studies suggest that addition of 
TGFβ and IL-23 is also required. In addition to the cytokine milieu, weak TCR 
signalling has been shown to promote Th17 differentiation (Mangan et al., 2006, 
Veldhoen et al., 2006, Acosta-Rodriguez et al., 2007a, Wilson et al., 2007, 
Volpe et al., 2008).   
 
There are a number of surface molecules that are associated with the Th17 
lineage. Natural killer lectin-like receptor CD161 is highly expressed on Th17 
cells and is induced by RORC expression. In fact, CD161 is now considered to 
be a marker of all IL-17-producing T cells and is identified on IL-17-producing T 
cell subsets as well as naïve T cell precursors with the potential for IL-17 
production(Maggi et al., 2010). Additionally, Th17 cells commonly express 
chemokine receptors CCR4 and CCR6(Acosta-Rodriguez et al., 2007b).  
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1.2.2.1.1.3 Regulatory T cells 
 
In addition to facilitating inflammation, Th cells, known as Treg, also play an 
important role in suppressing aberrant immune responses and controlling the 
inflammatory process. Treg produce anti-inflammatory cytokines such as IL-10. 
Other mechanisms of Treg suppression include inducing apoptosis of activated 
lymphocytes and inhibition of T cell activation via CTLA4-mediated interactions 
(Zheng et al., 2008, Walker and Sansom, 2011, Qureshi et al., 2011). CD25+ 
(IL-2 receptor alpha chain) CD4+ regulatory T cells (Treg) were first described 
by Sakaguchi, who noted that autoimmunity was prevented in athymic mice 
inoculated with effector T cells and subsequently reconstituted with 
CD4+CD25+ T cells(Sakaguchi et al., 1995). Since then, Treg have been 
extensively investigated in mice and in humans, where they can be identified by 
low expression of CD127 high CD25 expression and the transcription factor 
forkhead box P3 (FOXP3)(Baecher-Allan et al., 2001, Fontenot et al., 2003). 
Additionally, committed Treg can be distinguished from effector T cells 
transiently expressing FOXP3 by demethylation of the Treg-specific 
demethylated region (TSDR)(Baron et al., 2007).  
 
To add to the complexity, there is now also evidence of Treg populations with 
effector functions. Populations of Treg have been identified by divergent 
expressions of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) and 
CD226, with Th1- and Th17-like properties, including the expression of CXCR3, 
T-bet, CCR6 and RORC and production of inflammatory cytokines including 
IFNγ(Joller et al., 2014, Fuhrman et al., 2015).  Other effector Tregs can be 
identified by expression of CD161(Pesenacker et al., 2013). CD161+Treg 
represent a true Treg population. They have been shown to be predominantly 
demethylated at the TSDR and to be suppressive in vitro. However, unlike 
traditional (CD161-)Treg populations, CD161+Treg, are able to produce a 
plethora of pro-inflammatory cytokines. Furthermore, CD161+Treg share a 
transcriptional signature with CD161+ Th1 and Th17 cells(Duurland et al., 
2017a). Intriguingly, the CD161+ Treg population is expanded at the inflamed 
site in oligo-JIA patients, although it is currently unknown whether they are 
playing a pro- or anti-inflammatory role in this setting. However cytokine 
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producing Treg have been identified in autoimmune hepatitis where they are 
implicated in promoting inflammation (Arterbery et al., 2016).  
 
1.2.2.1.2 T cell plasticity 
 
Not long after the identification of Th subsets, it became clear that these defined 
lineages were not clear-cut. It is now evident that there is considerable plasticity 
within the Th17 subset, as IL-17 production by Th cells is often paired with 
production of other inflammatory mediators including IFNγ, IL-22 and GM-CSF. 
Th cell plasticity is driven by a combination of cytokine stimulation, the 
microenvironment and epigenetic modifications (Bonelli et al., 2014, Geginat et 
al., 2014).  
 
Th17 plasticity is widely reported at sites of inflammation. Previous members of 
the Wedderburn group have described Th cells in the inflamed joints of JIA 
patients, with a phenotype between Th1 and Th17(Nistala et al., 2010a). These 
Th1/Th17 cells readily produce both IFNγ and IL-17A and express gene 
transcripts for Tbet and RORC. This study also showed that culture of Th17 with 
IL-12 induced phenotype switching towards Th1 in vitro. A subsequent study 
confirmed this finding, and additionally showed that IL-12 stimulation also 
induced production of GM-CSF from Th17(Piper et al., 2014a). Whereby Th1 
and Th17 cells characteristically express CXCR3 and CCR6 respectively, 
Th1/Th17 intermediate cells can be identified by the co-expression of both of 
these chemokine receptors (Acosta-Rodriguez et al., 2007b). In addition to IL12, 
IL-1β is shown to be important for the differentiation of these pathogenic Th 
cells. In addition to demonstrating Th17 plasticity, Nistala et al also identified 
CD161 as a maker of Th1 cells with the ability to produce IL-17, so-called “ex 
Th17” cells (Nistala et al., 2010a).  
 
Th17 plasticity is not only associated with a Th1 phenotype. Cells with a 
Th17/Th2 intermediate phenotype have been described in the peripheral blood 
of asthma patients, and this phenotype can be induced by IL-4 stimulation 
(Cosmi et al., 2010). Finally, plasticity between Th17 and Treg may also exist, 
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and differentiation of Th17 cells to Tregs and vice versa has been demonstrated 
in mouse models (Komatsu et al., 2014, Gagliani et al., 2015). Although this 
plasticity has not been confirmed in human studies, CD161 expression is 
associated with a Treg population with effector, Th17-like, function in humans 
and supports parallel plasticity (Pesenacker et al., 2013, Duurland et al., 
2017a).  
 
Figure 1.3 Schematic showing T cell differentiation and plasticity. 
 
1.2.2.2 CD8 T cells 
 
Defined by expression of CD8 on their surface, cytotoxic T lymphocytes (CTL) 
are key mediators of immunity against intracellular pathogens. CD8 T cells 
recognize antigens presented on MHC class I molecules and their subsequent 
activation requires costimulation. Although CD8 T cells can respond without the 
help of CD4 T cells, additional CD4-derived cytokines and CD4 T cell licensing 
of APC may boost the CD8 T cells responses(Bennett et al., 1997).  
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The primary function of CD8 T cells is to kill infected or damaged cells. Upon 
activation, CTL acquire the machinery for efficient killing of target cells such as 
cytoplasmic granules containing cytotoxic proteins including perforin and 
granzymes, which, when injected into cells expressing the appropriate antigens, 
induce apoptosis(Chowdhury and Lieberman, 2008). CD8 T cells are also able 
to mediate killing in a granule-independent mechanism. Upon activation CD8 T 
cells upregulate of FAS ligand (FASL) on the cell surface. Ligation of this 
receptor results in caspase activation and apoptosis of the cognate 
cells(Rouvier et al., 1993a).  
 
In addition to killing functions, CD8 T cells also contribute to the inflammatory 
process via the production of cytokines. Most commonly CD8 T cells produce 
IFNγ, which functions to activate phagocytes and prolong the inflammatory 
loop, however subsets producing IL-17A and other cytokines have now been 
described. Similarly to Th cells, CD8 T cell subsets can be categorized 
according their transcription factor, cytokine and chemokine receptor profiles, 
which mirror their CD4 counterparts described above (Croft et al., 1994, 
Mosmann et al., 1997, Hamada et al., 2009).  
 
Of relevance to this thesis, a new population of innate-like CD8 T cells 
expressing high levels of CD161, a marker associated with IL-17A production 
have been identified, known as mucosal associated invariant T (MAIT) cells 
(Treiner et al., 2003). These cells are potent IL-17A-producers and have been 
identified in a plethora of inflammatory conditions (Cho et al., 2014, Willing et 
al., 2014, Serriari et al., 2014b). Additionally, MAIT cells have been implicated in 
adult arthropathies where they contribute to IL-17-mediated disease (Gracey et 
al., 2016). 
 
1.2.2.3 γδ T Cells 
 
T cells expressing the γδ TCR heterodimer constitute less than 5% of the T cell 
repertoire in peripheral blood, although γδ T cells are more abundant in 
epithelial surfaces, specifically the small intestine(Viney et al., 1990). Unlike 
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their αβ counterparts, antigen recognition by γδ T cells is typically not MHC-
restricted. Instead these cells function in a more innate-like way, recognizing 
conserved antigens using PRRs and antigens which are presented on MHC-like 
molecule, CD1c, via their TCRs. γδ T cells typically home to tissues rather than 
lymphoid organs where they respond in harmony with the innate immune 
system.  
 
γδ T cells have diverse functions (reviewed in (Vantourout and Hayday, 2013)). 
These cells may kill infected or damaged cells via interaction of FAS and the 
release of cytotoxic agents. Additionally, γδ T cells are potent cytokine 
producers. In response to activation, γδ T cells may secrete inflammatory, or 
modulatory cytokines including IFNγ, IL-6, IL-17A, GM-CSF and TNFα, all of 
which have been implicated in autoimmune pathogenesis. Although TCR 
stimulation is not required for all function, there is now some evidence that IL-
17A production from γδ T cells requires TCR ligation(MacLeod et al., 2013). 
There is evidence, as with the aforementioned T cell subpopulations, of γδ T 
cell functional plasticity although this has not been studied in great detail in 
humans.  
 
Although γδ T cell function is relatively poorly understood in humans, their 
contribution to maintaining immune competence should not be over looked. It 
has been shown that γδ T cells are rapidly reconstituted after transplantation, 
where their population size correlated with disease-free survival(Wu et al., 
2000, Godder et al., 2007).  Additionally, there is now growing evidence to 
support a role for pathogenic γδ T cells in promoting autoimmune disease(Bank 
et al., 2002).  
 
1.2.3 Chemokine mediated cell trafficking 
 
Chemokine proteins are important mediators of leukocyte trafficking, which 
instruct cellular migration via a concentration gradient. Leukocytes expressing 
the cognate chemokine receptors move along the chemokine concentration 
gradient towards the epicentre, where they may perform their functions(Charo 
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and Ransohoff, 2006). The two major families of chemokines are identified 
according to the localization of cysteine residues within their structure. Within 
CC chemokines, the first two cysteine residues are adjacent, whereas CXC 
chemokines have a single amino acid residue between their first two cysteine 
residues(Zlotnik and Yoshie, 2000). Chemokines from both of these families 
signal through chemokine receptors containing a seven-transmembrane-domain 
coupled to a G-protein(Holmes et al., 1991). Ligation of chemokines with their 
associated receptors results in conformational and morphological changes 
within the cell that enables movement.  
 
Chemokines may perform homeostatic or inflammatory functions(Charo and 
Ransohoff, 2006). CCR7, which migrates towards CCL19 and CCL21, is 
commonly expressed on naïve T cells and is important for their migration 
through lymphoid tissues and the maintenance of homeostasis(Campbell and 
Butcher, 2000). However, high levels of other specific chemokines have been 
reported in inflamed sites and in autoimmune diseases, paired with increased 
expression of their receptors on immune cells. In this position, chemokines 
maintain and exacerbate inflammation. Table 1.2 shows selected chemokine 
receptors, their typical expression and their respective ligands.    
 
Chemokine 
receptor 
Chemokine ligands Cell type expressing 
receptor 
CCR4 CCL2, CCL4, RANTES, 
CCL17, CCL22 
Th2, Th17, Treg, mDC, 
basophils, macrophages 
CCR5 CCL3, CCL4, RANTES, 
CCL11, CCL14, CCL16 
Th1, monocytes 
CCR6 CCL20 Th17, gut homing T cells, 
immature mDC 
CCR7 CCL19, CCL21 Naïve T cells 
CXCR3 CXCL4, CXCL9, CXCL10, 
CXCL11 
Th1, NK cells 
Table 1.2 Selected chemokine receptors, their ligands and typical 
expression. 
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1.2.4 The functions of IL-17 and associated cytokines 
 
1.2.4.1 IL-17A 
 
IL-17 denotes a family of cytokines including, IL-17A-F. Of these, the most 
thoroughly understood, and in focus in this thesis, is IL-17A, which has been 
implicated in mediating the pathogenesis of numerous inflammatory diseases 
and is an increasingly prominent target of therapy (unless otherwise specified, 
IL-17 will refer to IL-17A throughout this thesis)(Agarwal et al., 2008b, 
Henriques et al., 2010, Omoyinmi et al., 2012, Jansen et al., 2015, Gaur et al., 
2015). IL-17A was initially discovered in 1993, and comprises a homodimeric, 
disulphide-linked, glycoprotein of 155 amino acids(Rouvier et al., 1993b). Most 
often associated with Th cells, IL-17A is also produced by other cells of the 
innate and adaptive immune systems including γδ T cells, CD8 T cells and 
ILC(Ivanov et al., 2006, Michel et al., 2007, Roark et al., 2008, Hamada et al., 
2009). There are currently 5 known members of the IL-17 receptor family (IL-
17RA-E), and signalling of IL-17A requires a heterodimer receptor complex 
comprising IL-17RA and IL-17RC. Binding of IL-17A to the cognate receptors 
activates NFκB and MAPK in a TRAF-dependent cascade and triggers a highly 
pro-inflammatory gene expression program (reviewed in detail in (Gaffen, 
2009)).  
 
IL-17A is a potent inflammatory mediator, which acts predominantly on epithelial 
cells, B cells, T cells, synovial fibroblasts and vascular endothelial cells (Hwang 
et al., 2004), (Ouyang et al., 2008) IL-17A is known to be important in protection 
against fungal and bacterial infections e.g. Candida albiocans (Conti et al., 
2009) and Klebsiella pneumoniae (Happel et al., 2003). IL-17A functions to 
strengthen epithelial tight junctions in the gut (Kinugasa et al., 2000), which 
suggest that IL-17A is important for immune defence at mucosal surfaces. In 
the context of arthritis, IL-17A has been shown to be important for the 
production of RANKL, which contributes to the formation of bony erosions, as 
well as the induction of pro-inflammatory cytokine secretion from monocytes 
and synovial fibroblasts (Chabaud et al., 2001). 
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1.2.4.2 IL-22 
 
The functions of IL-22 are diverse and appear to be context dependent (Wolk et 
al., 2004). IL-22 plays important roles in promoting defence mechanisms by 
strengthening epithelial barrier functions, in wound healing and in supporting 
tissue homeostasis (Boniface et al., 2005, Nikoopour et al., 2014). On the other 
hand, IL-22 can also play an inflammatory role; chronic IL-22 exposure can lead 
to pathology. In this context, IL-22 has been shown induce epithelial hypoplasia 
in psoriasis, and increased serum levels have been associated with poorer 
prognosis in rheumatoid arthritis where it acts to induce release of inflammatory 
cytokines by synovial fibroblasts (Ikeuchi et al., 2005, Leipe et al., 2011).  
 
IL-22 belongs to the IL-10 family of cytokines and signals through a receptor 
composed of two subunits; the IL-10R2 and IL-22R1(Xie et al., 2000). IL-22 
signalling downstream of the receptor is STAT3 dependent.  IL-22 acts 
predominantly on non-immune cells such as epithelial cells and hepatocytes 
rather than leukocytes(Nagalakshmi et al., 2004).  
 
Members of both the innate and adaptive immune systems express IL-22, 
although it is most commonly associated with T cells and more specifically; 
Th17 cells (Liang et al., 2006). However, while the association of IL-17 and IL-
22 production by T cells is strong in the mouse, the association is much weaker 
in humans, where only 10-15% IL-22 producing CD4 T cells co-express IL-17, 
supporting the existence of a separate Th22 subset in humans (Eyerich et al., 
2009). In humans, IL-22-producing CD4 T cells are primed by IL-6 and TNFα 
and express only low levels of RORC, however additional culture with IL-1β is 
shown to induce IL-17A production demonstrating significant plasticity between 
these two subsets (Bachmann et al., 2010). Another significant source of IL-22 
are ILC. Unlike T cells, ILC expressing RORC commonly co-express IL-17 and 
IL-22, although IL-22 single producing ILC also exist (Hazenberg and Spits, 
2014a).  
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1.2.4.3 Granulocyte-macrophage colony stimulating factor (GM-CSF) 
 
GM-CSF is a pro-inflammatory cytokine now associated with pathogenic Th17 
cells (El-Behi et al., 2011). GM-CSF is produced by a number of cell types in 
addition to T cells including; monocytes, fibroblasts and endothelial cells 
(Burgess et al., 1977, Blanchard et al., 1991). GM-CSF signals through a 
heterodimeric receptor (GM-CSFR) composed of a specific α-subunit and 
signal-transducing β-subunit. Downstream of the receptor, signalling activates 
JAK2 and STAT5. The GMSCF receptor is predominantly expressed on DC and 
monocytes as well as other myeloid cells(Matsuguchi et al., 1998).  
 
The primary role of GM-CSF is as a growth factor, pivotal for the differentiation 
of myeloid cells, including CD103+mDC (King et al., 2010). More recently, GM-
CSF has also been implicated in mediating inflammation. GM-CSF is thought to 
influence the inflammatory activity of neutrophils by inducing formation of 
neutrophil extracellular traps (NETs) and is also shown to promote the 
differentiation of inflammatory macrophages (Akagawa et al., 2006, Yousefi et 
al., 2009, Rasouli et al., 2015). In murine models of inflammatory arthritis and 
multiple sclerosis (MS), GM-CSF has been shown to be crucial for disease 
development as GM-CSF-knock out animals were resistant to disease 
induction(Codarri et al., 2011).  The precise role for GM-CSF in human 
inflammatory disease has not been well explored. However, recent studies have 
identified expansions of GM-CSF-positive T cells at the inflamed site in 
rheumatoid arthritis, oligo-JIA and MS, where expression overlapped 
significantly with IL-17A production (Piper et al., 2014b). GM-CSF blockade is 
now also in trials for the treatment of rheumatoid arthritis and early reports have 
shown promise (Burmester et al., 2017). 
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1.3 Aims of this thesis 
 
While a Th17 phenotype has been described in other subtypes of JIA, little is 
known about the immune pathology of ERA JIA. This thesis investigates the 
role of IL-17-producing immune cells in disease pathogenesis, comparing the 
ERA subtypes to other subtypes of JIA, and with a specific focus on T cells and 
innate lymphoid cells.  
 
To begin these analyses, this thesis will: 
1. Examine cytokine production by T cells within the PBMC and SFMC from 
JIA patients and healthy controls. 
2. Explore the ILC signature at the inflamed site in JIA patients.  
3. Investigate the mechanisms by which ILC are selectively recruited to and 
maintained within the joints of JIA patients.  
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2  : Materials and Methods 
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2.1 Sample preparation  
 
2.1.1 Sample collection  
 
Children with all clinical subtypes of JIA, diagnosed according to International 
League of Associations for Rheumatology; ILAR; (Petty et al., 2004), were 
recruited to an on-going study investigating the pathogenesis of JIA (95RU04). 
Informed parental consent and age-appropriate assent were obtained. Patient 
and control demographics and clinical details are listed in Table 2.1.  
 
Synovial fluid (SF) was aspirated from the joints of JIA patients at the time of 
therapeutic intra-articular steroid injections. A small volume of extra peripheral 
blood was collected for research purposes when routine clinical blood tests 
were carried out. Blood samples were also obtained from healthy children and 
teenagers at local schools as part of a public involvement program instigated by 
the Arthritis Research Centre for Adolescent Rheumatology. In addition, 
peripheral blood samples from adult healthy volunteers at UCL GOS ICH with 
full informed consent were also obtained. All samples were anonymised by the 
allocation of codes with specific prefixes according to healthy status or JIA 
subtype, or CW for healthy child, AW for healthy adult. Informed consent was 
obtained from each patient and healthy control in accordance with the local 
ethics approval committee of Great Ormond Street Hospital and the Institute of 
Child Health (ref. 95RU04 and 07RU01).  
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Table 2.1 Clinical details of JIA patients recruited to this study 
 
2.1.2 Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
 
Peripheral blood was collected into sterile universals containing 35μl 
preservative-free sodium heparin (PFH) (Sigma). Samples were processed in a 
sterile fume hood within 4 hours of collection using sterile, endotoxin- free 
reagents and tissue culture grade plastics. An equal volume of RPMI 1640 
!
 Adult 
healthy 
control 
(n=20) 
Child 
healthy 
control 
(n=4) 
Oligo-
arthritis 
 
(n=47) 
Polyarticular 
arthritis 
 
(n=7) 
Enthesitis 
related 
arthritis 
(n=42) 
Psoriatic 
arthritis 
 
(n=5) 
No. male/female 8/12 4/0 10/37 3/4 41/1 2/3 
Age at sampling 
(years), median 
(IQR) 
26.15 
(23.97- 
30.36) 
6.24 
(5.48 – 
8.31) 
8.45 
(5.70 – 
10.66) 
11.22 
(8.74 – 13.66) 
13.22 (11.71 
– 15.42) 
13.52 (12.11 
– 14.29) 
Age at disease 
onset (years), 
median (IQR) 
n/a n/a 3.27  
(1.68 – 
5.68) 
2.42  
(1.89 – 6.09) 
10.00  
(7.87 – 
12.38) 
10.97  
(8.93 – 
10.97) 
Treatment 
received within 
preceding 6 
months of 
sample: MTX (%) 
n/a n/a 16/47  
(34.04%) 
6/7   
(85.71%) 
25/42  
(59.51%) 
3/5   
(60%) 
Treatment 
received within 
preceding 6 
months of 
sample:  
Biological 
therapy (%) 
n/a n/a 0/47 
(0%) 
1/7  
(14.29%) 
1/42   
(2.38%) 
0/5 
(0%) 
No. of 
swollen/tender 
joints involved 
at time of 
sampling,  
median (IQR) 
n/a n/a 1  
(1 -2) 
3.5  
(1.5 – 4.75) 
2  
(1 -3) 
2  
(2 – 3.5) 
ESR   mm/hr at 
time of 
sampling, 
median (IQR) 
n/a n/a 27  
(12.5 – 
52.5) 
86  
(72 – 94) 
32  
(15.5 - 50) 
16  
(14 – 25.5) 
HLA-B27+ (%) n/a n/a n/a n/a 33/42  
(78.57 %) 
 
n/a 
RF + (%) n/a n/a n/a 2/7   
(28.6%) 
 
n/a n/a 
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medium supplemented with Penicillin (100units/ml) and Streptomycin 
(100μg/ml) (RPMI) (all Gibco) was added to the blood sample.  In the ratio of 
2:1, the diluted blood was gently layered onto lymphoprep (Axis-Shield) for 
density centrifugation. To ensure minimal mixing of the layers, samples were 
centrifuged (800g for 20 minutes) with no brake. The PBMC-containing layer at 
the interface of the blood and lymphoprep was carefully aspirated, added to an 
equal volume of RPMI containing 10% foetal calf serum (FCS) in RPMI 
(10%RPMI), and centrifuged (500g for 10 minutes). The supernatant was 
discarded and the cell pellet was resuspended in 10% RPMI. A 10μl aliquot was 
removed for cell counting. Finally the cells were centrifuged (300g for 7 minutes) 
and frozen at -80°C and then stored in liquid nitrogen (see below) until required. 
 
2.1.3 Isolation of Synovial Fluid Mononuclear Cells (SFMC) 
 
Synovial fluid was diluted in an equal volume of pre-warmed 10% RPMI, and 
hyaluronidase (Sigma) was added to a final concentration of 10U/ml. This 
mixture was incubated at 37°C for 30 minutes to reduce the viscosity of synovial 
fluid and prevent cells clumping. The SF mix was then carefully layered onto 
lymphoprep and SFMC were isolated following the same protocol as described 
for PBMC isolation. 
 
2.1.4 Counting viable cells 
 
To quantify viable cells, an aliquot of the cell suspension was diluted in an equal 
volume of 0.4% Trypan blue (Sigma). After mixing, 10μl was transferred to a 
Neubauer counting chamber and viable cells were counted. Dead cells (stain 
blue due to dye influx) were also counted for sample viability calculation. 
Samples with less than 90% viable cells were discarded. To enumerate live 
cells in a sample the following formula was employed:  
 
Number of cells counted in 25 square box x 2 (dilution factor) x total volume of 
cell suspension (ml) x 104 (factor for counting chamber) = Total viable cell 
number.  
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2.1.5 Freezing and thawing of cells 
 
To freeze isolated PBMC/SFMC: the cell suspension was centrifuged (300g for 
7 mins) as described in 2.1.2. The cell pellet was carefully resuspended in 
filtered freezing medium (10% DMSO, 90% FCS) at a final concentration of 
10x106 cells per ml freezing medium. The cells were then aliquoted into 
cryovials (NUNC) and slowly frozen to -80°C in a freezing pot containing 
isopropanol (Nalgene), allowing a typical temperature drop of 1°C per hour. The 
next day samples were transferred to liquid nitrogen.  
 
To thaw:  cryo-preserved PBMC/SFMC were retrieved from liquid nitrogen and 
rapidly thawed in a water bath at 37°C. The thawed cells were added to pre-
warmed 10%RMPI. An aliquot was taken for cell enumeration, and the 
remaining mixture was centrifuged (300g for 7 minutes). Finally, the cell pellet 
was carefully resuspended in an appropriate volume of the appropriate medium 
for subsequent use.  
 
2.1.6 Serum and plasma preparation  
 
For serum samples and equivalent synovial fluid samples, 1ml venous blood or 
synovial fluid was collected into a sterile plastic tube without anticoagulant. The 
sample was left for 30 minutes to clot and subsequently spun for 10 minutes at 
10,000 rpm in the microfuge. The supernatant was collected, aliquoted, and 
frozen at -80°C for subsequent use.  
 
For plasma samples, and equivalent synovial fluid samples, 1ml venous blood 
or synovial fluid was collected into a sterile plastic tube containing EDTA as 
anticoagulant. The blood/synovial fluid was transferred to an Eppendorf tube 
and spun in the microfuge for 10 minutes at 1,000rpm. The supernatant was 
transferred to a clean Eppendorf tube and spun for a further 10 minutes at 
10,000 RPM. The supernatant was collected, aliquoted and frozen at -80°C for 
subsequent use. 
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2.2 Multiplex cytokine analysis by Luminex 
 
Multiplex cytokine analysis by Luminex analysis of JIA serum samples and JIA 
SF samples and pools was conducted in Dr de Jager’s group at the University 
of Utrecht.  
 
2.3 Flow Cytometry 
 
2.3.1 Antibodies used  
 
Monoclonal antibodies directly conjugated to fluorescent dyes and polyclonal 
biotinylated antibodies used in this study are listed in Table 2.2.  All new 
antibodies were titrated to identify the optimal concentration for use. All 
antibodies used were raised in mouse against human epitopes.  
 
Antibody 
specificity/ 
reagent 
Fluorochrome Supplier Clone Dilution 
Aldefluor FITC channel Stem Cell Technologies n/a 5ul/ reaction 
BDCA1 BV421 BioLegend L161 1 in 50 
BDCA2 FITC MILTENYI n/a 1 in 50 
BDCA2 PE BioLegend 201A 1 in 50 
BDCA3 BV510 BioLegend 1A4 1 in 50 
C-KIT BV421 BioLegend 104D2 1 in 25 
CCR4 BV510 BioLegend L291H4 1 in 25 
CCR5 PerCP-Cy5.5 BioLegend n/a 1 in 25 
CCR6 BV510 BioLegend n/a 1 in 25 
CD103 APC BioLegend n/a 1 in 50 
CD11C BV421 BioLegend 3.9 1 in 50 
CD11C PE BioLegend 3.9 1 in 50 
CD11C PE-CY7 BioLegend n/a 1 in 50 
CD123 PE BioLegend 6H6 1 in 50 
CD123 BV605 BioLegend 6H6 1 in 25 
CD127 FITC eBiosciences EBIORDR5 1 in 25 
CD127 BV711 BioLegend A019D5 1 in 25 
CD13 FITC BD Biosciences WM15 1 in 50 
CD14 FITC eBiosciences 61D3 1 in 200 
CD14 PE BioLegend HCD14 1 in 50 
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CD16 PE eBiosciences B73.1 1 in 100 
CD161 APC eBiosciences HP-3G10 1 in 25 
CD161 BV605 BioLegend HP-3G10 1 in 25 
CD161 PECY7 eBiosciences HP-3G10 1 in 25 
CD161 BV421 BioLegend n/a 1 in 25 
CD19 PE BioLegend HIB19 1 in 25 
CD19 PE-CY7 eBiosciences SJ25C1 1 in 50 
CD1A PE eBiosciences H149 1 in 50 
CD25 PE BD Biosciences MA251 1 in 25 
CD25 BV421 BioLegend MA251 1 in 25 
CD3 PE BioLegend UCHT1 1 in 50 
CD3 PerCP-Cy5.5 eBiosciences OKT3 1 in 50 
CD3 V500 BD Biosciences UCHT1 1 in 25 
CD3 BV605 BioLegend OKT3 1 in 50 
CD3 BV711 BioLegend n/a 1 in 50 
CD34 PE BioLegend 561 1 in 50 
CD4 BV711 BioLegend OKT4 1 in 50 
CD45 BV421 BioLegend HI30 1 in 200 
CD45 PE-CY7 BioLegend HI30 1 in 100 
CD45RA FITC eBiosciences HI100 1 in 50 
CD45RO PE-CY7 BioLegend UCHL1 1 in 25 
CD45RO APC eBiosciences UCHL1 1 in 50 
CD49D PerCP-Cy5.5 BioLegend 9F10 1 in 25 
CD56 PERCP-CY5.5 BioLegend HCD56 1 in 50 
CD56 PE eBiosciences CMSSB 1 in 25 
CD8a FITC BD Biosciences SK1 1 in 50 
CD8a APC eBiosciences SK1 1 in 200 
CD94 PE BioLegend DX22 1 in 50 
CRTH2 FITC BioLegend BM16 1 in 25 
CXCR3 PerCP-Cy5.5 BioLegend G025H7 1 in 25 
DAPI DAPI SIGMA n/a 1 in 500 
FCeR1 PE BioLegend AER-37 1 in 100 
FOXP3 APC eBiosciences 236A/E7 1 in 25 
GMCSF PE BD Biosciences n/a 1 in 25 
HLA-DR BV510 BioLegend L243 1 in 50 
IFNγ V500 BD Biosciences B27 1 in 50 
IL-17A V450 BD Biosciences N49-653 1 in 25 
IL-2 PE-CY7 BioLegend MQ1-17H12 1 in 100 
IL-22 PE BioLegend BG/IL22 1 in 10 
IL-22 PE-CY7 eBiosciences 22URTI 1 in 25 
IL-23R APC R&D Systems n/a 1 in 25 
IL-23R Biotin R&D Systems Polyclonal 1 in 10 
IL13 APC BioLegend JES10-582 1 in 100 
IL17A BV605 BioLegend BL168 1 in 25 
KI67 FITC eBiosciences 20RAJ1 1 in 25 
KI67 PerCP-Cy5.5 eBiosciences 20RAJ1 1 in 25 
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LIVEDEAD 
BLUE DAPI channel 
Life 
Technologies n/a 1 in 250 
NKP44 APC BioLegend P44-8 1 in 25 
NKP46 PE-CY7 BioLegend 9 e2 1 in 25 
PERFORIN FITC BioLegend DG9 1 in 50 
RORC APC eBiosciences AFKJS-9 1 in 10 
Streptavidin BV421 BioLegend n/a 1 in 100 
Streptavidin FITC BD Biosciences n/a 1 in 50 
TBET BV711 BioLegend 4B10 1 in 25 
TCRαβ PE BD Biosciences n/a 1 in 25 
TCRγδ PE BD Biosciences n/a 1 in 25 
Table 2.2 Antibodies and staining reagents employed in this thesis.  
 
2.3.2 Surface staining for analysis by flow cytometry 
 
Ex vivo or cultured cells were counted and centrifuged (300g for 7 minutes), and 
cell pellet resuspended in 10%RPMI at a concentration of 1-5 x 106 cells/ml. 
100μl of the cell suspension was then plated into wells of a round-bottomed 96 
well plate (Thermofisher). For cell concentrations <1x106/ml, cells were plated 
into a V-bottomed plate (Thermofisher). The 96-well plates were then 
centrifuged (300g for 3 minutes) and the supernatant was removed by flicking. 
Monoclonal antibodies to the surface epitopes of interest were diluted in FACS 
buffer (1 x phosphate-buffered saline (PBS) (Gibco) containing 1%FCS and 
0.1%sodium azide) and 25μl of antibody mix was added to each of the relevant 
wells. The plate was then incubated in the dark for 30 minutes at 4°C. 200μl 
FACS buffer was then added to each well and the plate was centrifuged to wash 
the cells. Finally the cell pellets were resuspended in 200μl FACS buffer and 
transferred to FACS tubes (Greiner Bio-One Ltd) and DAPI (Sigma) was added 
just before cells were acquired on the LSRII flow cytometer (BD Biosciences). 
 
 
 
2.3.3 Intracellular and cytokine staining  
 
As described, washed cells were resuspended in 10% RPMI and seeded onto a 
96 well plate. To investigate cytokine stimulation, cells were incubated at 37°C 
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and 5% CO2 for 4 hours with phorbol myristate acetate (PMA) (50ng/ml) 
(Sigma-Aldrich), Ionomycin (500ng/ml) (Sigma-Aldrich) and Brefeldin A (5μg/ml) 
(Sigma-Aldrich). The cells were then washed in 1 x PBS. The cell pellets were 
subsequently resuspended in Live/Dead fixable blue dead cell stain (Life 
Technologies), which was first diluted 1 in 250 in 1 x PBS, and incubated in the 
dark for 30 minutes at 4°C. Following incubation, the cells were washed in 
FACS buffer and surface markers were stained as described. After staining, the 
cells were washed with FACS buffer and the cell pellet was resuspended in 
100μl Fixation and Permeabilization (Fix/Perm) buffer (1 part fix/perm 
concentrate, 3 parts fix/perm diluent) (eBiosciences) and incubated in the dark 
for 45 minutes at 4°C. The cells were then washed in 1 x permeabilization 
(perm) buffer (eBiosciences). Monoclonal antibodies to the intracellular epitopes 
of interest were diluted in perm buffer and 25μl of antibody mix was added to 
each of the relevant wells. The plate was incubated in the dark for 45 minutes at 
4°C. The cells were washed in FACS buffer and the cell pellet was resuspended 
in FACS buffer ready to be acquired on the LSRII flow cytometer. 
 
2.3.4 Analysis of flow cytometry data collected on the LSRII 
 
Data were collected in the LSRII flow cytometer (BD). Maximal events were 
collected from each sample. Compensation and subsequent analysis was 
carried out using FlowJo version 10.1 (Treestar Inc.). 
 
2.3.5 Multispectral imaging flow cytometric analysis (ImageStream) 
 
Cells were stained as described above. After fixation, cells were resuspended at 
1x107 cells/ml in FACS buffer. Cells were acquired on the ImagestreamX Mark II 
(Merck Millipore) fitted with 405nm, 488nm and 642nm lasers. Analysis was 
carried out on the ImagestreamX Mark II instrument.  
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2.4 Cell sorting 
 
2.4.1 CD3 depletion by magnetic bead cell sorting  
 
For ILC isolation, total PBMC and SFMC were first depleted of T cells using 
EasySep CD3 positive selection kit (StemCell Technologies) according to the 
manufacturer’s instructions. Samples were thawed, counted and resuspended 
in sort buffer (1xPBS supplemented with 2% FCS and 4mM EDTA) at a 
concentration of 1 x 108 cells/ml.   The cell suspension was transferred to a 5ml 
polystyrene FACS tube (BD Biosciences), and positive selection CD3 antibody 
cocktail (100μl/ml cells) was added. Following 15 minute incubation at room 
temperature (RT), magnetic nanoparticles were added (50μl/ml cells) and 
mixture was incubated for a further 10 minutes at RT. The mixture was then 
topped up to 2.5ml with sort buffer and placed into the EasySep magnet for 5 
minutes. The supernatant (CD3 negative fraction) was carefully poured into a 
15ml falcon tube while the tube remained in the magnet. To ensure maximum 
yield the tube was washed twice. For this, the tube was topped up with 2.5ml 
sort buffer and placed in the magnet for a further 5 minutes before the 
supernatant was removed.  Finally the cells were counted as described above.  
 
2.4.2 Dendritic cell negative selection by magnetic bead cell sorting 
 
Myeloid dendritic cells (mDC) were isolated from total PBMC using EasySep 
Myeloid DC enrichment kit (StemCell Technologies) according to the 
manufacturer’s instructions. Samples were thawed, counted and resuspended 
in sort buffer at a concentration of 5 x 107 cells/ml. The cell suspension was 
transferred to a 5ml polystyrene FACS tube (BD Biosciences), and the FcR 
blocker was added (15μl/ml cells). The enrichment cocktail was added to the 
sample (50 μl/ml cells), and the mixture was incubated for 30 minutes at RT. 
Magnetic nanoparticles were then added (100μl/ml cells) and mixture was 
incubated for a 10 minutes at RT. The mixture was then topped up to 2.5ml with 
sort buffer and placed into the EasySep magnet for 5 minutes. Picking up the 
magnet, in one continuous movement, the supernatant (mDC enriched fraction) 
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was carefully poured into a new 5ml polystyrene tube. To ensure maximum 
purity, the new tube, containing the enriched mDC suspension was then placed 
in the magnet for further 5 minutes. Finally, the supernatant was poured off as 
before and the cells were counted.  
 
2.4.3 Fluorescent Activated Cell Sorting (FACS) using FACSAriaIII (BD) 
 
Antibody mixes were made up at the appropriate dilutions in sort buffer. CD3 
depleted, or total PBMC/SFMC were resuspended in the antibody mix to a final 
concentration of 10x106 cells per 100μl antibody mix, and incubated in the dark 
for 30 minutes at 4°C. The cells were washed in sort buffer and resuspended in 
sort buffer at ~30x106 cells per ml. The cell suspension was filtered through a 
50μm filter before sorting. Sorted cells were collected into an Eppendorf 
containing RPMI supplemented with 20% FCS.  
ILC were sorted as: CD45+lineage-CD127+CD161+ 
Naïve CD4+ T cells were sorted as: CD4+CD25-CD45RO- 
mDC were sorted as: CD3-CD19-CD56-CD14-CD11c+ 
Purity of all samples was assessed post sort.  For ILC purity, an aliquot of cells 
(~20μl) was taken from the collection Eppendorf tube and immediately run back 
through the FACSAriaIII to ensure no lineage+ cells had been collected. 1000 
sorted ILC were also stained for ILC subtype specific markers (CRTH2, c-Kit 
and NKp44) to ensure that the sorting process did not affect expression 
compared to pre-sort samples.  
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2.5 Gene expression by quantitative polymerase chain 
reaction (qPCR)  
 
2.5.1 RNA extraction 
 
Total cellular RNA was extracted using the Arcturus Picopure RNA isolation kit 
(Life Technologies) in accordance with the manufacturer’s instructions. RNA 
was extracted from sorted cell samples within 1 hour of sorting and stored in 
Picopure extraction buffer at -80°C until required. RNA was isolated from the 
frozen samples using spin columns, and DNA was removed by treatment with 
DNase as per the manufacturer’s protocol. RNA absorbance at 260nm was 
measured to ascertain yield and purity using the NanoDrop 1000 
Spectrophotometer and 260:280 ratio > 1.75 was deemed acceptable (Thermo 
Scientific) Since very low cell numbers of ILC were likely to be sorted from JIA 
PBMC and SFMC, the Picopure protocol was first validated to ensure RNA 
purity would be maintained for very low cell numbers. RNA was extracted from 
1x105, 0.5x105, 2.5x104 and 1.25x104 total PBMC, yield and purity remained 
high at the lowest cell concentration (Figure 2.1). Since the number of ILC 
sorted from JIA PBMC and SFMC fell within the validated range, Picopure was 
considered a suitable method for RNA extraction. 
 
2.5.2 cDNA synthesis 
 
For initial analyses of ILC signature cytokines and transcription factors, RNA 
was converted to cDNA for use in subsequent qPCR reactions. Random 
hexamers (90ng/μl) (Invitrogen) were added to the isolated RNA as primers for 
cDNA synthesis. The mixture was incubated for 10 minutes at 37°C and then 
cooled on ice. 8.5μl of the master mix (4μl-5x First strand B°; 2μl-0.1M DTT; 
1μl-10mM dNTPs; 1μl-RNase OUT; 0.5μl- Superscript RT) was added to the 
RNA/hexamer mix. This was then incubated for 10 minutes at RT, followed by 
60 minutes at 42°C and finally 10 minutes at 72°C.  20μl H2O was added and 
the resulting cDNA was stored at -80°C until use.  
 
 66 
For qPCR analysis of mDC cytokine gene expression (IL1B, IL6 and IL23A), 
and expression of aldehyde dehydrogenase (ALDH) genes (ALDH1A1, 
ALDH1A2 and ALDH1A3) and ILC expression retinoic acid receptor genes 
(RARA, RARB and RARG), RNA was extracted from FACS sorted cells using 
the Picopure protocol as described above. The RNA was subsequently 
converted to cDNA using iSCRIPT cDNA synthesis kit (Bio-Rad) according to 
the manufacturer’s instructions. Following synthesis, cDNA was stored at -80°C 
until use. 
 
 
 
Figure 2.1 Optimisation of RNA extraction for very low cell numbers.  
(A) RNA yield (ng) from samples of varying cell number ranging from 100K to 12.5K 
PBMC (B) NanoDrop analysis of RNA quality with decreasing cell number. (C) 
Summary of RNA quality achieved from varying cell number. Upper and lower bounds 
represent the highest and lowest number of ILCs FACS sorted. 
A" RNA yield Pico Pure
0 50 150Lower Upper
0
50
100
150
Yi
el
d 
(n
g)
Cells (K)
B"
1x105%cells%
0.5%x%105%cells%
2.5%x%104%cells%
1.25%x%104%cells%
C" RNA purity Pico Pure
0 50 150Lower Upper
0.0
0.5
1.0
1.5
2.0
2.5
Cells (K)
26
0/
28
0
 67 
2.5.3 qPCR 
 
Quiagen Quantitect validated primers were used for some analyses. 
Alternatively, primers were chosen from publications and ordered specifically 
(see Table 2.3); specificity for the gene of interest was verified using primer 
BLAST software, custom made (Life Technologies) and validated for specificity 
through the analysis of melt curves generated following PCR amplification using 
SYBR Green Mastermix (BioRad) on the Rotor-gene 6000 Corbert thermocycler 
(Qiagen). Each primer generated a single peak and the predicted size was 
confirmed by electrophoresis on a 1% agarose get in TRIS-EDTA buffer (Figure 
2.2).  
 
To make the gel, 1g of pure agarose was added to 100ml of 1xTRIS-EDTA 
buffer and melted in a microwave for 3 minutes on high setting. The high 
temperature allowed the agarose to dissolve, and the mixture was left for 5 
minutes to cool. Once cooled, 5μl GelRed (Biotum) was added and the mixture 
was carefully poured into an appropriate gel tray.  Samples were routinely 
prepared as follows: 
 
Samples: 2μl test DNA + 1μl loading buffer II (New England Biolabs) + 3μl 
nuclease free water. 5μl 100bp ladder (New England Biolabs) + 1μl loading 
bufferII (Ambion) was run in parallel at 150V for 30 minutes.  
 
The reaction mix consisted of: 
10μL 2XSYBR Green Mastermix 
6 μL DNase-free water, 
1 μL forward primer at 10μM (500 nM final concentration) 
1 μL reverse primer at 10μM (500 nM final concentration) 
2μl cDNA template or H20 for no template control (NTC) 
20μL Final Volume 
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The cycling conditions were: 
95°C 5 mins 
Followed by 40 cycles of: 
95°C 30s 
60°C 30s 
72°C 30s 
 
For the analysis of signature ILC cytokines and transcription factors, standard 
curves were generated from polarized T-cells, and used to quantify gene 
expression. For the analysis of mDC cytokines, mDC were isolated from healthy 
control PBMC and subsequently stimulated with LPS (100ng/ml for 15 hours). 
Post-stimulation, increased cytokine expression allowed the extraction of 
cytokine RNA and cDNA. This cDNA served as a template for the generation of 
cytokine-specific standard curve(s). To control for inter-PCR run variation, one 
point on the standard curve was included in each PCR run in order to calibrate 
the imported standard curve. This gave a value in arbitrary units (AU) for 
expression of each gene. Expression was calculated relative to housekeeping 
gene ACTB (beta-actin) by dividing through the ‘gene of interest’ expression in 
AU by ACTB expression.  
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Gene 
Primer 
Sequences 5’-
3’ 
Annealing 
Temp (°C) 
Amplicon 
Size (bp) 
Efficien
cy (%) Supplier 
ACTB 
F 
AGATGAC
CCAGATCA
TGTTTGAG 
60 187 91 
Life 
Technologies 
R 
AGGTCCA
GACGCAG
GATG 
TBX21 
F 
CCCCAAG
GAATTGAC
AGTTG 60 337 92 
Life 
Technologies 
R 
GGGAAAC
TAAAGCTC
ACAAAC 
IFNG 
F 
TGACCAG
AGCATCCA
AAAGA 60 236 95 
Life 
Technologies 
R 
CTCTTCGA
CCTCGAAA
CAGC 
GATA3 
F 
ACCACAAC
CACACTCT
GGAGGA 60 132 102 
Life 
Technologies 
R 
TCGGTTTC
TGGTCTG
GATGCCT 
IL13 
F 
ATTGCTCT
CACTTGCC
TTGG 60 152 81 
Life 
Technologies 
R 
GTCAGGTT
GATGCTC
CATACC 
RORC 
F 
AATCTGGA
GCTGGCC
TTTCA 60 129 98 
Life 
Technologies 
R 
CTGGAAG
ATCTGCAG
CCTTT 
AHR 
F 
CTTAGGCT
CAGCGTC
AGTTA 60 130 101 
Life 
Technologies 
R 
GTAAGTTC
AGGCCTT
CTCTG 
IL17A 
F 
AATCTCCA
CCGCAAT
GAGGA 60 95 97 
Life 
Technologies 
R 
ACGTTCCC
ATCAGCGT
TGA 
IL22 F CCCATCAGCTCCCA 60 257 88 
Life 
Technologies 
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Table 2.3 Primer pairs utilized in qPCR assays 
 
CTGC 
R 
GGCACCA
CCTCCTG
CATATA 
RARA n/a 60 148 97 Qiagen 
RARB n/a 60 118 n/a Qiagen 
RARG n/a 60 147 n/a Qiagen 
IL6 n/a 60 107 81 Qiagen 
IL23A n/a 60 149 71 Qiagen 
IL1B n/a 60 117 85 Qiagen 
ALDH1A1 n/a 60 97 73 Qiagen 
ALDH1A2 n/a 60 80 111 Qiagen 
ALDH1A3 n/a 60 125 n/a Qiagen 
GAPDH n/a 60 119 93 Qiagen 
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Figure 2.2 Optimisation of custom made primers for ILC qPCR  
Example of optimisation procedure for IFNG (A) Template titration; each curve 
represents PCR reaction with defined template (B) Standard curve generated from 
titration data shown in A (C) Representative melt curve. (D) Product size confirmation 
by agarose- gel electrophoresis (E) Reactions run with no template. Gel band sizes 
confirmed using ladder (lanes 1 and 12 on each gel). Lanes show amplification 
products for: Lane 2- ACTB; lane 3- GAPDH; lane 4-TBX21 (Tbet); lane 5- RORC; lane 
6- GATA3; lane 7- AHR; lane 8- IFNG (IFNγ); lane 9 – IL-13; lane 10 – IL-17A; lane 11- 
IL-22.  
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2.6 Cell culture  
 
2.6.1 T cell polarization 
 
FACS sorted naïve CD4+ T cells (CD4+CD21-CD45RO-) from healthy adult 
PBMC (sorted sample >98% pure) were seeded onto a 96-well round bottom 
plate coated with 1μg/ml anti-CD3 (R&D systems) and 5μg/ml anti-CD28 (BD 
Pharmingen) and incubated for 4 days (37°C and 5% CO2) with skewing 
cytokines. For skewing towards different T cell subsets, the cultures were 
supplemented with the following recombinant human cytokines (Peprotech Ltd)  
Th1 – IL-12 (10ng/ml final concentration) 
Th2 – IL-4 (50ng/ml final concentration) 
Th17 – TGF-β (10ng/ml final concentration), IL-6 (20ng/ml final concentration), 
IL-1β (10ng/ml final concentration), IL-23 (100ng/ml final concentration) 
 
Effective polarization of T cell subsets was confirmed by flow cytometry analysis 
and verified by amplification of transcripts for canonical transcription factors and 
cytokines following the protocol detailed above and normalized to ACTB using 
delta CT (Figure 2.3).  
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Figure 2.3 Relative expression of mRNA transcripts for selected signature 
genes in Th1, Th2 and Th17 polarised cells.  
RNA and cDNA were prepared from 4-day polarised CD4+CD25-CD45RO- FACS 
sorted T-cells. Cells were cultured in IL-12 for Th1, IL-4 for Th2 and TGFβ, IL-6, IL-1β 
and IL-23 for Th17 polarising conditions.  Relative expression in Th1 polarised, Th2 
polarised and Th17 polarised cells as shown, of mRNA for (A) TXB21 (B) GATA3 (C) 
RORC (D) AHR (E) IFNG (F) IL-13 (G) IL-17A and (H) IL-22. Each bar represents the 
mean value of duplicate wells run and expressed relative to the ACTB control. 
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2.6.2 LPS mediated mDC stimulation 
 
FACS sorted mDC (CD14-CD11c+) (1x105cells/well) were cultured overnight in 
10% RPMI supplemented with LPS (100ng/ml, 15 hours). After overnight 
culture, cells were washed with 10% RPMI and RNA was extracted following the 
Picopure protocol as described above.   
 
2.6.3 ILC activation culture for cytokine analysis 
 
FACS sorted ILC were seeded into a 96 well plate (2000 cells/well) in 10%RPMI 
medium, supplemented with recombinant human IL-2 (0.5ng/ml) (Peprotech) 
plus skewing cytokines or 10-50% SF serum. For specific activation of different 
ILC subsets, the cultures were additionally supplemented with the following 
cytokines (all 50ng/ml final concentration): 
 
ILC1 – IL-12, IL-18 
ILC2 – Thymic stromal lymphopoietin (TSLP), IL-25, IL-33 
ILC3 – IL-23, IL-1β      
 
Following 4 days incubation (37°C and 5% CO2), the cells were washed once 
with 10% RPMI and cytokines were stained as previously described. 
 
2.6.4 ILC skewing assays 
 
FACS sorted ILC were seeded into a 96 well plate in Yessel’s medium 
supplemented with 1% human AB serum (Gemino Bio-products) and IL-2 
(50ng/ml) with IL-6 (50ng/ml), SF (50%) or all-trans retinoic acid (RA) (1μM; 
Sigma-Aldrich) in the presence or absence of the subtype specific skewing 
cytokines (all 50ng/ml final concentration) described above.  Following 7 days 
incubation (37°C and 5% CO2), the cells were washed once with 10%RPMI and 
ILC skewing was assessed by surface marker expression and cytokine 
production.  
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2.7 Aldefluor Assay  
 
Retinoic acid (RA) production by PMBC and SFMC was assessed using the 
Aldefluor kit (StemCell Technologies) as per the manufacturer’s instructions. 
Frozen cells were thawed and resuspended in Aldefluor Assay Buffer (StemCell 
Technologies) at a concentration of 1 x 106 cells/test and the sample was split 
equally between two 1.5ml Eppendorf tubes. To the control tube, 10μl of 
Aldefluor diethylaminobenzaldehyde (DEAB) reagent was added to block 
binding of the aldefluor reagent to ALDH enzymes within the cells, and the 
solution was mixed using a vortex. 5μl of the activated Aldefluor reagent was 
added to each test and control sample. The samples were immediately vortexed 
to mix, and incubated for 45 minutes at 37°C. Next, the samples were 
centrifuged to pellet the cells (300g for 5 minutes) and the supernatant was 
carefully removed. The pellet was finally resuspended in Aldefluor buffer and 
subsequent surface staining was carried out in Aldefluor buffer instead of usual 
FACS buffer.  
 
2.8 Statistical analysis  
 
Statistical analysis was carried out on GraphPad Prism 6. Mean or median 
values are shown on summary plots, and error bars represent standard error of 
the mean (SEM).  Data were considered non-Gaussian and therefore non-
parametric statistical tests were employed. For comparison of two groups 
Mann-Whitney U Tests and for multiple comparison testing, Kruskal-Wallis tests 
were used with Dunn’s multiple comparisons tests. Spearman’s correlation was 
used for analysis of correlations. P values of less than 0.05 were considered 
significant and indicated on graphs as follows: *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001.  
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3 : Defining the T cell signature in ERA 
JIA  
 77 
3.1 Introduction 
 
Given the distinct features and genetic associations of the ERA JIA subtype of 
JIA compared to the other forms of childhood arthritis, discussed in Chapter 1, it 
is likely that distinct mechanisms may play a role in the pathogenesis of this 
form of arthritis. Investigation of the pathogenesis of ERA JIA to date has been 
limited and largely restricted to Asian populations, where the ERA JIA subtype 
of JIA is more prevalent (Agarwal et al., 2008a, Mahendra et al., 2009, Myles 
and Aggarwal, 2011, Myles et al., 2012, Gaur et al., 2015, Gaur et al., 2017). 
These studies have primarily focused on the involvement of innate immune cells 
in particular monocytes and monocyte derived inflammatory mediators (Saxena 
et al., 2005, Agarwal et al., 2009, Myles and Aggarwal, 2011, Myles et al., 
2012). However, initial studies allude to IL-17 production from NK and T cells in 
ERA JIA patients, and a role for IL-17 in disease pathogenesis has been 
suggested, although further analysis is warranted (Mahendra et al., 2009, Gaur 
et al., 2015). 
 
It is well known that T cell immunity plays a key role in the pathogenesis of 
inflammatory arthritis in adults and children (Froland et al., 1973, Nistala and 
Wedderburn, 2009, Nistala et al., 2010b, Omoyinmi et al., 2012, Shabgah et al., 
2014). While relatively little is known about the T cell involvement in ERA JIA, 
biological similarities with other JIA subtypes, or adult spondyloarthropathies 
have been hypothesized. Published reports of T cell derived- IL-17 in 
ankylosing spondylitis (AS), and the clear genetic and clinical parallels between 
adult AS and childhood onset ERA JIA strengthen the hypothesis of potential IL-
17 involvement in ERA JIA (Schlosstein et al., 1973, Newport et al., 2007, 
Wendling et al., 2007, Shen et al., 2009, Chen et al., 2014a). Furthermore, the 
immunophenotype of oligoarticular arthritis has been well investigated and CD4 
T cells producing inflammatory IL-17 have been implicated in disease (Nistala 
and Wedderburn, 2009, Nistala et al., 2010a, Spreafico et al., 2016). It is now 
well established that CD8 and γδ T cell populations can also produce IL-17 
(Walker et al., 2012, Kenna et al., 2012). At present, IL-17-production from 
these T cell populations has not been thoroughly investigated in JIA.  
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Regulatory T cells (Treg) have been extensively studied in JIA, where they are 
shown to have a reciprocal relationship to Th17 cells in oligoarthritis (Nistala 
and Wedderburn, 2009, Olivito et al., 2009). More recently, the presence of 
cytokine producing Treg, which express killer cell lectin-like receptor, CD161 
have been described at the inflamed site (Pesenacker et al., 2013). 
Interestingly, these CD161+Treg express RORC and share significant 
transcriptional homology with Th17 cells (Duurland et al., 2017a). Neither Treg, 
nor CD161+Treg have been examined in the synovial fluid from ERA JIA 
patients from UK cohorts.  
 
Informed by these preliminary studies in ERA JIA, as well as the known 
involvement of the IL-23/IL-17 pathway in AS and other subtypes of JIA, this 
chapter aimed to investigate the T cell profile in the blood and joints of ERA JIA 
patients with a focus on IL-17 and associated cytokines: IFNγ, IL-22 and GM-
CSF. It was hypothesised that poly-functional IL-17-producing T cells would be 
expanded in the synovial fluid of ERA JIA patients in all T cell compartments 
and would be associated with disease severity. In parallel, an expansion of 
CD161+Treg at the inflamed site in ERA JIA patients was also predicted. These 
aims were addressed by: 
 
1. Performing detailed immune cell phenotyping in the PBMC and SFMC 
from JIA patients including a significant cohort of patients with ERA JIA. 
2. Investigating cytokine production, and poly-functionality of CD4, CD8 and 
CD4-CD8- T cells from the blood and synovial fluid from JIA patients,  
3. Probing for associations between IL-17-positive (IL-17+) T cell 
populations and clinical measures of disease severity in ERA JIA. 
4. Analysing Treg populations in the blood and synovial fluid from ERA JIA 
patients. 
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3.2 Results 
 
3.2.1 mDC and CD8+ T cells are enriched in the SFMC of ERA JIA 
patients. 
 
While there are significant published data describing the immune phenotype in 
other subtypes of JIA, there has been limited investigation into the 
immunophenotype in ERA JIA. In order to gain an overview of the immune cells 
at the inflamed site in ERA JIA, multicolour flow cytometry analysis of immune 
cells from within the PBMC and SFMC of ERA JIA patients was carried out and 
results were compared to data from the PBMC and SFMC of other JIA subtypes 
(oligoarticular, polyarticular and psoriatic) and adult and child healthy control 
PBMC.  
 
Following the exclusion of dead cells and doublets (Figure 3.1A), the 
proportions of various mononuclear cell types (monocytes, mDC, B cells, NK 
cells and T cells) were enumerated within the scatter gate in PBMC and SFMC 
from patients (n=16, n=39) and PBMC of adult (n=12) and child (n=3) healthy 
controls. Figure 3.1 shows the gating strategy used for the identification of: 
monocytes (CD14+); mDC (CD14-CD11c+); B cells (CD3-CD19+); NK cells 
(CD3-CD56+); and T cell subpopulations (CD3+CD4+, CD3+CD8+ and 
CD3+CD4-CD8-γδTCR+) in PBMC (Figure 3.1B) and SFMC (Figure 3.1C) from 
a representative ERA JIA patient. Mononuclear cells from synovial fluid are 
typically larger and more granular than cells from PBMC according to forward 
and side scatter (SSC-A) (top left panel from Figures 3.1B and 3.1C).   
 
The summary data for these analyses are detailed in Figure 3.2. While 
significant differences were seen between PBMC and SFMC from JIA patients, 
no significant differences were noted in the immune cell populations as 
proportion of total live cells, within the PBMC between JIA subtypes, or within 
SFMC between JIA subtypes (Figure 3.2A-F). Proportions of monocytes, NK 
cells and CD4 T cells were not significantly different between PBMC and SFMC 
from ERA JIA patients (Figures 3.2A, 3.2D and 3.2E). mDC were significantly 
enriched (p<0.0001) in the SFMC from ERA JIA patients compared to paired 
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PBMC (Figure 3.2B). The role of enriched SFMC mDC is explored in greater 
detail in Chapter 5 of this thesis.  CD8 T cells were also significantly enriched in 
ERA JIA SFMC compared to the PBMC compartment (p=0.048; Figure 3.2F). 
This enrichment was further highlighted when the ratio of CD4:CD8 T cells was 
analysed in the PBMC from aHC and cHC and the PBMC and SFMC from all 
JIA subtypes and from ERA JIA patients. A significant decrease in the T cell 
ratio was seen between PBMC and SFMC in JIA patients, with a median 
CD4:CD8 ratio of 1.02 in the SFMC compared to 1.60 in paired PBMC from 
ERA JIA patients (p<0.001) (Figure 3.2H). Conversely, there was a significant 
reduction of B cells in the SFMC compared to PBMC of ERA JIA patients 
(p<0.0001) (Figure 3.2C). No significant difference was seen in the size of the 
γδ T cell population between PBMC and SFMC from ERA JIA patients, however 
ANOVA analysis revealed γδ T cells were significantly enriched in the SFMC 
compared to PBMC in other JIA subtypes combined (p<0.01) (Figure 3.2G).  
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Figure 3.1 Gating strategy for the identification of immune cell types from 
blood and synovial fluid mononuclear cells from JIA patients and 
controls. 
Representative gating strategy for (A) The exclusion of doublets and dead cells. Data 
generated from 1 adult control PBMC. (B and C) Enumeration of T cells (CD3+CD4+, 
CD3+CD8+ and CD3+CD4-CD8-γδTCR+), B cells (CD3-CD19+), NK cells (CD3-
CD56+), monocytes (CD14+) and mDC (CD14-CD11c+) after exclusion of dead cells 
and doublets, from (B) PBMC and (C) SFMC from a patient with ERA JIA. Black boxes 
represent gates. The numbers show % of events in a specific gate. 
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Figure 3.2 mDC and CD8+ T cells are enriched in the SFMC of ERA JIA 
patients.  
(A-G) Summary plots showing enumeration of immune cell types using gates as shown 
in Figure 3.1 within PBMC of healthy adult (aHC) and child controls (cHC)(n=10, n=3 
respectively) and PBMC and SFMC from ERA-JIA (n=9, n=18), oligo-JIA (n=3, n=12) 
poly-JIA (n=3, n=4) and PsA-JIA patients (n=3, n=4), shown as a percentage of total 
live mononuclear cells for (A) monocytes (CD14+); (B) mDC (CD14-CD11c+); (C) B 
cells (CD3-CD19+);(D) NK cells (CD3-CD56+); (E) CD4 T cells (CD3+CD4+);(F) CD8 T 
cells (CD3+CD8+) and (G) γδ T cells (CD3+CD4-CD8-γδTCR+). (H) Ratio of CD4:CD8 
T cells in the PBMC and SFMC of JIA and ERA JIA patients and healthy PBMC. (I) 
Summary plot showing γδ T cells as a % of CD3+CD4-CD8- cells. Bars represent 
median values. Statistical analysis by Kruskal Wallis and Mann-Whitney. 
*p<0.05**p<0.01***p<0.001****p<0.0001. 
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3.2.2 Cytokine-producing T cells are enriched in the SFMC of ERA JIA 
patients. 
 
Cytokine producing T cells, and in particular IL-17- producing CD4 T cells have 
been reported in the SFMC from oligo-JIA patients and are implicated in 
disease pathogenesis (Spreafico et al., 2016). While there are only limited data 
available on immune pathogenesis of ERA JIA, some studies have suggested a 
role for IL-17 production by T cells (Agarwal et al., 2008b, Mahendra et al., 
2009) To further our understanding of the role of T-cell derived cytokines in ERA 
JIA, IL-17, IFNγ, and IL-22 production from T cell subpopulations was analysed 
(in PBMC and SFMC samples) from ERA JIA, other JIA subtypes (oligo-JIA, 
poly-JIA and PsA-JIA) and PBMC from aHC and cHC by flow cytometry 
following 4 hour stimulation with PMA and Ionomycin in the presence of 
Brefeldin A. Due to time restrictions, T-cell derived GM-CSF production was 
only investigated from PBMC (ERA JIA and aHC) and SFMC from ERA JIA 
patients. Cytokine production was analysed from CD4, CD8 and CD4-CD8- T 
cell (CD3+) subpopulations (gating as shown in Figure 3.1B and 3.1C). γδ T 
cells represented >80% of the CD3+CD4-CD8- cell population in all PBMC and 
SFMC samples analysed (Figure 3.2I). For the purpose of these studies, CD4-
CD8- T cells were therefore deemed to be representative of γδ T cells. 
 
CD4 T cells from PBMC and SFMC of JIA patients and healthy controls were 
analysed for production of IFNγ (Figure 3.3A), IL-17 (Figure 3.3B), IL-22 (Figure 
3.3C) and GM-CSF (Figure 3.3D). Approximately 6-10% of CD4 T cells from the 
PBMC compartment of aHC (median=9.16 IQR=4.14-14.33), cHC 
(median=8.57 IQR=6.57-10.18) and ERA JIA patients (median=8.22 IQR=4.61-
10.88) were IFNγ producers. In contrast, typically >40% of SFMC CD4 T cells 
were IFNγ+ in the SFMC (median= 40.90 IQR=38.58-62/08) (p<0.0001, Figure 
3.3.E). Similarly, IL-17 and GM-CSF-production was also significantly increased 
in CD4 T cells from the SFMC from ERA JIA patients compared to paired PBMC 
(for IL-17: ERA JIA PBMC median= 0.62 IQR=0.40-1.57, ERA JIA SFMC 
median= 3.79 IQR=1.77-5.99; for GM-CSF: ERA JIA PBMC median= 4.55 
IQR=3.42-6.93, ERA JIA SFMC median= 12.09 IQR=9.26-15.33) (p=0.001 and 
p=0.0022 for IL-17 and GM-CSF respectively; Figures 3.3F and 3.3H). 
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Interestingly, IL-22 + CD4 T cells were not significantly different between PBMC 
and SFMC from ERA JIA patients (Figure 3.3G).  
 
When comparing cytokine production from CD4 T cells from the SFMC across 
JIA subtypes, significantly more IL-17+ cells were observed in ERA JIA patients 
compared to oligo-JIA (p=0.0054; Figure 3.3F), in whom elevated levels of IL-17 
have previously been reported (Spreafico et al., 2016). Additionally, there were 
increased IL-17+ CD4 T cells in the PBMC of ERA JIA compared to oligo-JIA 
patients, although this did not reach statistical significance (p=0.057) (Figure 
3.3F) perhaps due to small numbers of samples analysed.  Unlike IL-17+ CD4 T 
cells, the number of IL-22 + CD4 T cells in the PBMC from ERA JIA patients 
when compared to oligo-JIA patients, did show a statistical increase (p=0.0055; 
Figure 3.3G). 
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Figure 3.3 Cytokine-producing CD4 T cells are enriched in the SFMC of 
ERA JIA patients.  
Cytokine (IFNγ, IL17, IL-22 and GM-CSF) production by CD4 T cells (CD3+) was 
analysed by flow cytometry following 4 hours stimulation with PMA and Ionomycin in 
the presence of Brefeldin A, within PBMC from aHC and cHC (n=12, n=3 respectively) 
and PBMC and SFMC from ERA-JIA (n=13, n=18), oligo-JIA (n=3, n=8) poly-JIA (n=3, 
n=4) and PsA-JIA patients (n=3, n=3). (A-D) Representative plots showing the gating 
strategy for identification of cytokine positive CD4 T cells from aHC, cHC and PBMC 
and SFMC from an ERA JIA patient for (A) IFNγ; (B) IL-17A; (C) IL-22 and (D) GM-
CSF. (E-H) Summary plots of cytokine positive CD4 T cells for (E) IFNγ; (F) IL-17A; (G) 
IL-22 and (H) GM-CSF. GM-CSF was analysed only in the ERA group, n=6 for both 
PBMC ad SFMC. Bars represent median values. Statistical analysis by Kruskal Wallis 
and Mann-Whitney. *p<0.05**p<0.01***p<0.001****p<0.0001.  
 
 
 
 
 
 
When CD8 cells were analysed for production of the same cytokines, similar 
trends were seen (Figure 3.4A-D). Significantly more CD8 T cells + for IFNγ, IL-
17 and GM-CSF were found in the SFMC of ERA JIA patients compared to 
paired PBMC (for IFNγ: ERA JIA PBMC median= 18.20 IQR=10.05-27.18, ERA 
JIA SFMC median= 50.80 IQR=46.03-58.63; for IL-17: ERA JIA PBMC median= 
0.31 IQR=0.20-0.45, ERA JIA SFMC median= 0.79 IQR=0.46-1.63; for GM-
CSF: ERA JIA PBMC median= 3.06 IQR=2.83-3.22, ERA JIA SFMC median= 
5.42 IQR=3.93-7.23) (p<0.0001, p=0.0003 and p=0.0065 respectively; Figures 
3.4E, 3.4F and 3.4H). Again, significantly higher IL-17 production was seen in 
CD8 T cells in the SFMC of ERA JIA patients compared to oligo-JIA patients 
(ERA JIA median= 0.79 IQR=0.46-1.63; oligo JIA median= 0.18 IQR=0.09-0.90) 
(p=0.0093; Figure 3.4F). Increased IL-17+ CD8 T cells were seen in ERA JIA 
PBMC compared to oligo-JIA patients (ERA JIA median= 0.31 IQR=0.20-0.45; 
oligo JIA median= 0.11 IQR=0.11-0.12) (p=0.047) (Figure 3.4F). The 
abundance of IL-22 + CD8 T cells was not significantly different between PBMC 
and SFMC from ERA JIA patients (Figure 3.4G). 
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Figure 3.4 Cytokine-producing CD8 T cells are enriched in the SFMC of 
ERA JIA patients.  
Cytokine production by CD8 T cells (CD3+) was analysed by flow cytometry following 4 
hours stimulation with PMA and Ionomycin in the presence of Brefeldin A, within PBMC 
form aHC and cHC (n=12, n=3 respectively) and PBMC and SFMC from ERA-JIA 
(n=13, n=18), oligo-JIA (n=3, n=8) poly-JIA (n=3, n=4) and PsA-JIA patients (n=3, 
n=3). (A-D) Representative plots showing the gating strategy for identification of 
cytokine positive CD8 T cells from aHC, cHC and PBMC and SFMC from an ERA JIA 
patient for (A) IFNγ; (B) IL-17A; (C) IL-22 and (D) GM-CSF. (E-H) Summary plots of 
cytokine positive CD8 T cells for (E) IFNγ; (F) IL-17A; (G) IL-22 and (H) GM-CSF. GM-
CSF was analysed only in the ERA group, n=6 for both PBMC ad SFMC. Bars 
represent median values. Statistical analysis by Kruskal Wallis and Mann-Whitney. 
*p<0.05**p<0.01***p<0.001****p<0.0001. 
 
 
 
Finally, cytokine production from CD3+ CD4-CD8- T cells was analysed (Figure 
3.5A-D). No significant differences in the proportion of cells expressing IFNγ, IL-
22 or GM-CSF in CD4-CD8- T cells between PBMC and SFMC from ERA JIA 
patients was observed (Figures 3.5E, 3.5G and 3.5H). In contrast, significantly 
greater number of IL-17+ CD4-CD8- T cells were observed in the SFMC of ERA 
JIA patients compared to their PBMC (ERA JIA PBMC median= 0.43 IQR=0.22-
1.01, ERA JIA SFMC median= 1.05 IQR=0.56-1.65)(p=0.014; Figure 3.5F). In 
addition, CD4-CD8- T cells from PBMC and SFMC of ERA JIA patients had 
increased IL-17 production compared to similar cells from oligo-JIA patients 
from the same compartments (ERA JIA PBMC median= 0.43 IQR=0.22-1.01; 
oligo JIA PBMC median= 0.14 IQR=0.12-0.15; ERA JIA SFMC median= 1.05 
IQR=0.56-1.65; oligo JIA SFMC median= 0.15 IQR=0.12-0.43) (PBMC p=0.028 
and SFMC=0.001) (Figure 3.5F). Interestingly more CD4-CD8- T cells from the 
PBMC from ERA JIA patients produced IFNγ and IL-22 compared to PBMC 
from oligo JIA patients (for IFNγ: ERA JIA PBMC median= 38.10 IQR=25.68-
48.23; oligo JIA PBMC median= 4.90 IQR=4.19-7.60; for IL-22: ERA JIA PBMC 
median= 0.33 IQR=0.26-0.54; oligo JIA PBMC median= 0.0 IQR=0.0-0.04) 
(p=0.0044 and p=0.0055 respectively; Figures 3.5E and 3.5G). There was also 
an enrichment of IL-22 + CD4-CD8- T cells in the SFMC of ERA JIA patients 
compared to oligo-JIA SFMC (ERA JIA SFMC median= 0.36 IQR=0.26-0.73; 
oligo JIA SFMC median= 0.19 IQR=0.03-0.39) (p=0.047) (Figure 3.5G).  
  
 89 
  
 
  
 90 
 
Figure 3.5 IL-17-producing CD4-CD8- T cells are enriched in the SFMC of 
ERA JIA patients.  
Cytokine production by CD4-CD8- T cells (CD3+) was analysed by flow cytometry 
following 4 hours stimulation with PMA and Ionomycin in the presence of Brefeldin A, 
within PBMC form aHC and cHC (n=12, n=3 respectively) and PBMC and SFMC from 
ERA-JIA (n=13, n=18), oligo-JIA (n=3, n=8) poly-JIA (n=3, n=4) and PsA-JIA patients 
(n=3, n=3). (A-D) Representative plots showing the gating strategy for identification of 
cytokine positive CD4-CD8- T cells from aHC, cHC and PBMC and SFMC from an ERA 
JIA patient for (A) IFNγ; (B) IL-17A; (C) IL-22 and (D) GM-CSF. (E-H) Summary plots of 
cytokine positive CD4 T cells for (E) IFNγ; (F) IL-17A; (G) IL-22 and (H) GM-CSF. GM-
CSF was analysed only in the ERA group, n=6 for both PBMC ad SFMC. Bars 
represent median values. Statistical analysis by Kruskal Wallis and Mann-Whitney. 
*p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. 
 
 
 
 
Overall IL-17+ cells were enriched in the SFMC compared to PBMC of ERA JIA 
patients in all T cell compartments analysed (Figures 3.3F, 3.4F and 3.5F). 
These data were next explored for relationships between the populations of T 
cells expressing IL-17 using Spearman’s correlation to account for the non-
Gaussian distribution of the data. Strong positive correlations were seen 
between IL-17+ cells from within the SFMC from ERA JIA patients, analysed as 
follows:  
(a) CD4 T cells analysed against CD8 T cells (n=18, r=0.57, p=0.011) 
(Figure 3.6A) from within the SFMC of ERA JIA patients;  
(b) CD4 T cells analysed against CD4-CD8- T cells (n=18, r=0.49, p=0.038) 
(Figure 3.6B) from within the SFMC of ERA JIA patients; and  
(c) CD8 T cells analysed against CD4-CD8- T cells (n=18, r=0.59, p=0.01) 
(Figure 3.6C) from within the SFMC of ERA JIA patients. 
No significant correlations were seen when IL-17+ populations in the PBMC and 
SFMC from paired ERA JIA samples were analysed as follows:  
(d)  CD4 T cells from within the PBMC analysed against CD4 T cells from 
within the SFMC from ERA JIA patients (n=10, r=0.59, p=0.08) (Figure 
3.6D); 
(e) CD8 T cells from within the PBMC analysed against CD8 T cells from 
within the SFMC from ERA JIA patients (n=10, r=-0.15, p=0.65) (Figure 
3.6E); 
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(f) CD4-CD8- T cells from within the PBMC analysed against CD4 T cells 
from within the SFMC from ERA JIA patients (n=10, r=-0.12, p=0.73) 
(Figure 3.6F); 
 
Together, these data suggest that the IL-17 signature is strong across different 
T cell populations in a proportion but not all ERA JIA patients, which is restricted 
to the inflamed site. This raises the question of whether this synovial IL-17 
signature extends beyond the T cell compartment.  
 
 
 
Figure 3.6 ERA JIA patients have a strong IL-17 signature across all T cell 
subpopulations at the inflamed site.  
(A-C) Analysis of IL-17+ T cell subpopulations in the SFMC of ERA JIA patients (n=18) 
(A) IL-17+CD4 T cells analysed against IL-17+CD8 T cells (r=0.57, p=0.011); (B) IL-
17+CD4 T cells analysed against IL-17+CD4-CD8- T cells (r=0.49, p=0.038) and (C) 
IL-17+CD8 T cells analysed against IL-17+CD4-CD8- T cells (r=0.59, p=0.01). (D-F) 
Analysis of IL-17+ T cell subpopulations in the PBMC and SFMC from paired ERA JIA 
patients (n=10).  (D) IL-17+CD4 T cells from the PBMC analysed against IL-17+CD4 T 
cells from the SFMC (r=0.59, p=0.08); (E) IL-17+CD8 T cells from the PBMC analysed 
against IL-17+CD8 T cells from the SFMC (r=-0.15, p=0.65) and (F) IL-17+CD4-CD8- T 
cells from the PBMC analysed against IL-17+CD4-CD8- T cells from the SFMC (r=-
0.12, p=0.73). Correlation analysis by Spearman correlation.  
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3.2.3 Presence of dual cytokine positive T cells in ERA JIA.  
 
Polyfunctional T cells, meaning those that co-produce multiple inflammatory 
cytokines, have been shown to be enriched at the site of inflammation as well 
as in peripheral blood in oligo-JIA and other types of inflammatory arthritis, are 
thought of as highly pathogenic, and are associated with more severe disease 
(Ye et al., 2001, Spreafico et al., 2016). To study the presence of poly-functional 
IL-17+ T cells in ERA JIA, production of IFNγ and IL-22 from IL-17+ T cell 
subpopulations was analysed in PBMC and SFMC samples from ERA JIA 
(n=11, n=15), other JIA subtypes (oligo-JIA (n=3, n=4), poly-JIA (n=2, n=2) and 
PsA-JIA (n=3, n=3)) and PBMC from aHC (n=13) and cHC (n=3). Additionally, 
co-production of IL-17 and GM-CSF from T cell subpopulations from PBMC 
from aHC (n=4) and PBMC (n=6) and SFMC (n=6) from ERA JIA patients by 
flow cytometry following 4 hours stimulation with PMA and Ionomycin in the 
presence of Brefeldin A was investigated (Figures 3.7-3.9). 
 
Increased proportions of IL-17/IFNγ double positive cells were identified in CD4 
(p<0.0001) (ERA JIA PBMC median= 18.50 IQR=15.88-29.65; ERA JIA SFMC 
median= 64.00 IQR=52.50-69.90) and CD8 (p=0.0086) (ERA JIA PBMC 
median= 58.10 IQR=39.75-77.08; ERA JIA SFMC median= 79.17 IQR=63.60-
87.00) T cell compartments within SFMC compared to PBMC from ERA JIA 
patients (Figure 3.7B and 3.7C). It was interesting to note no difference in IL-
17/IFNγ double positive in the CD4-CD8- T cells between PBMC and SFMC 
(Figure 3.7D). When IL-17/IFNγ double positive cells from the SFMC were 
analysed between JIA subtypes, ERA JIA patients had a higher number of IL-
17/IFNγ double positive CD4 (p=0.0052) (ERA JIA SFMC median= 64.00 
IQR=52.50-69.90; oligo JIA SFMC median= 47.65 IQR=40.48-54.25) and CD4-
CD8- (p=0.0007) (ERA JIA SFMC median= 56.46 IQR=50.43-83.70; oligo JIA 
SFMC median= 26.87 IQR=0.0-38.73) T cells compared to oligo-JIA patients 
(Figure 3.7B and 3.7D). An expanded IL-17/GM-CSF double positive population 
was only observed in the CD4 T cell compartment (p=0.03) (Figure 3.8B). No 
differences were seen in the CD8 nor the CD4-CD8- T cell subpopulations 
(Figure 3.8C and 3.8D).  
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Only a small proportion of CD4, CD8 and CD4-CD8- T cells were double 
positive for IL-17 and IL-22 (<20%) and no significant differences were seen 
between PBMC and SFMC or between JIA subtypes. This finding suggests that 
IL-17 and IL-22 may be produced by discrete T cell subpopulations (Figure 3.9).     
Figure 3.7 IL-17/ IFNγ –double positive T cells are expanded in the SFMC 
of ERA JIA patients.  
Polyfunctional T cells were investigated in PBMC from aHC and cHC (n=12, n=3 
respectively) and PBMC and SFMC from ERA-JIA (n=13, n=18), oligo-JIA (n=3, n=8) 
poly-JIA (n=2, n=3) and PsA-JIA patients (n=3, n=3). (A) Representative flow cytometry 
plots showing IL-17 and IFNγ staining on CD4 T cells (top row), CD8 T cells (middle 
row) and CD4-CD8-T cells (bottom row) in PBMC from aHC and cHC and PBMC and 
SFMC from an ERA JIA patient. (B-D) Summary plots showing IL-17+IFNγ+ cells as a 
% of total IL-17+ T cells within (B) CD4 T cells; (C) CD8 T cells and (D) CD4-CD8-T 
cells. Bars represent median values. Statistical analysis by Kruskal Wallis and Mann-
Whitney. *p<0.05**p<0.01****p<0.0001.  
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Figure 3.8 IL-17/ GM-CSF–double positive CD4 T cells are expanded in the 
SFMC of ERA JIA patients.  
Polyfunctional T cells were investigated in PBMC from aHC (n=4) and PBMC and 
SFMC from ERA-JIA (n=6, n=6), (A) Representative flow cytometry plots showing IL-17 
and GM-CSF staining on CD4 T cells (top row), CD8 T cells (middle row) and CD4-
CD8-T cells (bottom row) in PBMC from aHC and PBMC and SFMC from an ERA JIA 
patient. (B-D) Summary plots showing IL-17+GM-CSF+ cells as a % of total IL-17+ T 
cells within (B) CD4 T cells; (C) CD8 T cells and (D) CD4-CD8-T cells. Bars represent 
median values. Statistical analysis by Kruskal Wallis and Mann-Whitney. *p<0.05 
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Figure 3.9 IL-17/ IL-22–double positive T cells are not expanded in the 
SFMC of ERA JIA patients.  
Polyfunctional T cells were investigated in PBMC from aHC and cHC (n=12, n=3 
respectively) and PBMC and SFMC from ERA-JIA (n=13, n=18), oligo-JIA (n=3,n=8) 
poly-JIA (n=2,n=3) and PsA-JIA patients (n=3, n=3). (A) Representative flow cytometry 
plots showing IL-17 and IL-22 staining on CD4 T cells (top row), CD8 T cells (middle 
row) and CD4-CD8-T cells (bottom row) in PBMC from aHC and cHC and PBMC and 
SFMC from an ERA JIA patient. (B-D) Summary plots showing IL-17+IL-22+cells as a 
% of total IL-17+ T cells within (B) CD4 T cells; (C) CD8 T cells and (D) CD4-CD8-T 
cells. Bars represent median values.   
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3.2.4 IL-17 positive CD4 T cells are weakly associated with more severe 
disease. 
 
In order to explore the significance of IL-17+ subpopulations in relation to ERA 
JIA disease severity, IL-17+ CD4 T cells were analysed as a proportion of total 
CD4 T cells and correlated to measures of disease severity. Active joint count, 
ESR and physicians VAS (0.0-10.0 with 0 signifying no active disease, 10 worst 
disease activity) at time of joint sample were included and correlations were 
assessed by Spearman’s correlation to account for non-Gaussian data. IL-17+ 
CD4 T cells were weakly associated with the number of active joints (r=0.35, p 
=0.19) Physician’s VAS (r=0.43, p=0.16) and at the time of synovial fluid sample 
collection, although neither of these associations reached statistical significance 
(Figure 3.10A and 3.10C). No correlation was found between IL-17+ CD4 T 
cells and the ESR at the time of synovial fluid sample collection (r=0.16, 
p=0.62).  
 
Since polyfunctional T cells are generally considered to be more pathogenic, IL-
17/IFNγ double positive CD4 T cells were also analysed against active joint 
count, ESR and physicians VAS (0.0- 10.0) at time of joint sample. Double 
positive cells were not more closely associated with these measures of disease 
severity compared to total IL-17+ CD4 T cells. However, they maintained similar 
associations with active joint count (r=0.36, p=0.19) and Physician’s VAS 
(r=0.38, p=0.22) at the time of synovial fluid sample collection (Figure 3.10D 
and 3.10F). Again, no correlation was found between IL-17/IFNγ double positive 
CD4 T cells and the ESR at the time of synovial fluid sample collection (r=0.02, 
p=0.95). A weak correlation was found when IL-17+ CD4 T cells were analysed 
against the age of the patient at the time of joint sample, although this did not 
reach significance (r=0.41, p=0.086) (Figure 3.11A). Interestingly, IL-17+ CD4 T 
cells were not preferentially expanded in the SFMC from patients who were 
positive for the HLA-B27 allele (Figure 3.11B). In this study, treatment with MTX 
prior to or at time of joint sample did not significantly affect the proportion of IL-
17+ CD4 T cells at the inflamed site (Figure 3.11C). 
 
 
 97 
 
 
Figure 3.10 Proportion of IL-17-producing CD4 T cells in the SFMC of ERA 
JIA patients are weakly associated with more severe disease.  
(A-C) Correlations in the SFMC of ERA JIA patients between IL-17+ CD4 T cells 
analysed as a % of total CD4 T cells and clinical measures of disease severity.  IL-17+ 
CD4 T cells analysed against (A) Active joint count at time of sample (n=15, r=0.35, 
p=0.2); (B) ESR at time of sample (n=12, r=0.16, p=0. 62) and (C) Physician’s VAS as 
time of sample (n=12, r=0.43, p=0.16). (D-F) Correlations in the SFMC of ERA JIA 
patients between IL-17+IFNγ- double positive CD4 T cells analysed as a % of total 
CD4 T cells and clinical measures of disease severity.  IL-17+IFNγ+ CD4 T cells 
analysed against (D) Active joints at the time of sample (n=15, r=0.36, p=0.19); (E) 
ESR at time of sample (n=12, r=0.02, p=0.95); (F) Physicians VAS (n=12, r=0.38, 
p=0.22). Correlation analysis by Spearman correlation.  
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Figure 3.11 Proportion of IL-17-positive CD4 T cells within the synovial 
fluid T cells is correlated with patient age at time of sampling.  
(A) Correlation analysis between IL17+ CD4 T cells and age at time of sample in SFMC 
of ERA JIA patients (n=18, r=0.41, p=0.086). (B) Summary plot showing IL-17+ CD4 T 
cells in the SFMC from ERA JIA patients grouped according to carriage of the HLA-B27 
allele (HLA-B27- n=4, HLA-B27+ n=14). (C) Summary plot showing IL-17+ CD4 T cells 
in the SFMC from ERA JIA patients grouped according to treatment received within the 
last 6 months (treatment naïve n=6, HLA-B27+ n=12). Correlation analysis by 
Spearman correlation.  
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3.2.5 ‘Ex’-IL-17-producing T cells are enriched in the SFMC from ERA JIA 
patients. 
 
CD161 expression has been linked to expression of RORC, the master 
transcription factor of IL-17 producing T cells, and is associated with T cells with 
the potential for IL-17 production(Ivanov et al., 2006, Maggi et al., 2010). 
Therefore, CD161 protein was analysed on CD4, CD8 and CD4-CD8- T cells 
from aHC PBMC and PBMC and SFMC from ERA JIA patients by flow 
cytometry, and IL-17/CD161 co-expression was also assessed (gating shown in 
Figure 3.12A).  CD161+ CD4 and CD8 T cells were expanded in the SFMC from 
ERA JIA patients compared to paired PBMC or aHC PBMC (CD4 T cells: ERA 
JIA PBMC median= 16.00 IQR=11.18-21.78; ERA JIA SFMC median= 55.90 
IQR=41.05-62.30; CD8 T cells: ERA JIA PBMC median= 5.46 IQR=2.98-9.14; 
ERA JIA SFMC median= 16.40 IQR=11.31-21.03) (Figure 3.12B and 3.12C). 
Interestingly, fewer CD161+ CD4-CD8- T cells were seen within the SFMC from 
ERA JIA patients compared to paired or aHC PBMC (ERA JIA PBMC median= 
45.25 IQR=24.90-60.90; ERA JIA SFMC median= 35.05 IQR=23.53-44.13) 
(Figure 3.12D).  As expected IL-17+ T cells were also predominantly positive for 
CD161 expression, although fewer IL-17+CD8 T cells were positive for CD161 
(Figures 3.12E-G). No differences in CD161+IL-17+ T cells were seen between 
PBMC from aHC or ERA JIA patients and SFMC from ERA JIA patients 
(Figures 3.12E-G). CD161 was expressed on >60% of all IL-17+ CD4 and CD4-
CD8-T cells (Figures 3.12E and 3.12G). Typically within CD8+ cells the 
proportion of IL-17+ cells expressing CD161 was lower than compared to other 
IL-17+ T cell populations (Figure 3.12 E-G).  
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Figure 3.12 T cells expressing CD161 are enriched in the inflamed joints 
of patients with ERA JIA.  
(A) Representative flow cytometry plots showing gating strategy for CD161+ cells, 
analysed against IL-17, from within the CD4 (top row), CD8 (middle row) and CD4-
CD8- (bottom row) T cells, in PBMC from aHC (left column) and PBMC (middle 
column) and SFMC (right column) of an ERA JIA patient. (B-D) Summary plots for 
CD161 positive cells as % of T cells populations for (B) CD4 (C) CD8 and (D) CD4-
CD8- T cells within the PBMC from aHC (n=4) and PBMC (n=6) and SFMC (n=6) from 
ERA JIA patients (E-G) Summary plots for CD161 positive cells as % of IL-17A positive 
T cells (E) CD4 (F) CD8 and (G) CD4-CD8- T cells within the PBMC from aHC (n=4) 
and PBMC (n=6) and SFMC (n=6) from ERA JIA patients. Statistical analysis by 
Kruskal Wallis and Mann-Whitney. *p<0.05**p<0.01.  
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Previous studies from the Wedderburn group, and others have identified CD161 
as a marker for a population of IFNγ+IL-17- CD4 T cells with a Th17 ancestry, 
so called “ex Th17” cells, with pathogenic potential (Nistala et al., 2010a, Maggi 
et al., 2010, Nistala, 2011, Maggi et al., 2012). This population, as well as its 
CD8 and CD4-CD8- counterparts were analysed in the PBMC from aHC and 
the PBMC and SFMC from ERA JIA patients following 4 hour stimulation with 
PMA and Ionomycin in the presence of Brefeldin A (Figures 3.13, 3.14 and 
3.15). IFNγ+IL-17- CD4 T cells were identified as shown in Figure 3.13A and 
CD161 expression was assessed on this population (Figure 3.13B and 3.13C). 
CD161 was expressed on 50% of these cells (aHC PBMC median= 60.05 
IQR=53.08-64.40; ERA JIA PBMC median= 43.90 IQR=40.53-52.80; ERA JIA 
SFMC median= 58.30 IQR=51.18-65.65). No significant differences were seen 
between the proportion of CD161+ cells within IFNγ+IL-17- CD4 T cells 
between PBMC and SFMC form aHC or ERA JIA patients (Figure 3.13C). 
CD161+ and CD161- IFNγ+IL-17- CD4 T cells were subsequently analysed for 
production of the IL-17-associated cytokines, IL-22 and GM-SCF (Figure 
3.13D). There was a significant enrichment of GM-CSF+ cells within the 
IFNγ+IL-17- CD4 T cell population in the SFMC of ERA JIA patients compared 
to paired and aHC PBMC (p>0.0001; Figure 3.13D). Additionally, there was a 
significant expansion of GM-CSF + cells within the IFNγ+IL-17- CD4 T cell 
population in the CD161+ compared to the CD161-population (p=0.011) (Figure 
3.13E). IL-22+ cells within the IFNγ+IL-17- CD4 T cell population were not 
significantly different between PBMC and SFMC, or between CD161- and 
CD161+ populations (Figure 3.13F). Similarly, GMCSF/IL-22 double positive 
cells were not significantly different between PBMC and SFMC, or between 
CD161- and CD161+ populations (Figure 3.13G).  
 
The same analysis was applied to CD8 T cells (Figure 3.14) and CD4-CD8- T 
cells (Figure 3.15). Fewer IFNγ+IL-17- CD8 T cells expressed CD161, 
compared to their CD4 counterparts, where <40% of all cells expressed the 
marker (aHC PBMC median= 38.60 IQR=23.68-41.75; ERA JIA PBMC median= 
17.45 IQR=13.60-32.13; ERA JIA SFMC median= 20.30 IQR=15.33-24.33). 
Again, no differences in the proportion of CD161+ cells were seen within the 
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IFNγ+IL-17- CD8 T cell population between PBMC and SFMC. As was seen in 
CD4 T cells, GM-CSF-positive cells within the IFNγ+IL-17- CD8 T cell 
population were expanded in the SFMC (p<0.05) and were significantly 
enriched in the CD161 population (p=0.015)(Figure 3.14E). Neither IL-22+ cells, 
nor GM-CSF/IL-22 double positive cells within the IFNγ+IL-17- CD8 T cell 
population were significantly different between PBMC and SFMC, or between 
CD161- and CD161+ populations (Figures 3.14F and 3.14G).  
 
A high proportion of IFNγ+IL-17- CD4-CD8- T cells from aHC and ERA JIA 
PBMC expressed CD161 (>60%) compared to IFNγ+IL-17- CD4-CD8- T cells 
from within the SFMC from ERA JIA patients (aHC PBMC median= 78.20 
IQR=74.48-86.65; ERA JIA PBMC median= 64.55 IQR=53.50-92.90; ERA JIA 
SFMC median= 47.10 IQR=39.30-66.75) (Figure 3.15C). Again, GM-CSF+ cells 
were enriched within the IFNγ+IL-17- CD4-CD8- T cell population in the SFMC 
compared to patient or aHC PBMC (p<0.01), but no differences were seen 
between CD161+ and CD161- populations (Figure 3.15E).  Finally, neither IL-
22+ cells, nor GM-CSF/IL-22 double positive cells were significantly different 
within the IFNγ+IL-17- CD4-CD8- T cell population between PBMC and SFMC, 
or between CD161- and CD161+ populations (Figures 3.15F and 3.15G).  
 
Together these results show that synovial CD161+ cells may share functional 
similarities with IL-17+ T cells, including increased GM-CSF production.  
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Figure 3.13 Polyfunctional CD4 T cells express CD161 and are expanded 
at the inflamed site.  
(A-C) IFNγ+IL-17- T cells were analyses for expression of CD161 in PBMC from aHC 
(n=4) and PBMC and SFMC from ERA JIA patients (n=6)(A) Representative gating 
strategy for the identification of IFNγ+IL17- CD4 T cells. (B) Representative histogram 
showing the identification of CD161+ and CD161- cells. (C) Summary plot showing 
CD161+ cells as a proportion of IFNγ+IL-17-CD4 T cells. (D-G) CD161+ and CD161- 
cells were analysed for coproduction of GM-CSF and IL-22. (D) Representative flow 
cytometry plots showing GM-CSF and IL-22 staining on IFNγ+IL-17-CD4 T cells within 
the CD161+(top row) and CD161- populations (bottom row) in PBMC from aHC and 
PBMC and SFMC from an ERA JIA patient. (E-G) Summary plots comparing 
polyfunctionality between CD161+ and CD161- IFNγ+IL-17-CD4 T cells analysing cells 
positive for (E) GM-SCF; (F) IL-22 and (G) GM-CSF and IL-22. Bars represent median 
values. Statistical analysis by 2-way ANOVA and paired T test. *p<0.05***p<0.001  
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Figure 3.14 Polyfunctional CD8 T cells express CD161 and are enriched at 
the inflamed site. 
(A-C) IFNγ+IL-17- T cells were analysed for expression of CD161 in PBMC from aHC 
(n=4) and PBMC and SFMC from ERA JIA patients (n=6)(A) Representative gating 
strategy for the identification of IFNγ+IL17- CD8 T cells. (B) Representative histogram 
showing the identification of CD161+ and CD161- cells. (C) Summary plot showing 
CD161+ cells as a proportion of IFNγ+IL-17-CD8 T cells. (D-G) CD161+ and CD161- 
cells were analysed for coproduction of GM-CSF and IL-22. (D) Representative flow 
cytometry plots showing GM-CSF and IL-22 staining on IFNγ+IL-17-CD8 T cells within 
the CD161+(top row) and CD161- populations (bottom row) in PBMC from aHC and 
PBMC and SFMC from an ERA JIA patient. (E-G) Summary plots comparing 
polyfunctionality between CD161+ and CD161- IFNγ+IL-17-CD8 T cells analysing cells 
positive for (E) GM-SCF; (F) IL-22 and (G) GM-CSF and IL-22. Bars represent median 
values. Statistical analysis by 2-way ANOVA and paired T test. *p<0.05***p<0.001 
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Figure 3.15 Polyfunctional CD4-CD8- T cells are enriched at the inflamed 
site.  
(A-C) IFNγ+IL-17- T cells were analyses for expression of CD161 in PBMC from aHC 
(n=4) and PBMC and SFMC from ERA JIA patients (n=6)(A) representative gating 
strategy for the identification of IFNγ+IL17- CD4-CD8- T cells. (B) Representative 
histogram showing the identification of CD161+ and CD161- cells. (C) Summary plot 
showing CD161+ cells as a proportion of IFNγ+IL-17-CD4-CD8- T cells. (D-G) CD161+ 
and CD161- cells were analysed for coproduction of GM-CSF and IL-22. (D) 
Representative flow cytometry plots showing GM-CSF and IL-22 staining on IFNγ+IL-
17-CD4-CD8- T cells within the CD161+(top row) and CD161- populations (bottom row) 
in PBMC from aHC and PBMC and SFMC from an ERA JIA patient. (E-G) Summary 
plots comparing polyfunctionality between CD161+ and CD161- IFNγ+IL-17-CD4-CD8- 
T cells analysing cells positive for (E) GMSCF; (F) IL-22 and (G) GM-CSF and IL-22. 
Bars represent median values. Statistical analysis by 2-way ANOVA and paired T test. 
*p<0.05***p<0.001  
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3.2.6 ERA JIA patients have an expanded memory CD4 population 
compared to healthy controls 
 
It is known that the memory T cell compartment is significantly expanded in the 
SFMC from JIA patients (Silverman et al., 1993, Wedderburn et al., 2000a, 
Chiesa et al., 2004)). Additionally, it has been shown that IL-17-producing T 
cells originate from a memory population in adult AS (Shen et al., 2009). Since 
IL-17-producing T cells were enriched in the PBMC from some ERA JIA 
patients, I hypothesized that this expansion may be indicative of an expanded 
memory T cell population in this compartment. In order to test this hypothesis, 
naïve (CD45RA+CD45RO-) and memory (CD45RA-CD45RO+) CD4 T cells 
were enumerated in the PBMC from aHC (n=4) and cHC (n-=3) and the PBMC 
(n=5) and SFMC (n=6) from ERA JIA patients (Figure 3.16 A and 3.16B).  The 
majority of all CD4 T cells at the inflamed site (median= 90.20 IQR=89.15-
95.08) had a memory phenotype (CD45RA-CD45RO+), which was a significant 
enrichment compared to memory CD4 T cells found within PBMC 
(median=29.00 IQR=27.30-44.90) from the same patients (p=0.0043). 
Intriguingly, a larger memory CD4 population was found in the PBMC from ERA 
JIA patients (median=29.00 IQR=27.30-44.90), compared to cHC PBMC 
(median=15.00 IQR=8.12-15.30) (p=0.357) (Figure 3.16B).  
 
To further probe the role of memory in the IL-17 signature of ERA JIA patients, 
cells were stimulated for 4 hour with PMA and Ionomycin in the presence of 
Brefeldin A, and subsequently analysed for IL-17 production after gating on the 
memory population. Within the memory compartment (CD45RO+), IL-17+ cells 
were expanded within the PBMC and SFMC of ERA JIA patients, but not PBMC 
from aHC. (Figures 3.16C and 3.16D).   These data suggest that inflammation 
may be more ‘systemic’ in a proportion of ERA JIA patients, which could 
account for the expansion of cytokine producing T cells in the PBMC of these 
patients.  
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Figure 3.16 Synovial CD4+T cells of ERA JIA patients are predominantly 
of the memory phenotype.  
(A) Representative flow cytometry plots showing gating of naïve (CD45RA+CD45RO-) 
and memory (CD45RA-CD45RO+) CD4 T cells from PBMC from aHC and cHC and 
PBMC and SFMC from ERA JIA patients. (B) Summary plot showing CD45RA-
CD45RO+ memory cells as a % of total CD4 T cells from PBMC from aHC and cHC 
(n=4 and n=3 respectively) and PBMC and SFMC from ERA JIA patients (n=5, n=6). 
PBMC from aHC and PBMC and SFMC from ERA JIA patients were stimulated for 4 
hours with PMA and Ionomycin in the presence of BrefeldinA and the naïve/ memory 
status of the IL-17+ CD4 T cells was analysed by flow cytometry (C) Representative 
flow cytometry plots showing gating of IL-17 + cells within the memory (CD45RA-
CD45RO+) CD4 T cell population from PBMC from aHC and PBMC and SFMC from 
ERA JIA patients. (D) Summary plot showing IL-17+ cells as a % of total CD45RA-
CD45RO+ memory cells CD4 T cells. Bars represent median values. Statistical 
analysis by Kruskal Wallis and Mann-Whitney. *p<0.05**p<0.01****p<0.0001.  
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3.2.7 Treg are inversely correlated with IL-17+CD4 T cells at the inflamed 
site in ERA JIA 
 
Treg are often expanded at sites of inflammation and have been shown to be 
enriched in the SFMC from JIA patients (de Kleer et al., 2004, Olivito et al., 
2009, Spreafico et al., 2016). Additionally, previous published data from our 
laboratory has demonstrated an enrichment of cytokine producing Treg, which 
can be identified by the expression of CD161(Pesenacker et al., 2013). Neither 
total, nor CD161+Treg have been previously analysed in this cohort of ERA JIA 
patients. To investigate the contribution of this cell-type, Treg 
(CD3+CD4+CD127low CD25+FOXP3+) were enumerated in the PBMC of aHC 
and cHC and the PBMC and SFMC of ERA JIA patients as well as other JIA 
subtypes (oligo, poly and PsA) (Figure 3.17A). 
 
As has been previously shown, Treg were enriched in the SFMC from JIA 
patients compared to paired PBMC, and this was observed for all subtypes 
(p<0.0001; Figure 3.17B). However, interestingly the proportion of Treg in 
SFMC from ERA JIA patients was significantly lower than in SFMC from oligo-
JIA (p=0.0072), Treg were non-significantly expanded in the SFMC compared to 
PBMC from ERA JIA patients (Figure 3.17B). In line with previously published 
data investigating these populations in oligo-JIA (Nistala et al., 2008a), a 
negative correlation was seen between Treg and IL-17+ CD4 T cells in the 
SFMC although this association did not reach statistical significance (r=-0.40, 
p=0.16) (Figure 3.17C).   
 
CD161+ Treg were also investigated. As hypothesised, a significant enrichment 
of CD161+ Treg were found in the SFMC compared to PBMC from ERA JIA 
patients (p=0.015). No association was seen between CD161+ Treg and IL-17+ 
CD4 T cells at the inflamed site (r=0.051, p=0.87) (Figures 3.17D and 3.17E).  
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Figure 3.17 Analysis of Treg populations in different JIA subtypes and 
their relationship to IL-17+ and CD161 expression.  
Treg (CD3+CD4+CD127lowCD25+FOXP3+) were enumerated and analysed for 
expression of CD161 in the PBMC from aHC and cHC (n=8 and n=3 respectively) and 
the PBMC and SFMC from ERA-JIA (n=11, n=14), oligo-JIA (n=3,n=5) poly-JIA 
(n=3,n=3) and PsA-JIA patients (n=3, n=4). (A) Representative plots showing the 
gating strategy for identification of CD161+Treg cells from aHC, cHC and PBMC and 
SFMC from an ERA JIA patient; (B) Summary plot showing Treg as a % of total CD4 T 
cells; (C) Correlation analysis showing Treg as a % of total CD4 T cells analysed 
against IL17+ CD4 T cells as a % of total CD4 T cells in the SFMC of ERA JIA patients 
(n= 14, r=-0.40, p=0.16); (D) Summary plot showing CD161+Treg as a % of total Treg 
cells; (E) Correlation analysis showing CD161+ Treg analysed against IL-17+ CD4 T 
cells in the SFMC of ERA JIA patients (n= 14, r=0.051, p=0.87). Bars represent median 
values. Statistical analysis by Kruskal Wallis and Mann-Whitney. Correlation analysis 
by Spearman correlation. *p<0.05**p<0.01***p<0.001****p<0.0001. 
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3.3 Discussion 
 
The ERA subtype of JIA has a strong genetic association with HLA-B27 and 
shares many clinical similarities with adult AS (Saurenmann et al., 2007, Layh-
Schmitt and Colbert, 2008). While the pathogenesis of AS is associated with the 
IL-23/IL-17 axis, how closely the pathogenesis of ERA JIA overlaps with AS is 
not well established. This chapter presents detailed analyses of the 
immunological phenotype in ERA JIA and confirms an IL-17+ T cell expansion 
at the inflamed site.  
 
Whilst analysis of SFMC allows unique access to the site of inflammation and 
provides an insight into the immunopathology, it is not a direct assessment of 
the cells contained within the synovial tissue at the primary disease site. Due to 
ethical restrictions, the majority of children undergoing joint fluid aspiration do 
not have synovial biopsy material sampled. It was therefore not possible to 
analyse the immune composition within the synovial tissue of JIA patients in this 
study. The analysis in this thesis is therefore confined to the PBMC and SFMC 
compartments. 
 
Initial analyses allowed an insight into the cellular composition of the PBMC and 
SFMC from ERA JIA patients compared to other JIA subtypes as well as 
healthy control PBMC from aHC and cHC. No significant differences were seen 
in the relative proportions of the immune cells analysed between JIA subtypes. 
For the purpose of this chapter only results related to ERA JIA will be 
discussed, although the same conclusions may also be applied to other JIA 
subtypes when differences are not specified.  
 
Some noticeable differences were found in the immunological phenotype 
between PBMC and SFMC in ERA JIA patients. mDC were significantly 
enriched in the SFMC from ERA JIA patients compared to paired PBMC. This 
finding builds upon previously published data, which demonstrated an 
enrichment of mDC subsets in the joints of oligo- and poly-JIA patients (Varsani 
et al., 2003, Gattorno et al., 2007, Smolewska et al., 2008). During my study, a 
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population of CD14-CD11c- cells with monocyte morphology was routinely 
seen, and appeared enriched in the synovial fluid compared to blood of JIA 
patients. This population may represent activated monocytes that have down-
regulated CD14, or a population of lymphoid derived DC (CD11c-
CD123+)(Rovati et al., 2008). Although this population was not investigated 
during this thesis, further examination of this cell population and its possible 
contribution to pathogenesis would be warranted.  
 
There was a dramatic reduction of B cells noted in the SFMC from ERA JIA 
patients compared to paired PBMC; a phenomenon that has been previously 
corroborated in other JIA subtypes (Corcione et al., 2009). Although not 
investigated in this thesis, B cells in the synovial fluid of JIA patients have been 
analysed in detail by the Wedderburn group and others (Corcione et al., 2009, 
Morbach et al., 2011, Botta Gordon-Smith et al., 2015). These studies have 
shown significant functional differences between blood and synovial B cells 
including reduced expression of CD73 on synovial B cells, suggesting reduced 
anti-inflammatory capacity of B cells at the inflamed site (Botta Gordon-Smith et 
al., 2015). In addition to demonstrating functional diversity in JIA, these studies 
have also identified associations between synovial B cells and disease severity. 
The differences observed in synovial B cells act as a reminder that although the 
relative proportions of immune cells, such as monocytes and NK cells, may not 
differ significantly between PBMC and SFMC from ERA JIA patients, or may 
represent only a small proportion of the total mononuclear cell population (B 
cells), there may be significant functional differences and these cells may 
remain significant players in disease pathogenesis.  
 
In healthy individuals, a mean value for the ratio of PBMC CD4:CD8 T cells of 
2:1 is expected, and, an inverted synovial fluid CD4 to CD8 T cell ratio has been 
linked to poor prognosis in oligo-JIA (Hunter et al., 2010). An altered CD4 to 
CD8 ratio (median = 1.02) was demonstrated here within the SFMC from ERA 
JIA patients, and may be indicative of poor clinical outcomes. Analysis of long-
term clinical data from ERA JIA patients could be conducted to elucidate 
whether this is the case.  
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Cytokine production was analysed from CD4, CD8 and CD4-CD8- T cell 
subpopulations within the PBMC of healthy controls and PBMC and SFMC from 
JIA patients following ex vivo stimulation with PMA and Ionomycin in the 
presence of Brefeldin A. There are some limitations associated with stimulation 
of this kind, including the supra-physiological strength of the stimulatory signal.  
Some investigators use an alternative system using stimulation through the 
TCR, with or without costimulation. Stimulation with PMA and Ionomycin 
identifies all cells capable of cytokine production at a given time point, rather 
than a true demonstration of cell function in vivo. However, this limitation is 
mitigated by technical consistency. PBMC and SFMC were stimulated in an 
identical way throughout this study and therefore variances described between 
groups are most likely representative of true differences.  
 
For the purpose of cytokine analyses, CD4-CD8- T cells were investigated as a 
surrogate of the γδ T cell population. Due to insufficient space on the panel, it 
was not possible to include γδTCR in the cytokine panels, as its inclusion would 
have resulted in significant technical complications. Although γδ T cells 
represented the predominant CD4-CD8- population (>80%), analysis of this 
population should be treated with some caution. It is possible that the cells that 
did not stain positively for the γδTCR were activated CD4 or CD8 cells that had 
down regulated their respective markers, or alternatively may represent a small 
population of NKT cells. The possibility of NKT cell contamination is perhaps 
supported by the abundance of CD4-CD8-T cells that expressed CD161, 
particularly within the PBMC from aHC, which was higher than has been 
previously reported in γδ T cells (Battistini et al., 1997, Poggi et al., 1999). 
However, in line with the data presented in this Chapter, significant variability of 
CD161 expression on circulating γδ T cells has been reported, and the high 
proportion of CD161-expressing cells observed here may not necessarily be 
indicative of contamination (Kenna et al., 2004). Due to this uncertainty, it is not 
possible to precisely determine cytokine production by γδ T cells in this study 
and further analysis with the inclusion of γδTCR should be conducted. 
However, these data do identify cytokine-producing T cells at the inflamed site 
of ERA JIA patients and some very cautious conclusions may be drawn.  
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Th17 cells have been previously implicated in the pathogenesis of JIA as well 
as adult inflammatory arthropathies (Spreafico et al., 2016). In particular, IL-17 
has been heavily implicated in the pathogenesis of adult AS, which shares 
clinical and genetic features with ERA JIA (Berntson et al., 2008, Shen et al., 
2009). This chapter investigated the role of IL-17-producing T cell subsets and 
their association with disease in ERA JIA patients from a British cohort. A role 
for IL-17 in pathogenesis of ERA JIA could have dramatic implications for 
treatment decisions in the future as novel biological therapies targeting the IL-
23/IL-17 axis have been developed, and have shown promise in the treatment 
of adult psoriatic arthritis and AS (Braun et al., 2015).  
 
As hypothesized, and in accordance with similar data collected in an Indian 
cohort, Th17 cells were enriched in the synovial fluid of ERA JIA patients 
(Mahendra et al., 2009). In fact, the expansion of IL-17-producing T cells was 
not restricted to the CD4 compartment in the joints of ERA JIA patients, but 
extended to CD8 and CD4-CD8- T cells. Although IL-17+ cells were fewer in the 
CD8 T cell compartment compared to CD4 T cells, the potential contribution of 
CD8-derived IL-17 should not be underestimated. Here, it has been shown that 
CD8 T cells are significantly expanded in the joints of ERA JIA patients, and 
therefore the IL-17+CD8 T cells may be underrepresented by these analyses.  
 
In parallel to IL-17 production, IL-17-associated, GM-CSF+ cells were also 
expanded in synovial CD4 and CD8 T cell populations from ERA JIA patients. 
This observation has been previously been reported in oligo-JIA patients (Piper 
et al., 2014a).  Additionally, IL-17+ T cells at the inflamed site showed 
considerable co-production of inflammatory IFNγ and GM-CSF suggesting a 
highly pathogenic phenotype. Indeed, polyfunctional T cells have been 
previously reported in the joints of patients with adult and childhood arthritis, 
where they are associated with poor clinical outcomes (Aarvak et al., 1999, 
Piper et al., 2014a, Spreafico et al., 2016). Moreover, analysis of clinical 
measures of disease severity revealed that Th17 cells at the inflamed site in 
ERA JIA are weakly associated with more severe disease measured by active 
joint count and Physician’s VAS at the time of sampling, implicating these cells 
in disease pathogenesis. It was unexpected that double positive, IFNγ/IL-17, 
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CD4 T cells were not more closely associated with disease severity than single 
positive Th17 cells. This may be attributed to all cells within the inflamed joint 
being highly active and therefore more pathogenic than their Th17 counterparts 
within the PBMC.  
 
The HLA-B27 allele is commonly associated with IL-17 mediated disease, via 
mechanisms described in Chapter 1. With this in mind, it was perhaps 
surprising that there was no significant difference found in the proportion of 
Th17 cells within the SFMC of HLA-B27+ compared to HLA-B27- patients. 
~80% of the ERA JIA patients analysed during this study were HLA-B27+. As 
the number of samples for these analyses from HLA-B27- patients was small, 
the results are likely to be underpowered and more significant differences may 
have been seen with larger sample numbers.  
 
Killer cell lectin-like receptor, CD161, is induced by RORC and is associated 
with IL-17-producing T cells(Cosmi et al., 2008, Maggi et al., 2010).  CD161 
expression was more common on CD4 and CD8 T cells from the SFMC of ERA 
JIA patients compared to paired PBMC. This further supports a strong IL-17 
signature at the inflamed site in ERA JIA. As expected CD161 was expressed 
on the majority of IL-17+ CD4 and CD4-CD8- T cell subsets. Distinct 
populations with low, intermediate and high CD161 expression were seen within 
IL-17+ CD8 population. Human mucosal associated invariant T (MAIT) cells are 
defined by very high expression of CD161 and originate from committed IL-17-
type CD8 precursors(Walker et al., 2012). These cells have tissue-homing 
properties and are expanded at sites of inflammation(Billerbeck et al., 2010, 
Serriari et al., 2014a). It is likely that the CD161high IL-17+CD8 T cells identified 
represent a population of MAIT cells.  
 
In addition to IL-17+ T cells, an expansion of CD161+IFNγ+ “ex-IL-17” was 
noted. A previous study from the Wedderburn group has implicated these cells 
in the pathogenicity of JIA (Nistala et al., 2010a, Nistala, 2011). 
CD161+IFNγ+IL-17-CD4 T cells expressed higher levels of chemokine receptor 
CCR6, which has been shown to be crucial for the entry of pathogenic cells to 
the inflamed sites in rheumatoid arthritis and in animal models (Hirota et al., 
 116 
2007). Additionally, these cells are shown to express high levels of IL-23R and 
produce elevated IFNγ and TNFα in response to IL-23 stimulation (Nistala, 
2011). As previously mentioned the HLA-B27 allele is associated with aberrant 
IL-23 production (DeLay et al., 2009, Goodall et al., 2010). CD161+IFNγ+ T 
cells are often overlooked in analyses, however, the response of these cells to 
IL-23 makes this population particularly interesting in the context of ERA JIA 
and other HLA-B27 associated disease.  
 
Taken together, these cytokine data highlight imprinting of the IL-23/IL-17 axis 
in ERA JIA pathogenesis. It is noteworthy that IL-17+ cells are expanded in all T 
cell compartments. The clear expansion of IL-17+ populations at the inflamed 
site in ERA JIA has significant clinical implications as new biological therapies 
targeting the IL-23/IL-17 pathway are now gaining momentum for proposed 
trials in JIA. A simple robust method to detect this synovial IL-17 signature, in 
the peripheral blood, could be a valuable way to select a subset of patients for 
these specific targeted therapies. 
 
In addition to IL-17, these analyses also demonstrate an expansion of IL-22+ T 
cells from all T cell subpopulations (CD4, CD8 and CD4-CD8-). This data 
corroborates previously published data in adult arthropathies, and may allude to 
a role for IL-22 in pathogenesis of ERA JIA. Although this hypothesis has not 
been examined in detail, IL-22 has been implicated in the pathogenesis of other 
inflammatory conditions including adult rheumatoid arthritis where it has been 
shown to exacerbate disease by inducing activation and proliferation of synovial 
fibroblasts(Ikeuchi et al., 2005). Many reports have been made of the close 
association and co-production of IL-17 and IL-22. There is still no consensus on 
whether these cytokines arise from a common T cell subset, or whether they 
represent parallel or plastic populations (Eyerich et al., 2009). Interestingly, 
there was limited overlap between IL-22 and IL-17 production during this study, 
suggesting that IL-17 and IL-22 producing cells may be distinct subtypes in this 
environment. 
 
T cell memory at the inflamed site in ERA JIA has not previously been studied 
in detail. In line with previous reports of other subtypes, the memory population 
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represented >90% of all CD4 T cells within the SFMC compared to ~30% seen 
in paired PBMC (Silverman et al., 1993, Wedderburn et al., 2000a, Chiesa et 
al., 2004)The memory pool is known to increase with age in response to antigen 
exposure (Cossarizza et al., 1996, Farber et al., 2014). It is interesting that the 
memory pool within the PBMC from ERA JIA patients was significantly larger 
than the memory pool in cHC PBMC (median age = 6.24) and was more aligned 
with the T cell memory population size in aHC PBMC despite the age difference 
between these two groups (aHC median = 26.15, ERA JIA PBMC median= 
13.22). Additionally, within the gated memory CD4 T cells there was an 
expansion of IL-17+ cells in the PBMC from ERA JIA patients compared to 
aHC. This expanded IL-17+ memory population within the PBMC of ERA JIA 
patients, may be indicative of systemic disease although this is difficult to 
conclude from the low number of samples analysed. For more accurate analysis 
it would be prudent to analyse the ERA JIA PBMC memory population against 
more closely age matched controls and also against PBMC from other JIA 
subtypes, in a validation cohort.  
 
To investigate regulation by T cells at the inflamed site, FOXP3+Treg 
populations were analysed. A non-significant enrichment of Treg was seen in 
the SFMC from ERA JIA patients compared to paired PBMC. However, fewer 
Treg were identified in the SFMC of ERA JIA patients compared to other JIA 
subtypes. This is not entirely surprising given the reciprocal relationship of Treg 
with Th17, shown here and in previous publications, and the dramatic 
expansion of Th17 in the ERA JIA subtype(Spreafico et al., 2016).  
 
It is likely that these analyses represent an underrepresentation of the true Treg 
population at the inflamed site en ERA JIA. During the analysis, a population of 
CD25+FOXP3low cells was observed. This population has also been identified in 
other JIA subtypes and analysed in detail in the Wedderburn group. These 
previous studies show that despite reduced expression of the FOXP3 protein, 
the CD25+FOXP3low population of Treg are demethylated at the Treg‐specific 
demethylated region (TSDR), which is an intronic enhancer region that can be 
used to discriminate Treg from other FOXP3-expressing cells, where FOXP3 
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expression may have been upregulated due to T cell activation. Additionally, 
these FOXP3low cells were shown to maintain their suppressive capacity in 
vitro (Bending et al., 2014, Bending et al., 2015). I therefore believe it would be 
reasonable to include these cells in future analyses of regulatory T cells in sites 
of inflammation.  
 
As previously mentioned, CD161 is commonly associated with Th17 cells, but 
has more recently been identified on a population of FOXP3+Treg with an 
inflammatory signature (Cosmi et al., 2008, Maggi et al., 2010, Pesenacker et 
al., 2013). CD161+ Treg were significantly enriched in the joints of ERA JIA 
patients. CD161+ Treg are demethylated at the TSDR and are suppressive in 
vitro. However, they also have a Th1/Th17 transcriptional signature, are able to 
produce inflammatory cytokines, including IL-17 and IFNγ, and are enriched in 
the joints of oligo JIA patients (Pesenacker et al., 2013, Afzali et al., 2013, 
Duurland et al., 2017b). It is not currently known whether these cells act in an 
inflammatory or regulatory role in the joints of JIA patients, however cytokine 
producing Treg have been identified in autoimmune hepatitis where they are 
implicated in promoting inflammation (Arterbery et al., 2016). CD161+Treg and 
their inflammatory potential should not be overlooked in ERA JIA, as 
CD161+Treg may contribute to the IL-17 signature and pathogenesis, and 
represent another prospective target of biological therapies affecting the IL-
23/IL-17 axis.  
 
Taken together, the results presented in this chapter highlight a strong IL-17 
signature within the joints of patients with ERA JIA and suggest that similarities 
between ERA JIA and adult AS may extend beyond clinical features or genetic 
associations, to key pathological mechanisms in the joint. It is clear that IL-17 
‘imprinting’ is not restricted to the CD4 T effector population, but is also evident 
in CD8 and γδ T cell populations and has even infiltrated the regulatory T cell 
compartment. This suggests that synovial milieu is supportive of the recruitment 
and survival of IL-17 producing cells. I therefore hypothesize that this may 
extend beyond the T cell compartment, and the ERA JIA synovial environment 
may also promote IL-17 production from other cell types, which may also 
contribute to disease pathogenesis. The following chapter will investigate the 
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innate lymphoid cell (ILC) signature in ERA JIA, with the hypothesis that IL-17+ 
ILC will also be expanded at the inflamed site. 
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4 : Defining the Innate Lymphoid Cell 
Signature in JIA 
  
 121 
4.1 Introduction 
 
Innate Lymphoid cells (ILC) are a newly described population of immune cells, 
which can be divided into three subsets (ILC1, ILC2 and ILC3), which mirror T 
cell subsets (Th1, Th2 and Th17) cells based on their transcription factor and 
cytokine profiles. (Spits and Cupedo, 2012).  
 
ILC have been implicated in a plethora of inflammatory and autoimmune 
diseases including, but not restricted to, asthma(Chang et al., 2011), 
inflammatory bowel disease(Bernink et al., 2013b), and skin 
inflammation(Teunissen et al., 2014a). To date, there have been very few 
reports of ILC involvement in inflammatory rheumatic diseases. Synovial ILC 
have only been characterised in adult forms of arthritis, in particular psoriatic 
arthritis, where group 3 ILC were enriched at the inflamed site and were 
associated with disease severity (Leijten et al., 2015). No studies have been 
published implicating ILC in JIA. 
 
The aims of this chapter were to characterize the ILC populations at the 
inflamed site in childhood arthritis and to test the hypotheses that IL-17-
producing NCR-ILC3 are enriched in the synovial fluid of JIA, and in particular 
ERA JIA, patients and are associated with more severe disease. These aims 
were addressed by: 
 
1. Developing an effective strategy for the identification of ILC populations in 
synovial fluid from patients with JIA.  
2. Enumerating the ILC subpopulations and interrogating functionality of ILC 
subpopulations at the inflamed site. 
3. Probing for associations between ILC populations and clinical measures of 
disease severity in JIA.  
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4.2 Results 
 
4.2.1  CD161 is useful for the identification of ILC in synovial fluid 
 
ILC are a relatively newly discovered population of immune cells and until 
recently there was little consensus on an efficient strategy for their identification. 
Due to limited published data about ILC and their characteristic cell markers, 
significant optimisation was required in order to generate a strategy for the 
identification of ILC in arthritis.   
 
It was first important to consider the most appropriate scatter gate for the 
identification of ILC. Cells within the SFMC population are typically highly 
activated and as such have higher forward and side scatter properties than 
similar cells from within PBMC. During preliminary optimisation assays, ILC 
were identified as those cells lacking makers associated with known immune 
cell lineages (B cells, T cells, NK cells, monocytes, DC, stem cells, mast cells 
and eosinophils), which expressed the IL-7Rα chain (CD127). Antibodies used 
as listed in Chapter 2. In order to elucidate the best scatter gate, the lineage-
CD127+ ILC populations from within the lymphocyte gate (based on forward 
and side scatter) were compared to the same population from a scatter gate, 
which included all live cells. No difference was seen between the sizes of the 
ILC population within the lymphocyte gate compared to the total cell gate in the 
PBMC of healthy controls (Figure 4.1A). However, a significant difference was 
seen between the ILC populations from within the two gates in SFMC, with the 
emergence of a lineagelowCD127+ population within events from the total cell 
gate (Figure 4.1B).  Back gating analysis showed that the lineagelow populations 
were larger cells, which appeared to have an intermediate scatter profile, 
positioned between the lymphocyte and monocyte populations (Figure 4.1C).  
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Figure 4.1 Optimisation of gating strategy for the identification of innate 
lymphoid cells (ILC) in the PBMC and SFMC from JIA patients.  
A ‘dump’ channel (‘ lineage’ as shown) was constructed to identify and exclude cells of 
known lineages, using antibodies all labelled with the PE fluorochrome against CD1a, 
CD3, CD11c, CD14, CD16, CD19, CD34, CD94, CD123, BDCA2, FcεRIα, αβTCR and 
γδTCR. (A, B) Analysis by flow cytometry of (A) PBMC, and (B) SFMC, representative 
samples. Upper plots show scatter plots gated on the lymphocyte (upper left plots A 
and B) or total cell gate (upper right plots, A and B) following exclusion of dead cells 
and doublets (not shown); lower plots show gated events of lineage–CD127+ cell 
population within the lymphocyte (lower left plots A and B) or total cell gate (lower right 
plots, A and B); (C) Representative plot of back-gating analysis shows size and 
granularity of lineagelowCD127+ve population from SFMC assessed by forward scatter 
area (FSC-A) and side scatter area (SSC-A). All gated events form the left hand plot 
are indicated as red cells on right hand plot. 
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The NK cell receptor CD161 has been proposed by experts in the field to be an 
effective marker for the identification of CD127+ ILC subsets in 
humans(Mjosberg et al., 2011a, Spits et al., 2013). In order to assess the value 
of CD161 as a tool for the identification of ILC in synovial fluid, healthy control 
PBMC and SFMC from patients were stained with the ILC flow cytometry panel 
(containing lineage markers and CD127) with the addition of CD161. CD45 was 
also included in the amended ILC panel in order to exclude non-leukocytes from 
analysis (Figure 4.2A).      
 
Results of this preliminary experiment showed the CD161 was expressed on a 
high number of lineage-CD127+cells in the PBMC of healthy controls 
(median=73.8%, IQR=61.5-85.7%). CD161 was expressed on a lower 
proportion of lineage-CD127+ cells in the SFMC (median=41.1%, IQR=37.2-
49.3%) (Figure 4.2B). The scatter profiles of the CD161+ ILC populations were 
then investigated. CD161+ ILC from PBMC has a scatter profile consistent with 
lymphoid cells. In the SFMC CD161+ ILC had a mixed scatter profile (Figure 
4.2A bottom row).   Informed by these preliminary experiments, CD161 was 
added to the ILC panel for all subsequent analyses. 
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Figure 4.2 CD161 is useful for the identification of ILC in SFMC.   
(A) Representative flow cytometry plots showing adapted ILC gating strategy including 
CD45 and CD161 in aHC PBMC (left panels) and SFMC from JIA patients (right 
panels). ILC populations were investigated within the total cell gate (top row) dead cells 
and doublets were excluded (data not shown). Leukocytes were selected based on 
expression of CD45 (second row) and CD161 expression was analysed on lineage-
CD127+ cells (third and fourth rows). Bottom line shows back-gating analysis to show 
the size and granularity of CD161+/- cells from within the lineage-CD45+CD127+ 
population (B) Combined data showing proportion of CD161+ cells as a % of total 
lineage-CD45+CD127+ cells from within the PBMC of healthy controls (n=7) and 
SFMC of JIA patients (n=7). Statistical analysis by Mann- Whitney. p=0.0006  
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4.2.2 Group 3 ILC are enriched in the synovial fluid of JIA patients. 
 
Following successful optimisation, ILC (lineage-CD45+CD127+CD161+) were 
enumerated within the PBMC and SFMC of JIA patients, and the PBMC of adult 
and child healthy controls (Figure 4.3A).  The ILC population was small, as a 
proportion of all live mononuclear cells, in both PBMC and SFMC samples 
(0.005-0.5% of total live leukocytes). These data are consistent with other 
reports of the typical population frequency of ILC within human adult PBMC 
(Hazenberg and Spits, 2014a). No significant difference in the proportion of all 
live mononuclear cells identified as ILC by this strategy was seen between 
healthy or disease PBMC samples or SFMC (Figure 4.3B). Additionally, no 
differences were seen between ILC, as a proportion of all live mononuclear 
cells, between JIA subtypes analysed, namely, enthesitis-related arthritis, 
oligoarticular, polyarticular, and psoriatic arthritis (Figure 4.3C). 
 
Based upon available literature at the time of these analyses, ILC were 
subsequently divided into subpopulations of ILC, defined according to 
expression of surface markers CRTH2, cKit and NKp44. ILC1 were defined as 
ILC which lacked expression of both CRTH2 and cKit; ILC2 were defined by 
expression of CRTH2; and ILC3 were identified as CRTH2 negative cells which 
expressed cKit, and could be further divided into NCR+ and NCR- groups based 
on expression of NKp44 (Figure 4.4A)(Mjosberg et al., 2011a, Hazenberg and 
Spits, 2014a).  
 
These ILC subpopulations were then analysed as proportions of total ILC. This 
showed that ILC1 cells were significantly enriched, as proportion of all ILC, in 
the SFMC cells of JIA patients (median= 24.45%, IQR=16.63-37.3%) compared 
to patient or control PBMC (JIA PBMC median= 10.2%, IQR=8.67-14.2%) 
(p>0.0001) (Figure 4.4B). ILC2 were the most prevalent ILC population, as 
proportion of all ILC, in all PBMC samples analysed (median ILC2 in JIA 
PBMC= 60.8%, IQR=48.2-70.1%). In contrast a significant depletion of ILC2, as 
proportion of all ILC, was observed across SFMC samples (median= 7.7%, 
IQR=3.89-13.33%)(p<0.0001) compared to PBMC of patients or controls 
(Figure 4.4C). NCR- ILC3 were significantly enriched, as a proportion of total 
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ILC in the SFMC of JIA patients (median = 51.1%, IQR=42.6-60.38%) 
compared to PBMC of patients or controls (median JIA PBMC NCR-ILC3= 29%, 
IQR=20.0-34.4%) (p<0.0001) (Figure 4.4D). Analysis of ILC3 expressing NKp44 
revealed the emergence of an NCR+ILC3 population in the JIA SFMC cells 
(median= 8.44%, IQR=6.2-15.8%), which was significantly different to PBMC; I 
observed a near absence of this population in the PBMC samples of either 
patients or controls (median NCR+ILC3 in JIA PBMC= 0.25%, IQR=0-0.71%).  
 
Although significant differences in ILC subpopulations were observed between 
PBMC and SFMC samples, no significant differences were seen between 
relative proportions of ILC subpopulations between the PBMC of adult and child 
controls or patient PBMC. Furthermore, no differences were seen in relative 
proportions of ILC populations between JIA clinical subtypes in the SFMC 
(Figure 4.4F-I). Although small numbers of patients were analysed for some 
clinical subtypes, given that the distinct pattern of relative proportions within 
SFMC compared to JIA PBMC was the same across all subtypes, in 
subsequent ILC investigations, JIA subtypes were grouped together and not 
analysed individually.    
  
 128 
Figure 4.3 Enumeration of total ILC from the blood and synovial fluid of 
JIA patients and healthy controls.   
Mononuclear cells were stained by multi colour flow cytometry for cell surface proteins 
to identify ILC populations. (A) Representative plots showing optimised gating strategy 
for identification of ILC ex vivo in PBMC from aHC and cHC and PBMC and SFMC 
from JIA patients. ILC were identified within gated total cells based on FSC-A and SSC-
A (top row) and then as CD45+ leukocytes (second row) which are lineage- CD127+ 
(third row) and express CD161 on analysis (fourth row); (B) Combined data showing 
enumeration of ILC as % of total live CD45+ cells within PBMC of aHC (n=12) and cHC 
(n=4) controls, and blood PBMC (n=15) and joint SFMC (n=33) of JIA patients ex vivo; 
(C) Summary plot of enumeration of ILC defined as CD45+Lineage-CD127+CD161+ 
cells within PBMC of healthy adult and child controls (n=12, n=4 respectively) and 
PBMC and SFMC from ERA-JIA (n=8, n=17), oligo-JIA (PBMC n=4, SFMC n=13) poly-
JIA (n=2,n=3) and PsA-JIA patients (n=3, n=5), shown as a percentage of total live 
mononuclear CD45+ cells. Statistical analysis by Kruskal Wallis. Bars represent 
median values. 
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Figure 4.4 ILC1 and ILC3 subpopulations are significantly enriched in the 
synovial fluid mononuclear cells of JIA patients.  
ILC subpopulations were identified by multicolour flow cytometry within control PBMC 
from aHC and cHC. (n=12, n=4) and PBMC and SFMC from ERA-JIA (n=8, n=17) 
oligo-JIA (n=4, n=13) poly-JIA (n=2,n=3) and PsA patients (n=3, n=5). (A) 
Representative plots showing the gating strategy for the identification of ILC 
subpopulations, (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) within the total ILC population 
identified ex vivo (gating as shown in Figure 4.3) in PBMC from aHC and cHC and 
PBMC and SFMC from JIA patients. Subpopulations defined according to phenotype: 
ILC1 (CRTH2-cKit-) ILC2 (CRTH2+) NCR-ILC3 (CRTH2-cKit+NKp44-) and NCR+ILC3 
(CRTH2-cKit+NKp44+); (B-E): Summary data showing frequency of (B) ILC1 (C) ILC2 
(D) NCR-ILC3 and (E) NCR+ILC3, each as a percentage of total ILC within healthy 
control PBMC (aHC n=12, cHC n=4) and JIA PBMC (n=15) and SFMC (n=33); (F-I): 
Combined data summary plots enumerating of ILC subpopulations as % of total ILC, 
within PBMC of adult (aHC, n=12) and child (cHC n=4) controls, and blood PBMC 
(n=15) and joint SFMC (n=33) of JIA patients divided by clinical JIA subtype ex vivo. 
(F) ILC1 (G) ILC2 (H) NCR-ILC3 and (I) NCR+ILC3. Statistical analysis carried out by 
Kruskal Wallis.  *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001. Bars represent median 
values. 
 
4.2.3 Multispectral imaging flow cytometric analysis of paired blood and 
synovial fluid ILC confirms lymphoid cell morphology 
  
Multispectral imaging flow cytometric analysis (ImageStream) was used to 
visualise ILC subpopulations from the PBMC and SFMC of JIA patients, and 
confirm membrane staining of the cell surface proteins. Cells were selected 
based on aspect ratio intensity and area measurements, and focused cells 
(Gradient RMS>50) were selected and analysed using the optimised ILC panel 
in order to identify lineage-CD45+CD127+CD161+ ILC (Figure 4.5A).   
 
Multispectral images of ILC subsets were generated by ImageStream software 
and analysed for cell morphology and cell marker localization. ILC cell markers 
were restricted to the cell surface. Additionally, the cells showed very little 
fluorescence in the side scatter plots supporting a lymphocyte phenotype. ILC 
from PBMC and SFMC show lymphoid cell morphology. All ILC detected 
appeared to have a characteristically dense single nuclei and thin halo of 
perinuclear cytoplasm. Additionally, although ILC from the SFMC appear to be 
slightly larger than parallel PBMC ILC, cells from both compartments measured 
~7μm, the approximate size expected for lymphocytes, (Figure 4.5B and 4.5C, 
left hand of each set of panel).  
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Figure 4.5 ImageStream analysis of ILC populations confirms lymphoid 
cell morphology and surface protein expression.  
Paired PBMC and SFMC from JIA patients were analysed by Image Stream ex vivo 
after depletion of T cells by removal of CD3+ cells using magnetic beads. (A) Image 
stream gating strategy for identification of ILC populations. Cells were identified 
according to aspect ratio intensity and area. Focused cells were selected with Gradient 
RMS>50; ILC were identified as Lineage- CD45+CD127+CD161+ cells; (B, C) ILC 
subpopulations were identified according to fluorescence of subset specific protein 
expression by analysis of individual cell images as shown. Representative images of 
ILC subpopulations from (B) PBMC and (C) SFMC from JIA patients. Left hand panel 
(grey) in each panel shows the brightfield image of the cell.  
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4.2.4 High purity ILC can be sorted by flow cytometry from mononuclear 
cells prepared from blood and synovial fluid 
 
In order to validate the analysis of ILC identified in PBMC and SFMC, I 
investigated transcription factor and cytokine expression profiles of ILC. Total 
ILC (lineage-CD45+CD127+CD161+) were sorted by flow cytometry from aHC 
PBMC and JIA SFMC samples following depletion of T cells by CD3 immuno-
magnetic selection. To ensure that the sorting procedure did not affect ILC 
populations, or the expression of crucial surface markers (CRTH2, cKit and 
NKp44), a sample was removed after each stage of the sorting process and 
stained with the full ILC subtyping panel. The sorting process did not affect ILC 
subpopulations as shown in Figure 4.6B. ILC were sorted according to the 
sorting strategy shown in Figure 4.6A and highly pure samples were isolated 
from each sort from both PBMC and SFMC (>92% pure) (Figure 4.6C and 
summary of sort purity data, 4.6D). 
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Figure 4.6 Validation of strategy for sorting ILC.  
Total ILC (lineage-CD45+CD127+CD161+) were sorted by flow cytometry from healthy 
control PBMC (n=7) and JIA SFMC (n=6) (A) Sorting strategy based on expression of 
CD45, lineage markers, CD127 and CD161; (B) ILC from healthy PBMC analysed for 
ILC subpopulation markers, before sorting (top row, pre-sort), after CD3 depletion by 
magnetic beads (middle row, CD3-), and after sorting (bottom row, post-sort), as 
shown, to verify that sorting process did not affect critical marker expression. Total ILC 
(left plot) were split into CRTH2+ (ILC2) and CRTH2- populations (middle plot) and 
subsequently the CRTH2- cells were divided into ILC1 (cKit-NKp44-), NCR-ILC3 
(cKit+NKp44) and NCR+ILC3 (cKit+NKp44+) subpopulations (right plot); (C) 
Representative dot plots showing purity of ILC (based on CD161+ CD127+) isolated 
from healthy PBMC and the SFMC of JIA (ERA subtype) patients, following exclusion 
of dead cells; (D) Summary plot showing sort purities from sorting of ILC from PBMC 
and SFMC, defined as % live cells that were CD45+lineage-CD127+CD161+, post 
sorting.  
 
 
 
 
 
4.2.5 qPCR analysis of sorted ILC show altered transcription factor and 
cytokine profiles between blood and synovial fluid 
 
The transcription factor and cytokine profiles of ILC (lineage-
CD45+CD127+CD161+) were analysed for specific transcripts by qPCR. Gene 
expression of transcription factors TBX21 (Tbet) (ILC1), GATA3 (ILC2), RORC 
(ILC3) and AHR (ILC3) were analysed in FACS-sorted ILC from healthy PBMC 
and SFMC from JIA patients. Data were expressed as relative expression 
compared to gene expression from skewed CD4+ T cells prepared and 
analysed as detailed in chapter 2, and normalized to β-actin expression 
(ACTB). Relative expression of GATA3 was higher in ILC isolated from healthy 
PBMC samples compared to those sorted form SFMC. Conversely, expression 
of TBX21, RORC and AHR were all increased in SFMC relative to healthy 
PBMC (Figure 4.7).    
 
In parallel, expression of signature cytokine genes IFNG (IFNγ), IL13, IL17A 
and IL22 were analysed. Higher expression of IFNG, IL17A and IL22 were 
detected in SFMC ILC, while IL13 expression was increased in ILC isolated 
from healthy control PBMC samples (Figure 4.8).  
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Taken together, these qPCR data show that the relative proportions of ILC in 
SFMC from JIA patients compared to healthy PBMC are mirrored in the ratio of 
gene expression of signature transcription factors and cytokines in synovial: 
blood ILC. The ILC subpopulation proportions and the qPCR data were then 
analysed as ratios, comparing the data from blood ILC of aHC to synovial fluid 
ILC. In the SFMC I observed an enrichment of ILC1 and ILC3 populations, and 
in parallel, increased expression of transcripts for the related genes (TXB21, 
RORC, AHR, IFNG, IL17A and IL22) compared to PBMC ILC. On the other 
hand I observed a relative depletion of ILC2 in the SFMC, and reduced GATA3 
and IL13 gene expression compared to expression in ILC from PBMC (Figure 
4.9). 
 
 
Figure 4.7 Relative expression of mRNA transcripts for master 
transcription factor genes in ILC.  
qPCR was performed to amplify specific transcripts from cDNA generated from ILC 
sorted from aHC PBMC (n=3) and JIA SFMC (n=3). Relative expression of specific 
transcripts for (A) TXB21 (B) GATA3 (C) RORC (D) AHR. Bars represent the mean 
value of the 3 ILC samples, error bars represent SEM. 
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Figure 4.8 Relative expression of mRNA transcripts for signature cytokine 
genes in ILC.  
qPCR was performed to amplify specific transcripts from cDNA generated from ILC 
sorted from aHC PBMC (n=3) and JIA SFMC (n=3). Relative expression of specific 
transcripts for (A) IFNG (B) IL13 (C) IL17A (D) IL22. Bars represent the mean value of 
the 3 ILC samples, error bars represent SEM. 
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Figure 4.9 Comparison of ILC proportions analysed by flow cytometry and 
expression of transcription factors and cytokine transcripts, analysed by 
qPCR, in healthy PBMC and JIA SFMC.  
(A) Relative difference between mean proportions of ILC cell types (ILC1, ILC2, NCR-
ILC3 and NCR+ILC3) in healthy PBMC and JIA SFMC identified by flow cytometry 
(data from Figure 4.3); (B) Ratio of mean gene expression of signature transcription 
factors in SFMC: PBMC (data from Figure 4.7).  (C) Ratio of mean gene expression of 
signature cytokines in SFMC: PBMC (qPCR), (data from Figure 4.8). 
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4.2.6 Synovial ILC produce reduced IL-13 ex vivo 
 
In order to interrogate the functionality of ILC, mononuclear cells from patient 
PBMC and SFMC, and aHC PBMC were stimulated for 4 hours with PMA and 
Ionomycin in the presence of Brefeldin A and signature cytokines IFNγ, IL-13, 
IL-17A and IL-22 were measured by intracellular staining by flow cytometry. The 
gating strategy for ILC is shown in Figure 4.3, and for subsequent analysis of 
cytokine positive cells, as shown in Figure 4.10A. Low levels of IFNγ, IL-17A 
and IL-22 were observed in all samples, with only slight trend to more of these 
cytokines being produces by ILC from SFMC. There were no significant 
differences in cytokine positive cells seen between PBMC and SFMC ILC for 
IFNγ, IL-17A and IL-22 (Figure 4.10B, 4.10D and 4.10E). 
 
A significant reduction in IL-13 production was seen in synovial ILC (median= 
7.53%, IQR=2.45-18.65%) compared to JIA PBMC (median= 39.95%, 
IQR=22.78-51.2%) (Figure 4.10C). This result correlated well with the observed 
significant reduction in ILC2 (p=0.019), as proportion of total ILC2 population 
within SFMC. As the number of samples for these analyses was small the 
results may be relatively underpowered and more significant differences may 
have been seen with larger sample numbers.  
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Figure 4.10 Cytokine production by ILC analysed ex vivo upon 
stimulation.  
PBMC from blood of aHC (n=4) and JIA patients (n=4), and SFMC from JIA patients 
(n=5) were analysed for cytokine production by flow cytometry following 4 hours 
stimulation with PMA and Ionomycin in the presence of Brefeldin A. Cells were first 
gated on total ILC as shown in figure 4.3 and subsequently analysed for each cytokine 
(A) Representative flow cytometry plots showing IFNγ (top row), IL-13 (second row), IL-
17A (third row) and IL-22 (bottom row) in blood of aHC (left column), JIA PBMC (middle 
column) and SFMC of JIA patients (right column). Summary plots showing proportion of 
ILC producing (B) IFNγ (C) IL-13 (D) IL-17A and (E) IL-22 within each sample. Line 
represents median value for each data set. Statistical analysis carried out by Kruskal 
Wallis.  *p<0.05. 
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4.2.7 FACS sorted synovial ILC produce inflammatory cytokines in 
response to cytokine stimulation 
 
ILC are known to potently produce cytokines in response to the surrounding 
cytokine milieu. In order to investigate the response of ILC from aHC PBMC and 
JIA SFMC to activating cytokines, ILC were sorted by flow cytometry as detailed 
in section 4.2.4 and Figure 4.6. Sorted pure ILC were stimulated for 4 days in 
the presence of IL-2 and cytokine cocktails designed to activate ILC1, ILC2 or 
ILC3 populations as detailed in chapter 2. All cultures were supplemented with 
IL-2 plus: for ILC1 addition of IL-12 and IL-18; for ILC2 addition of TSLP, IL-25 
and IL-33; for ILC3 addition of IL-1β and IL-23. For the final 4 hours of culture, 
the cells were stimulated with PMA and Ionomycin in the presence of Brefeldin 
A.  
 
Under ILC1-activating conditions (IL-12 and IL-18) synovial ILC potently 
produced IFNγ (median= 51.25%, IQR=43.0-59.5%), while only a small 
proportion of blood ILC were observed to produce the cytokine (median= 
15.20%, IQR=11.61-30.3%), Figure 4.11A and 4.11B. Under ILC2-activating 
conditions (TSLP, IL-25 and IL-33) IL-13 production was induced in a significant 
proportion of blood ILC (median= 62.95%, IQR=51.45-68.08%) while synovial 
ILC showed a smaller proportion of cells able to produce IL-13 (median = 
18.30%, IQR=13.2-23.4%) Figure 4.11A and 4.11C. Finally, under ILC3-
activating conditions (IL-23 and IFNβ), little IL-17A production was seen from 
either blood or synovial ILC (median= 3.64%, IQR=2.67-4.09 and 
median=3.38%, IQR=2.48-4.7% respectively) Figure 4.11A and 4.11D. 
However, increased IL-22 production was seen from synovial ILC 
(median=9.17%, IQR=6.04-12.3%) compared to aHC blood ILC (median= 3.2%, 
IQR=2.2-3.88%) (Figure 4.11A and 4.11E). 
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Figure 4.11 Cytokine production by cultured ILC.  
Total ILC were sorted from healthy PBMC (n=5) and JIA SFMC (n=2), cultured for 4 
days in the presence of IL-2 plus skewing cytokines as follows: IL-12 and IL-18 for 
ILC1, IL-33, TSLP and IL-25 for ILC2, and IL-23 and IL-1β for ILC3 and then stimulated 
for 4 hours with PMA and Ionomycin in the presence of Brefeldin A. (A) Representative 
flow cytometry plots showing production of IFNγ, IL-13, IL-17 and IL-22; (B) summary 
data for IFNγ (C) IL-13 (D) IL-17A and (E) IL-22 cytokine production from synovial and 
blood ILC. Lines represent median value for each data set. 
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4.2.8 CD127 and CD161 are down regulated upon activation of ILC in 
vitro 
 
ILC sorted form healthy PBMC that were cultured with stimulating cytokines (as 
detailed in Figure 4.11) grew larger as they became activated, which could be 
detected as the forward and side scatter profile of the ILC transformed during 
the course of the stimulation assay (Figure 4.12A). When these cells were 
analysed on day 4 of the culture assays, expression of CD127 and CD161 was 
significantly lower on the activated ILC compared to unstimulated control ILC 
from the same aHC. This is demonstrated by the >3 fold reduction in mean 
protein expression (analysed by MFI value) of both CD127 and CD161. 
 
 
 
Figure 4.12 The effect of cytokine driven activation on ILC cell size and 
expression of CD127 and CD161.  
(A) Representative dot plot showing increase in size and granularity of ILC after 4 days 
culture with activating cytokines IL-2, IL-25, IL-33 and TSLP. Cells were analysed for 
expression of CD127 and CD161 by flow cytometry; (B) CD127 expression on ILC 
before (blue line) and after (red line) cytokine stimulation; (C) CD161 expression on 
synovial ILC before  (blue line) and after (red line) cytokine stimulation. Plots in B and C 
are gated on live single cells. Figures represent MFI values for CD127 (B) and 
CD161(C). 
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4.2.9 Proportions of ILC populations change over time in the joints of JIA 
patients and are associated with disease status 
 
To ascertain whether there was a time-dependent relationship between relative 
proportions of ILC subpopulations in disease, ILC were characterised within 
SFMC taken from 3 serial time points of 3 JIA patients. The medication status of 
the patients and physicians overall disease activity score, VAS (0-10 with 0 
signifying no active disease, 10 worst disease activity), were collected for each 
patient at each time point (Table 4.2). Serial samples used during this 
preliminary investigation were collected from 3 were oligoarthritis patients. Since 
joint fluid is only aspirated for clinical indications, all patients from whom 
synovial fluid is collected have some on-going disease activity, as indicated by 
the physicians VAS scores, here ranging from 1.4 to 5.0.  
 
The proportions of ILC2 as a percentage of total ILC remained relatively stable 
over time in all 3 patients and were consistently low in all samples (represented 
by blue lines in Figure 4.13). Relative proportions of ILC1 and NCR- and NCR+ 
ILC3 varied over time in all 3 patients. This preliminary investigation suggests 
that higher proportions of NCR-ILC3 were seen when patients had worse 
disease, as defined by higher physicians VAS. Conversely, both ILC1 and 
NCR+ILC3 proportions rose when NCR-ILC3 fell suggesting that the proportion 
of these ILC subpopulations, within SFMC may be linked to less severe disease 
as assessed according to the physicians VAS (Figure 4.13D, 4.13E, 4.13F and 
Table 4.1). 
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  Patient 1 Patient 2 Patient 3 
Sample 
1 
Physicians VAS 1.0 4.0 5.0 
Medications MTX MTX Nil 
Duration of disease 
(years) 
11.2 6.5 1.1 
Sample 
2 
Physicians VAS 4.0 2.0 1.7 
Medications MTX MTX MTX 
Duration of disease 
(years) 
11.9 10.8 4.7 
Sample 
3 
Physicians VAS 2.0 1.7 1.4 
Medications MTX MTX MTX 
Duration of disease 
(years) 
14.4 11.5 7.25 
Table 4.1 Physicians VAS scores, (range 0.0-10.0), medication and 
disease duration of the patients at each of the 3 time points of sampling  
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Figure 4.13 Proportions of ILC populations within SFMC from the inflamed joint 
of JIA patients fluctuate between serial clinical samples.  
(A-C)Summary plots showing relative proportions of ILC subpopulations identified by 
surface marker expression (as defined in Figure 4.4) in serial SFMC samples collected 
from JIA patients (n=3) over several years. (D-F) Correlation analysis of ILC 
subpopulations in the SFMC against physician’s VAS scores. Combined data from 3 
serial clinical samples from 3 JIA patients. (D) ILC1 analysed against physicians VAS 
(E) NCR-ILC3 analysed against physicians VAS and (F) NCR+ILC3 analysed against 
physicians VAS.  
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4.2.10 Proportions of synovial NCR- and NCR+ ILC3 are inversely 
correlated with each other, and are associated with clinical 
measures of disease severity 
 
Analysis of relationships between relative proportions of ILC subpopulations in 
the serial SFMC samples from JIA patients suggested that the NCR- and NCR+ 
ILC3 populations appeared to be inversely associated. To analyse this trend at 
a population level ILC3 subpopulations, as proportion of total ILC in SFMC, 
were correlated in a larger set of SFMC from 33 JIA patients. Analysis of the 
relative proportions of ILC subpopulations within the SFMC samples from the 33 
JIA patients analysed here showed a weak but significant inverse correlation 
between NCR- and NCR+ ILC3 (r=-0.43, p=0.043) (Figure 4.14).  
 
 
Figure 4.14 Proportions of NCR+ILC3 and NCR-ILC3 subpopulations 
within SFMC are inversely correlated. 
Analysis of ILC subpopulations in SFMC of JIA patients n=33 ex vivo. Correlation 
analysis by Spearman correlation r=-0.43, p=0.043.  
 147 
In order to explore the significance of the two distinct ILC3 subpopulations in 
relation to JIA disease severity, relative proportions of NCR- and NCR+ ILC3, 
here analysed as a proportion of total live cells, were analysed against 
measures of disease severity. For this analysis, active joint count, ESR and 
physicians VAS (0.0- 10.0) at time of joint sample were included, as well as the 
JADAS3 score (range 0-30). The JADAS3 is calculated as a composite score 
using 3 disease activity variables, namely the active joint count, physicians VAS 
and a parent global score of disease scored as a VAS (0.0- 10.0)(McErlane et 
al., 2013). Higher proportions of NCR-ILC3 were positively associated with the 
number of active joints affected at the time of synovial fluid sample collection 
(r=0.55, p=0.0055) (Figure 4.15A). The proportion of NCR-ILC3 was also 
weakly associated with ESR (r=0.39, p=0.08) and significantly correlated with 
the physician’s VAS (r=0.55, p=0.005) and JADAS3 score (r=0.75, p=0.004) at 
the time of sample collection (Figure 4.15B, 4.15C, 4.15D). No association was 
found between NCR+ILC3 as a proportion of total live cells and active joint 
count (0.04, p=0.85), ESR (0.32, p=0.15) or JADAS3 score (r=-0.38, p=0.20) at 
the time of sample collection (Figure 4.15E, 4.15F and 4.15H). However, a 
significant negative correlation was found between NCR+ILC and physician’s 
VAS (r=-0.43, p=0.04).  
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Figure 4.15 Proportion of IL-17-producing ILC3 in the SFMC correlate 
positively with disease severity 
(A-H) Correlations in the SFMC of JIA patients between ILC subpopulations analysed 
as a % of total live cells and clinical measures of disease severity (A) NCR-ILC3 
analysed against active joint count at time of sample (n=27, r=0.51, p=0.0055); (B) 
NCR-ILC3 analysed against ESR at time of sample (n=20, r=0.39, p=0.08); (C) NCR-
ILC3 analysed against physician’s VAS as time of sample (n=24, r=0.55, p=0.005); (D) 
NCR-ILC3 analysed against JADAS3 score as time of sample (n=13, r=0.75, p=0.004); 
(E) NCR+ILC3 analysed against active joints at the time of sample (n=27, r=0.04, 
p=0.85); (F) NCR+ILC3 and ESR at time of sample (n=21, r=0.32, p=0.15); (G) 
NCR+ILC3 analysed against physicians VAS (n=24, r=-0.43, p=0.04); (H) NCR+ILC3 
analysed against JADAS3 score as time of sample (n=13, r=-0.38, p=0.20) Correlation 
analysis by Spearman correlation. 
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4.2.11 Synovial ILC3 correlate with inflammatory IL-17+ CD4, CD8 cells, 
and regulatory CD4 T cells. 
 
Correlation analysis was carried out on ILC3 subpopulations, IL-17A-producing 
CD4, CD8 and CD4-CD8- T cell subpopulations and Foxp3-ve CD4 Treg within 
mononuclear cell populations of the PBMC and SFMC of JIA patients in order to 
elucidate associations between ILC and T cell subtypes.  
 
Significant positive correlations were seen in SFMC between NCR-ILC3 as a 
proportion of total live cells, and IL-17A-positive cells in the CD4+ (r=0.49, 
p=0.042) and CD8+ (r=0. 59, p=0.011) T cell compartments, a trend towards 
association with γδ (defined as CD4-CD8- T cells) (r= 0.37, p=0.16) T cells. 
(Figure 4.16A, 4.16B and 4.16C). In contrast no correlations were found 
between these cell types in the PBMC of JIA patients (Figure 4.16D, 4.16E and 
4.16F).  
 
Given that our group has previously demonstrated an inverse correlation 
between Th17 (CD4+ IL-17+) cells and Treg within SFMC, potential 
relationships between ILC3 and Treg in SFMC were next explored. Significance 
was not reached when ILC3 subpopulations were analysed against the 
proportion of CD4+ Treg in the PBMC or SFMC of JIA patients, however some 
trends were evident in SFMC. Thus a negative trend was seen between NCR-
ILC3 as a proportion of total live cells and Foxp3+CD4+Treg as % of all CD4+ T 
cells at the inflamed site (r=-0.379, p=0.20) (Figure 4.17A). Conversely, a 
positive trend was seen between NCR+ILC3 as a proportion of total live cells 
and Foxp3+CD4+ Treg as % of all CD4+ T cells at the inflamed site (r=0.495, 
p=0.08) (Figure 4.17B). Although similar trends were seen when comparing 
these cell populations in PBMC, no significant associations were found between 
NCR- or NCR+ILC3 and Treg in the PBMC of JIA patients (Figure 4.17C and 
4.17D).  
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Figure 4.16 IL-17-producing ILC3 correlate with IL-17-producing CD4+ and 
CD8+ T cells within SFMC.  
(A-C) Correlations in the SFMC of JIA patients between (A) NCR-ILC3 and IL-
17+CD4+ T cells (n=18, r=0.49, p=0.042); (B) NCR-ILC3 and IL-17+CD8+ T cells 
(n=18, r=0. 59, p=0.011);  (C) NCR-ILC3 and IL-17+CD4-CD8- T cells (n=18, r= 0.37, 
p=0.16) and (D-F) Correlations in the PBMC of JIA patients between (D) NCR-ILC3 
and IL-17+CD4+ T cells (n=12, r=0.108, p=0.735); (E) NCR-ILC3 and IL-17+CD8+ T 
cells (n=12, r=0.102, p=0.754);  (F) NCR-ILC3 and IL-17+CD4-CD8- T cells (n=12, r= 
0.105, p=0.744). Correlation analysis by Spearman correlation 
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Figure 4.17 IL-22-producing ILC3 correlate with regulatory T cells within 
SFMC.  
Correlations in the SFMC of JIA patients between (A) NCR-ILC3 and FOXP3+CD4+T 
cells (n=13, r=-0.379, p=0.20); (B) NCR+ILC3 and FOXP3+CD4+T cells (n=13, 
r=0.495, p=0.08) and correlations in the PBMC of JIA patients between (C) NCR-ILC3 
and FOXP3+CD4+T cells (n=11, r=-0.146, p=0.673); (D) NCR+ILC3 and 
FOXP3+CD4+T cells (n=11, r=0.448, p=0.17) Correlation analysis by Spearman 
correlation. 
 
 
 
 
  
 152 
4.3 Discussion 
 
This chapter presented novel data characterizing ILC populations at the 
inflamed site in JIA, by analysis of SFMC and comparison to PBMC of both JIA 
patients and controls, and demonstrated the approaches taken to investigate 
their functionality and associations with disease pathogenesis. 
 
ILC are a newly described population of lymphoid cells, which have been 
implicated in the pathogenesis of numerous inflammatory conditions via the 
production of influential cytokines (Spits and Cupedo, 2012). It is known that 
Th17 are important mediators of disease in JIA, and the significance of this 
population in ERA JIA was further illustrated in Chapter 3 of this thesis (Nistala 
et al., 2008a, Nistala and Wedderburn, 2009). Given the evidence for 
involvement of T cells in disease pathogenesis in JIA, the parallels that exist 
between T cells and ILC suggest that ILC may be an important new focus for 
investigation in relation to JIA (Nistala et al., 2008a, Mjosberg and Spits, 2016). 
The significance of the IL-17 and IL-23 axis is acknowledged in numerous 
autoimmune and inflammatory diseases, and new biological therapies targeting 
this pathway, such as Secukinumab which blocks IL-17 and Guselkumab and 
Ustekinumab which block IL-23 are now gaining momentum for proposed trials 
in JIA after proving useful for the treatment of adult ankylosing spondylitis, 
psoriasis and psoriatic arthritis (Chiricozzi and Krueger, 2013, McInnes et al., 
2014, Poddubnyy et al., 2014, Sofen et al., 2014, Baeten et al., 2015). When 
considering a new biologic as a possible novel treatment, it is important to 
consider all the potential targets it may have. Similarly to Th17 cells, ILC3 
populations are reliant on IL-1β and IL-23 for their development as well as their 
subsequent activation and have been shown be potent producers of IL-17 
(Cupedo et al., 2009, Cella et al., 2010, Walker et al., 2013). It was therefore 
hypothesized that a significant enrichment of these ILC3 would be present at 
the inflamed site and that their proportion would be associated with a more 
severe disease status. ILC3 represent one population, which would likely be 
significantly affected by treatment with new biologics that target IL-17 or IL-23. 
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Unlike other immune cell types, no definitive protein markers have been 
identified which are exclusive to or specific for ILC. For this reason effective 
strategies for their exclusive identification have been difficult to develop and 
until recently there has been little consensus on the most appropriate approach 
for their analysis.  In order to accurately characterize ILC at the inflamed site in 
JIA, it was imperative to validate an effective strategy for their identification. It is 
broadly accepted that cells defined as ILC are negative for markers associated 
with previously defined lineages (T cells, B cells, NK cells, monocytes, DC and 
granulocytes), and that ILC rely on IL-7 for their development and so express 
high levels of the IL-7Rα chain (CD127) (Neill et al., 2010, Wong et al., 2012). 
Additionally, ILC are defined as having lymphoid morphology, which is 
associated with characteristically low forward and side scatter properties when 
analysed by flow cytometry (Hazenberg and Spits, 2014a).  
 
Cells from the synovial fluid of JIA patients are highly activated and therefore 
lymphocytes typically have a higher forward and side scatter profile than seen in 
PBMC. Therefore, larger cells should, where possible, be included in analyses 
of SFMC in order to avoid exclusion of activated ILC. Identification of ILC using 
lineage markers and CD127 expression alone appears to be insufficient in the 
inflamed site due to the emergence of a large lineagelowCD127+ population of 
cells in the synovial fluid with unexpectedly high scatter properties, which 
suggested a further cell population had been identified which were 
lineagelowCD127+. Due to the increased size of cells in the SFMC, it is possible 
that this lineagelow population were in fact ILC with high auto fluorescence. It is 
also possible that some protein markers were relatively down regulated on the 
surface of some lineage positive cells due to their chronic activation within the 
joint leading to the appearance of a lineagelow population of cells. To address 
this issue, additional markers were added to the ILC selection panel. NK cell 
receptor CD161 was suggested by a group of experts as a characteristic marker 
of CD127+ ILC(Spits et al., 2013). CD161 is a known NK- cell marker also 
expressed on subpopulations of CD8 and CD4 T cells but is now also accepted 
to be expressed on ILC(Cosmi et al., 2008, Maggi et al., 2010, Mjosberg et al., 
2011b, Pesenacker et al., 2013). The inclusion of the analysis of CD161 in this 
study allowed for identification of an ILC population in blood and synovial fluid of 
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patients irrespective of cell size. In order to maintain consistency between 
samples, and to ensure that the same ILC population was analysed between 
blood and SFMC, expression of CD161 was subsequently considered an 
essential criterion for ILC classification throughout this project. 
 
No significant difference was seen between the total numbers of ILC in the joint 
compared the blood of JIA patients. It is important to consider that ILC are 
generally considered to be tissue resident cells(Hazenberg and Spits, 2014a). 
Due to ethical restrictions meaning that the majority of children undergoing joint 
fluid aspiration do not have synovial biopsy material sampled, it was not 
possible to analyse ILC within the synovial tissue of JIA patients in this study, 
but such analysis would surely be interesting. Additionally, despite stringent 
optimization, data from culture assays performed indicate that identification of 
synovial ILC may be significantly more complicated in the synovia than 
previously appreciated. Preliminary results after culture of aHC ILC in activating 
cytokines showed that activation of ILC may lead to down regulation of surface 
protein levels CD127 and CD161, two markers essential for ILC identification. 
Unlike peripheral blood ILC, synovial ILC are likely to be highly activated. It is 
therefore reasonable to suggest that a proportion of activated ILC in the joint 
may have down regulated these influential markers and therefore may not be 
detected via current analyses. It is therefore possible that the ILC proportions 
detected in this study within SFMC samples could represent an underestimation 
of the true ILC population.  
 
This study has shown significantly altered ILC signatures between the 
mononuclear cell populations from blood and joints of JIA patients as 
determined by surface receptor, cytokine expression and transcription factor 
analysis. In agreement with previously published data, the ILC analysis 
performed here shows ILC2 to be the predominant ILC population in peripheral 
blood of healthy controls (adults and children) as well as JIA patients (Mjosberg 
et al., 2011b). A significant ablation of ILC2 as a proportion of total ILC detected 
was seen in the SFMC of JIA patients in accordance with previously published 
data in other inflammatory settings(Leijten et al., 2015). This raises the question 
as to whether ILC subtypes are selectively recruited to the joint, or whether the 
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inflamed synovial environment leads to downregulation of the CRTH2 marker, 
and ILC plasticity. 
 
NCR+ILC3 were almost completely absent from peripheral blood samples, while 
similarly to results shown in psoriatic skin and psoriatic arthritis, a significant 
enrichment of NCR+ILC3 was detected at in SFMC samples of JIA 
patients(Teunissen et al., 2014a, Leijten et al., 2015). Furthermore, these cells 
showed an association with less severe disease as determined by physician’s 
global disease visual analogue score, (VAS). Although this is a subjective 
assessment of disease severity, it is intriguing in the context of these IL-22 
producing cells. The link with improved physicians VAS, without association 
with ESR or active joint count, suggests that these cells are related to the 
patient feeling and presenting better to the clinician even though on a 
biochemical level they may still have significant inflammation (measured by 
ESR). It is interesting that there was no clear association seen between 
NCR+ILC3 and JADAS3 scores. The JADAS3 includes the physician’s VAS 
score as well as the parent global score of disease and active joint count.  This 
may be due to the low power of this study, in part due to significant missing 
data.  The association seen between NCR+ILC3 and regulatory T cells in the 
synovial fluid further supported the concept that these cells may be having a 
‘protective’ influence. Although IL-22 is often considered to be an inflammatory 
cytokine, it is also implicated in homeostasis and repair mechanisms in the skin 
and other organs. In the skin, IL-22 to has been shown to promote wound 
healing through interaction with fibroblasts (McGee et al., 2013). NCR+ILC3 
have also been shown to play a significant role in maintaining barrier integrity in 
the gut (Geremia et al., 2011). It is possible that NCR+ILC3 mediate reparatory 
actions via IL-22 production and interaction with synovial fibroblasts. 
 
IL-17 producing T cells have been identified in JIA and are implicated in disease 
pathogenesis (Nistala et al., 2008a). In parallel to IL-17 producing T cell 
subtypes, NCR-ILC3 were significantly enriched in the joints of JIA patients. 
These finding supports the hypothesis that the IL-17 signature extends beyond 
the T cell compartment in some patients and is further reinforced by the 
correlations that were found between these different cell types. The strong 
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associations shown between NCR-ILC3 and measures of disease severity 
implicate this population in disease pathogenesis. It is clear that this ILC subset 
may also be targeted when considering treatments, which are designed to 
ablate IL-17 in these patients. Animal models of arthritis would be useful tools to 
further investigate the true extent of ILC3 involvement in disease progression 
and protection. Unlike in the T cell data presented in Chapter 3, NCR-ILC3 were 
not significantly enriched in ERA JIA patients compared to other JIA subtypes. 
This may be due to an insufficient number of patient samples being analysed for 
other JIA subtypes.  
 
As ILC are considered to be innate immune cells it would be reasonable to 
suggest that the role of ILC could be relatively restricted to the initiation and 
early stages of disease. However, while they are important for the induction of 
acute inflammation in response to pathogen, considerable evidence suggests 
that they also play pivotal roles in resolution from inflammation as well as repair 
(Dudakov et al., 2012, Gladiator et al., 2013). Preliminary longitudinal analysis 
of ILC subtypes in synovial fluid over time shows that relative proportions can 
vary over time with disease severity and higher proportions of NCR-ILC3 are 
found at time points when patients were experiencing more severe symptoms. 
 
Taken together, the results shown in this chapter demonstrate an altered ILC 
phenotype in the SFMC compared to blood of JIA patients with a significant 
enrichment of two populations of group 3 ILC (NCR-ILC3 ad NCR+ILC3), able 
to produce IL-17 and IL-22 at the inflamed site. Synovial NCR-ILC3, known to 
be potent producers of inflammatory IL-17 are associated with more severe 
disease, suggesting a role for these cells in disease pathogenesis. Additionally, 
NCR-ILC3 are correlated with IL-17-producing T cell subsets, supporting the 
initial hypothesis that the IL-17 signature extends beyond the T cell 
compartment in these patients. In parallel a significant enrichment of IL-22 
producing NCR+ILC3 was detected in the joint. Conversely to their IL-17-
producing counterparts, these NCR+ILC3 were found to be associated with less 
severe disease when the patients are assessed holistically via the physicians 
VAS. Further supporting the suggestion that these cells may play a protective 
role, NCR+ILC3 were shown to correlate with regulatory T cells at in the 
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synovial fluid. The following chapter will focus on elucidating a rationale behind 
the altered ILC phenotype observed at the inflamed site in JIA patients. 
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5 : Investigation of Innate Lymphoid 
Cell Migration and Plasticity  
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5.1 Introduction  
 
The data presented in Chapter 4 demonstrated an enrichment of IL-17 and IL-
22 producing ILC3 and an ablation of ILC2 within the mononuclear cell 
compartment at the inflamed site in children with arthritis, compared to the 
peripheral blood mononuclear cell population. The mechanisms underlying how 
this signature is achieved in the joints of JIA patients is currently unclear.   
 
There is relatively little known about ILC recruitment to inflamed sites; a recent 
study has shown that chemokine receptor expression on ILC largely mirrors 
their respective T cell subpopulation counterparts (Roan et al., 2016b).  
Significant presence of chemokines such as CCL2, CCL5, CCL20 and CXCL10 
and an enrichment of T cells expressing their corresponding receptors, CCR4, 
CCR5, CCR6 and CXCR3, has been demonstrated in the inflamed synovial fluid 
of patients with JIA (Wedderburn et al., 2000b, Pharoah et al., 2006, Nistala et 
al., 2008b, Issekutz et al., 2011). To date, no studies have reported on ILC 
migration and their presence in the inflamed site in JIA. One possible 
explanation for the altered ILC phenotype in the joint (compared to PBMC) 
could be due to the selective recruitment of ILC via the interaction of chemokine 
receptors on ILC with their ligands at the inflamed site. 
 
There is now significant evidence supporting plasticity between ILC 
subpopulations (Artis and Spits, 2015). Thus it is clear that under the influence 
of a specific cytokine/chemokine milieu, ILC may ‘switch’ their 
phenotype/functional characteristics. Several groups have explored the effects 
of cytokines in promoting the transition of ILC between subpopulations. There is 
clear plasticity between ILC1 and ILC3 subpopulations. Similarly to T cells, 
under the influence of IL-12, ILC3 are shown to skew towards an ILC1 
phenotype (Nistala et al., 2010a, Bernink et al., 2013a, Bernink et al., 2015). 
Conversely, ILC1 can be driven towards ILC3 by culture with IL-1β and IL-23 
(Bernink et al., 2015). There is even some recent indication that inflammatory 
cytokines can induce ILC2 switching to other ILC subpopulations (Silver et al., 
2016a). As plasticity has previously been demonstrated in T cell subpopulations 
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in the joint in JIA (Nistala et al., 2010b), it is reasonable to suggest that 
cytokines at the inflamed site in JIA may also drive changes in ILC phenotype, 
potentially switching towards ILC1 and ILC3 populations. 
 
The aim of this Chapter was to investigate mechanism(s) that lead to the altered 
relative proportions of ILC subpopulations at the inflamed site compared to the 
peripheral blood compartment. I hypothesized that selective migration of 
specific subpopulation of ILC, in response to specific chemokines contributes to 
ILC recruitment to the inflamed site. I additionally hypothesized that cytokines at 
the inflamed site would induce ILC phenotype switching towards the ILC1/ILC3 
subpopulations.  
 
Experimental objectives: 
1. To investigate the chemokines in the joint and the expression of their 
respective receptors on synovial ILC populations.  
2. To investigate cytokines at the inflamed site and their effects on ILC 
plasticity. 
3. To investigate cells within the SFMC which may contribute to the cytokine 
milieu and therefore influence the ILC phenotype.  
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5.2 Results  
 
5.2.1 Differential chemokine receptor expression on synovial ILC 
compared to healthy ILC 
 
Chapter 4 demonstrated an altered ILC phenotype in the synovial fluid 
mononuclear cells from joints of JIA patients compared to their peripheral blood: 
however the mechanisms by which this distinct population profile is achieved 
are still unclear. In order to test the hypothesis that ILC are selectively recruited 
to the inflamed site due to specific chemokine gradients, the concentration of 
specific chemokines and the expression of their respective receptors on 
synovial ILC was assessed, by multiplex chemokine analysis and flow 
cytometry, respectively. 
 
Multiplex chemokine analysis (Luminex platform) was carried out on the JIA 
patient cohort in collaboration with Dr W. de Jager, University of Utrecht (de 
Jager et al., 2007). 16 paired JIA SF and blood serum samples, collected at 
time of active clinical disease when patient attend clinic for joint injection, were 
analysed to determine the relative concentrations of CCL2, CCL3, CCL4, CCL8, 
CCL20, CCL25, CXCL6, CXCL8, CXCL9, CXCL10 and CXCL11 quantification 
(Figure 5.1). The dynamic range of the Luminex assay is ~5pg/ml-10,000pg/ml. 
For concentrations above this range, values were generated by extrapolation of 
the standard curve. Concentrations below the lower limit of detection were 
allocated a concentration of 0pg/ml, however the true value is likely to be above 
zero.  
 
The synovial fluid concentrations of the detected chemokines were highly 
variable between clinical samples. Significantly higher concentrations of CCL2, 
CCL20, CXCL8, CXCL9 and CXCL10 were observed in the SF (samples 
collected and stored by same protocol as serum), compared to serum (Figure 
5.1 A-E, Table 5.1). No differences were seen in the concentrations of CCL3, 
CCL4, CCL8, CCL25, CXCL6 or CXCL11 between serum and SF (Figure 5.1F-
K, Table 5.1).  
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Figure 5.1 Multiplex chemokine analysis of synovial fluid and peripheral 
blood serum from JIA patients.  
Paired JIA SF and peripheral blood serum samples (n=16), collected at time of active 
clinical disease when patients attend for joint injection, were analysed for specific 
chemokine concentrations using the Luminex platform. Summary plots showing 
concentrations of (A) CCL2; (B) CCL20; (C) CXCL8; (D) CXCL9; (E) CXCL10; (F) 
CCL3; (G) CCL4; (H) CCL8; (I) CCL25; (J) CXCL6 and (K) CXCL11. Statistical analysis 
carried out by paired T test. Bars represent median values. * p<0.05 **p<0.01 
***p<0.001 ****p<0.0001. 
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 Serum 
Median (IQR) 
SF 
Median (IQR) 
CCL2 102.6 (46.88-165.4) 299.2 (228.0-633.8) 
CCL3 10.34 (1.19-63.19) 37.8 (2.45-119.0) 
CCL4 60.84 (39.13-74.85) 69.21 (14.41-231.2) 
CCL8 7.0 (3.38-10.86) 11.76 (2.76-49.64) 
CCL20 0.54 (0-1.21) 7.22 (1.79-38.65) 
CCL25 312.5 (203.9-485.9) 278.6 (110.3-476.2) 
CXCL6 118.4 (56.19-437.8) 80.49 (21.13-711.4) 
CXCL8 30.14 (0.09-244) 454.3 (38.81-1502) 
CXCL9 7.76 (0.7-46.78) 128.3 (54.93-812.4) 
CXCL10 85.55 (45.59-162.7) 4056 (3025-5331) 
CXCL11 
 
49.64 (21.75-95.04) 
 
29.13 (8.43-166.8) 
 
Table 5.1 Concentrations of cytokines in serum and SF from JIA patients. 
 
 
Based on the results from the multiplex chemokine analysis, cell surface 
chemokine receptor expression was assessed on peripheral blood and synovial 
ILC by flow cytometry in order to gain evidence for selective ILC recruitment to 
the inflamed site.  
 
CXCR3+ ILC: CXCR3 is the receptor for chemokines CXCL9, CXCL10 and 
CXCL11 (Groom and Luster, 2011). Both CXCL9 and CXCL10 were shown to 
have significantly elevated concentrations in the SF compared to serum from 
JIA patients (Figure 5.1D and 5.1E). After gating for ILC (CD45+lineage-
CD127+CD161+), as shown in Chapter 4, the expression of CXCR3 was 
analysed according to % CXCR3+ ILC (Figure 5.2A) and MFI of CXCR3 (Figure 
5.2B) on the total ILC population and subsequently on the individual ILC 
subpopulations.  A significant increase in the expression of CXCR3 on total ILC 
was identified, when analysed either by %CXCR3+ cells within the ILC 
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population, (Figure 5.2C) or by MFI on the total population (Figure 5.2D),  
(p=0.036 and p=0.0006 respectively). Interestingly, 3 of the 5 SFMC samples 
tested showed very high CXCR3 expression on total ILC (Figure 5.2C and 
5.2D). When the ILC subpopulations (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) 
were studied (Figure 5.2E and 5.2F), CXCR3 expression was found to be 
highest on the SFMC ILC1 population: this expression was significantly greater 
compared to paired PBMC ILC1 (p<0.005 for %CXCR3+ and MFI) (Figures 
5.2G and 5.2H).  A trend towards high expression of CXCR3 was also observed 
on NCR-ILC3 synovial population but this was not significantly different from the 
expression on blood NCR-ILC3. 
 
CCR4+ ILC: CCR4+ cells migrate towards CCL2, CCL4, CCL17 and CCL22 
(Yoshie and Matsushima, 2015). Statistically significant CCL2 protein levels 
were recorded at the inflamed site compared to serum levels (Figure 5.1A). 
Next, the cell surface CCR4 expression was investigated. Percentage CCR4+ 
ILC and MFI of CCR4 are shown in Figure 5.3A and 5.3B respectively. 
Surprisingly, CCR4 expression on total ILC was reduced on synovial ILC 
compared to paired PBMC ILC by both %CCR4+ cells (p<0.0001) and MFI 
(p<0.0001)(Figures 5.3C and 5.3D). This could be in part due to the relative 
paucity of ILC2 cells within SFMC compartment (Chapter 4). When ILC 
subpopulations were analysed (Figure 5.3E and 5.3F), ILC2 showed 
significantly higher CCR4 cell surface expression compared to other ILC 
subpopulations (p=0.008). No significant difference was detected in CCR4 
expression on ILC2 SFMC and PBMC compartments. However CCR4 
expression was significantly reduced on synovial ILC1 (p=0.04) and appeared 
to show a trend towards reduced expression on NCR-ILC3 populations in SFMC 
compared to PBMC of JIA patients (Figures 5.3G and 5.3H).  
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Figure 5.2 CXCR3 is expressed more highly on ILC1 relative to other ILC 
populations  
Expression of chemokine receptor CXCR3 measured on total ILC from aHC PBMC 
(n=4) and PBMC (n=5) and SFMC (n=5) from JIA patients. (A) Representative plots 
showing the gating strategy for the identification of CXCR3 positive cells as a % of total 
ILC (CD45+lineage-CD127+CD161+) (B) Representative histograms showing the 
protein expression of CXCR3 by MFI on total ILC from one aHC PBMC, JIA PBMC and 
SFMC sample (C) Summary plot showing CXCR3 positive cells as % of total ILC. (D) 
Summary plot showing protein expression of CXCR3 by MFI on total ILC. (E) 
Representative plots showing the strategy used for the identification of CXCR3 positive 
cells as a % of each ILC subpopulation (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) from 
paired PBMC and SFMC from JIA patients. (F) Representative histograms showing the 
protein expression of CXCR3 by MFI on each ILC subpopulation (ILC1, ILC2, NCR-
ILC3 and NCR+ILC3) from paired PBMC and SFMC from JIA patients. (G) Summary 
plot showing CXCR3 positive cells as % of ILC subpopulations. (H) Summary plot 
showing protein expression of CXCR3 by MFI on ILC subpopulations. Statistical 
analysis carried out by Kruskal – Wallis or by paired T test. Bars represent median 
values * p<0.05 **p<0.01 
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Figure 5.3 CCR4 is highly expressed on ILC2 relative to other ILC 
populations  
Expression of chemokine receptor CCR4 measured on total ILC from aHC PBMC (n=4) 
and PBMC (n=5) and SFMC (n=5) from JIA patients. (A) Representative plots showing 
the gating strategy for the identification of CCR4 positive cells as a % of total ILC 
(CD45+lineage-CD127+CD161+) (B) Representative histograms showing the protein 
expression of CCR4 by MFI on total ILC from one aHC PBMC, JIA PBMC and SFMC 
sample (C) Summary plot showing CCR4 positive cells as % total ILC. (D) Summary 
plot showing protein expression of CCR4 by MFI on total ILC. (E) Representative plots 
showing the strategy used for the identification of CCR4 positive cells as a % of each 
ILC subpopulation (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) from paired PBMC and 
SFMC from JIA patients. (F) Representative histograms showing the protein 
expression of CCR4 by MFI on each ILC subpopulation (ILC1, ILC2, NCR-ILC3 and 
NCR+ILC3) from paired PBMC and SFMC from JIA patients. (G) Summary plot 
showing CCR4 positive cells as % of ILC subpopulations. (H) Summary plot showing 
protein expression of CCR4 by MFI on ILC subpopulations. Statistical analysis carried 
out by Kruskal – Wallis or by paired T test. Bars represent median values * p<0.05 
****p<0.0001  
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CCR5+ ILC: Despite low concentrations of CCL3 and CCL4 in the serum and 
SF samples, the expression of CCR5 on ILC was also analysed given that it is 
known to interact with RANTES (CCL5), which has been previously shown to be 
abundant at the inflamed site in JIA (Figures 5.2-5.5) (Pharoah et al., 2006). 
Within the whole ILC population, the % of CCR5+ ILC was significantly higher in 
the SFMC compared to PBMC from JIA patients (p=0.049) (Figure 5.4A and 
5.4C). No significant difference was seen in MFI of CCR5 between PBMC and 
SFMC (Figure 5.4B and 5.4D), although a trend towards a larger CCR5+ ILC1 
population was seen in the SFMC (p=0.102) (Figure 5.4E and 5.4G). No 
difference was seen in the MFI of CCR5 expression on total ILC between SFMC 
and PBMC, or between ILC subpopulations, which may be due to high 
variability and underpowered analyses (Figures 5.4B, 5.4F and 5.4H).  
 
CCR6+ ILC: CCR6 the receptor for CCL20, which this study and others have 
demonstrated to be elevated at the inflamed site in several types of 
inflammatory arthritis. The expression of CCR6 was analysed according to % 
CCR6+ ILC (Figure 5.5A) and MFI of CCR6 (Figure 5.5B) on ILC within both 
SFMC and PBMC. Surprisingly, no significant difference in CCR6 expression on 
total synovial ILC was observed according to either %CCR6+ cells (Figure 
5.5C) or by MFI (Figure 5.5D). Additionally, no difference was seen in CCR6 
expression between the ILC subpopulations. However, significantly higher 
CCR6 expression was detected on synovial ILC2 compared to paired PBMC 
ILC2 (p=0.049) (Figures 5.5E-H). It should be noted that in the synovial fluid a 
significant increase in CCL20 may have been driven by high levels in a minority 
of samples and there was considerable heterogeneity in sample concentrations 
(Figure 5.1). Therefore, a larger set for samples may need to be analysed to 
understand the heterogeneity of chemokine receptor expression in the ILC 
populations found in the JIA synovial fluid cells.   
 
CXCL8 has been predominantly been described to be significant for the 
migration of neutrophils to the sites of inflammation and was therefore not 
examined further in this investigation (Russo et al., 2010). 
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Figure 5.4 CCR5 is expressed on ILC1 relative to other ILC populations  
Expression of chemokine receptor CCR5 measured on total ILC from aHC PBMC (n=3) 
and PBMC (n=5) and SFMC (n=5) from JIA patients. (A) Representative plots showing 
the gating strategy for the identification of CCR5 positive cells as a % of total ILC 
(CD45+lineage-CD127+CD161+) (B) Representative histogram showing the protein 
expression of CCR5 by MFI on total ILC from one aHC PBMC, JIA PBMC and SFMC 
sample (C) Summary plot showing CCR5 positive cells as % total ILC. (D) Summary 
plot showing protein expression of CCR5 by MFI on total ILC. (E) Representative plots 
showing the strategy used for the identification of CCR5 positive cells as a % of each 
ILC subpopulation (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) from paired PBMC and 
SFMC from JIA patients. (F) Representative histograms showing the protein 
expression of CCR5 by MFI on each ILC subpopulation (ILC1, ILC2, NCR-ILC3 and 
NCR+ILC3) from paired PBMC and SFMC from JIA patients. (G) Summary plot 
showing CCR5 positive cells as % of ILC subpopulations. (H) Summary plot showing 
protein expression of CCR5 by MFI on ILC subpopulations. Statistical analysis carried 
out by Kruskal – Wallis or by paired T test. Bars represent median values * p<0.05 
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Figure 5.5 CCR6 is expressed on ILC2 from SFMC compared to ILC2 from 
paired PBMC  
Expression of chemokine receptor CCR6 measured on total ILC from aHC PBMC (n=3) 
and PBMC (n=5) and SFMC (n=5) from JIA patients. (A) Representative plots showing 
the gating strategy for the identification of CCR6 positive cells as a % of total ILC 
(CD45+lineage-CD127+CD161+) (B) Representative histogram showing the protein 
expression of CCR6 by MFI on total ILC from one aHC PBMC, JIA PBMC and SFMC 
sample (C) Summary plot showing CCR6 positive cells as % total ILC. (D) Summary 
plot showing protein expression of CCR6 by MFI on total ILC. (E) Representative plots 
showing the strategy used for the identification of CCR6 positive cells as a % of each 
ILC subpopulation (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) from paired PBMC and 
SFMC from JIA patients. (F) Representative histogram showing the protein expression 
of CCR6 by MFI on each ILC subpopulation (ILC1, ILC2, NCR-ILC3 and NCR+ILC3) 
from paired PBMC and SFMC from JIA patients. (G) Summary plot showing CCR6 
positive cells as % of ILC subpopulations. (H) Summary plot showing protein 
expression of CCR6 by MFI on ILC subpopulations. Statistical analysis carried out by 
Kruskal – Wallis or by paired T test. Bars represent median values * p<0.05 
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5.2.2 Cytokines at the inflamed site may play a role in ILC phenotype 
switching 
 
Evaluation of chemokines and chemokine receptors suggested that selective 
migration and recruitment of subpopulations of ILC may contribute to ILC 
recruitment into the inflamed joint in patients with JIA. Whilst selective 
recruitment could explain some ILC subpopulation frequencies within SFMC, 
ILC are also known to exhibit plasticity dependent on local cytokine milieu 
(Hazenberg and Spits, 2014b). In order to test the hypothesis that ILC undergo 
phenotype switching within the inflamed site in the joints of patients with JIA, 
cytokines in the SF from JIA patients were measured by multiplex cytokine 
analysis, and the influence of specific cytokines on ILC phenotype was 
analysed in vitro culture studies.  
 
IL-1β, IL-2, IL-6, IL-7, IL-10, IL12, IL-13, IL-15, IL-17A, IL-17F, IL-18, IL-22, IL-
23, IL-25, IL-27, IL-33, IFNα, IFNβ, IFNγ, GM-CSF, TNFα and TSLP were 
analysed in paired blood serum and SF samples from 16 JIA patients by 
multiplex cytokine analysis, in collaboration with Dr W. de Jager, University of 
Utrecht using the Luminex platform (de Jager et al., 2007). The dynamic range 
of the Luminex assay is ~5pg/ml-10,000pg/ml. For concentrations above this 
range, values were generated by extrapolation of the standard curve. 
Concentrations below the lower limit of detection were allocated a concentration 
of 0pg/ml, however the true value is likely to be above zero.  
  
Significantly higher concentrations of IL-1β, IL-6 and IL-15 were demonstrated 
in the SF compared to serum protein levels (Figures 5.6A-C). In this set of 16 
samples, and in contrast to previous data, IL-17A and associated cytokines IL-
17F, IL-23, IL-22 and GM-CSF were not detected in higher concentrations in the 
SF compared to serum although some individual SF samples showed high 
levels (Figures 5.6D-H). No differences were seen between SF and serum for 
any other cytokines analysed (Figure 5.6I-V). There was significant variability in 
cytokine protein levels between samples and a larger cohort analysis would be 
required to be adequately powered to draw firm conclusions. 
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Figure 5.6 Multiplex cytokine analysis of synovial fluid and peripheral 
blood serum of JIA patients.  
Paired JIA SF and peripheral blood serum samples (n=16), collected at time of active 
clinical disease when patient attend for joint injection were analysed for specific 
cytokine concentrations using the Luminex platform. (A-C) Summary plots showing 
concentrations of cytokines that were significantly different between serum and SF (A) 
IL-1β; (B) IL-6 and (C) IL-15. (D-H) Summary plots showing concentrations of IL-17-
associated cytokines (D) IL-17A;(E) IL-17F;(F) GMCSF;(G) IL-22 and (H) IL-23. (I-V) 
Summary plots showing concentrations of cytokines that were not significantly different 
between serum and SF (I) IL-2;(J) IL-7;(K) IL-10;(L) IL12;(M) IL-13;(N) IL-18;(O) IL-
25;(P) IL-27; (Q) IL-33;(R) TNFα;(S) IFNα; (T) IFNβ; (U) IFNγ and (V) TSLP. Statistical 
analysis carried out by paired T test. Bars represent median values. **p<0.01 
****p<0.0001.  
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 Serum (pg/ml) 
Median (IQR) 
SF (pg/ml) 
Median (IQR) 
IL-1β 0.0(0.0-0.82) 1.48(0.0-16.31) 
IL-2 0.0(0.0-9.10) 0.0(0.0-16.38) 
IL-6 0.0(0.0-28.58) 3484(1477-30433) 
IL-7 0.0(0.0-29.14) 0.0(0.0-33.69) 
IL-10 0.0(0.0-107.7) 15.36(0.77-153.1) 
IL-12 0.0(0.0-0.0) 0.0(0.0-23.13) 
IL-13 13.96(3.35-129.6) 29.65(4.68-146.0) 
IL-15 1.27(0.0-23.97) 18.6(12.38-43.93) 
IL-17A 0.0(0.0-0.0) 3.83(0.0-26.77) 
IL-17F 0.0(0.0-68.81) 0.0(0.0-28.81) 
IL-18 51.68(40.34-151.4) 101.7(62.91-138.8) 
IL-22 0.0(0.0-0.0) 0.0(0.0-3.08) 
IL-23 82.89(0.0-783) 0.0(0.0-1847) 
IL-25 0.0(0.0-1479) 20.47(0.0-1625) 
IL-27 348.4(161.5-751) 358.7(213.3-1280) 
IL-33 0.0(0.0-32.25) 0.0(0.0-102.7) 
TNFα 0.0(0.0-4.96) 0.03(0.0-14.09) 
IFNα 0.0(0.0-13.0) 0.42(0.0-17.26) 
IFNβ 49.57(3.12-279.9) 37.74(0.0-311.4) 
IFNγ 0.0(0.0-207.8) 0.0(0.0-194.6) 
TSLP 0.4(0.0-17.45) 0.1(0.0-26.55) 
GM-CSF 0.0(0.0-1.13) 0.0(0.0-3.55) 
Table 5.2 Cytokine concentrations in serum and SF from JIA patients  
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Based on the results of the multiplex cytokine analysis, the effect of cytokines 
on ILC phenotype was investigated by culturing ILC in vitro in the presence of 
recombinant human (rh) cytokines that promote specific differentiation (n=5).  
Briefly, total ILC (CD45+lineage-CD127+CD161+) were sorted by flow 
cytometry from aHC  (n=5) (as described in Chapter 2) and cultured for 7 days 
with (a) IL-2 alone (medium), or IL-2 medium with (b) IL-1β and IL-23 (known to 
skew towards ILC3 populations (Bernink et al., 2015)); or (c) IL-1β, IL-23 and 
IL-6; or (d) IL-6 (in order to test the hypothesis that IL-6 may drive ILC 
plasticity). At the end of 7-day culture in vitro, cells were firstly assessed for 
viability and proliferative activity. ILC were >80% viable (as determined by 
staining with a live dead dye) under all culture conditions (Figure 5.7A and 
5.7B). ILC at the start of culture had very low proportion of cells in active 
proliferation as measured by Ki67 expression. However, cells proliferated 
significantly during culture in all conditions (p>0.0001) (Figures 5.7C and 5.7D).  
 
Next, I investigated the impact of the skewing conditions on the ILC 
subpopulations, for this purpose, expression of ILC markers CRTH2, cKit and 
NKp44 was analysed before and after culture (Figure 5.8A, B). After culture, the 
ILC2-specific surface protein, CRTH2, could not be detected. This made it 
impossible to accurately determine ILC subpopulation on day 7, since it was not 
known whether this resulted from downregulation of CRTH2, or from true 
phenotype switching (Figure 5.8A).   
 
cKit+NKp44- ILC, which in this context may represent NCR-ILC3 subpopulation, 
were significantly increased after culture with IL-6 alone compared to ILC 
cultured under other cytokine conditions (Figure 5.8C). None of the culture 
conditions significantly affected NKp44 expression; however a small increase of 
cKit+NKp44+ cells were seen after culture in the presence of IL-1β and IL-23, or 
IL-1β, IL-23 and IL-6 conditions, compared to cells cultured with IL-2 alone, 
which could represent skewing of ILC cells in vitro towards the NCR+ILC3 
population (Figure 5.7D). Treatment with PMA, Ionomycin and Brefeldin A on 
day 7 resulted in significant cell death and it was therefore not possible to 
accurately determine cytokine production by ILC after these cultures (data not 
shown).  
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Figure 5.7 ILC survive 7-day culture and proliferate.  
FACS-sorted total ILC (CD45+lineage-CD127+CD161+) from aHC PBMC (n=5) were 
cultured for 7 days in the presence of IL-2 alone, or IL-2 with skewing cytokine 
combinations (IL-23 and IL-1β; IL-23, IL-1 β and IL-6; or IL-6) as shown. (A) 
Representative plots showing scatter profiles (top row) and viability staining (bottom 
row) of ILC after culture under various skewing environments. (B) Summary plot 
showing live cells as % of total cultured cells on day 7 of culture. (C) Representative 
histogram showing intracellular Ki67 expression by ILC before (baseline) and after 
culture (conditions as shown). (D) Summary plot showing Ki67+ cells as a % of total 
live ILC ex vivo and after 7 days culture with skewing cytokines.  Statistical analysis 
carried out by Kruskal -Wallis. Bars represent median values. **** p<0.0001. 
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Figure 5.8 CRTH2 is down-regulated on cultured ILC.  
FACS-sorted total ILC (CD45+lineage-CD127+CD161+) from aHC PBMC (n=5) were 
cultured for 7 days in the presence of IL-2 alone, or IL-2 with skewing cytokine 
combinations (IL-23 and IL-1β; IL-23, IL-1 β and IL-6; or IL-6) as shown. (A) 
Representative plots showing CRTH2 expression on ex vivo ILC and ILC after 7 days 
culture. (B) Representative plots showing expression of cKit and NKp44 by ex vivo ILC 
and ILC after 7 days culture with skewing conditions. (C) Summary plot showing 
cKit+NKp44- ILC before (baseline) and after culture (conditions as shown), and (D) 
Summary plot showing cKit+NKp44+ ILC before and after culture. Statistical analysis 
carried out by Kruskal -Wallis. Bars represent median values. * p<0.05. 
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While the in vitro culture experiments revealed some change in phenotype of 
ILC, it was important to attempt to mimic the synovial inflamed environment 
more closely in these experiments. Therefore to investigate the physiological 
effect of synovial fluid on ILC phenotype, total ILC (CD45+lineage-
CD127+CD161+) were again FACS sorted from aHC PBMC and cultured for 7 
days with IL-2 alone (medium) or IL-2 with 50% synovial fluid (n=4). Given the 
observed heterogeneity of concentrations of different cytokines and chemokines 
within the 16 SF samples (Table 5.2) a strategy of a pooled sample of mixed SF 
was applied.  
 
A pool of synovial fluid was made by combining synovial fluid samples from 10 
JIA patients. Cytokine protein levels in the SF pool were measured by multiplex 
cytokine analysis as described above.  Significant amounts of IL-6 (7.23μg), IL-
25 (2.09ng/ml), IL-27 (0.013μg/ml) and IFNβ (1.2ng/ml) were detected (Figure 
5.9A).  All cytokine concentrations from the SF pool are shown in Table 5.3. In 
relation to the in vitro system used in initial cultures above, the synovial pool 
contained a significantly higher concentration of IL-6, but lower concentrations 
of IL-1β and IL-23. Of note, although IL-2 concentrations in the SF pool were 
relatively low (5.17pg/ml), all cultures contained additional IL-2, supplemented 
at a final concentration of 0.5ng/ml as above. The pool of SF was used at a 
concentration of 50%. The actual culture concentrations of each cytokine were 
as shown in left column of Table 5.3. 
 
ILC after culture in IL-2/50% SF medium (Figure 5.8) remained >60% viable 
after 7 days (Figure 5.9B and 5.9C). Interestingly, higher proliferation was seen 
from samples cultured with 50% SF compared to IL-2 alone (Figure 5.9D). As 
seen previously, a down regulation of ILC2 marker CRTH2 was observed 
(Figure 5.9E).  In contrast, IL-2/50% SF did not affect cKit or NKp44 ILC 
expression compared to cells cultured with IL-2 alone (Figure 5.9F, 5.9G and 
5.9H). Low cell numbers after culture meant it was not possible to accurately 
assess the cytokine production by ILC on day 7 (data not shown).  
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Together, these results identify the presence of cytokines at the inflamed site 
that are known to play a role in ILC plasticity. The culture assays performed do 
not conclusively demonstrate ILC plasticity in vitro, but may suggest an effect of 
IL-6 on the ILC3 population at the inflamed site.  
 
Table 5.3 Concentration of cytokines within the synovial fluid pool 
  
 Concentration in SF 
pool (pg/ml) 
Final concentration used 
in cultures (pg/ml) 
IL-1β 141 
 
70.5	  
 
IL-2 5.17 
 
2.585	  
 
IL-6 7232674 
 
3616337	  
 
IL-7 0 0 
IL-10 40.79 
 
20.395	  
 
IL-12 43.07 
 
21.535	  
 
IL-15 33.32 
 
16.66	  
 
IL-17A 19.8 
 
9.9	  
 
IL-22 19.5 
 
9.75	  
 
IL-23 105.64 
 
52.82	  
 
IL-25 2087.31 
 
1043.655	  
 
IL-27 12762.34 
 
6381.17	  
 
TNFα 1.26 
 
0.63	  
 
IFNα 13.88 
 
6.94	  
 
IFNβ 1202.84 
 
601.42	  
 
IFNγ 0 0 
GM-CSF 19.93 
 
9.965	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Figure 5.9 Synovial fluid does not cause skewing of ILC after 7 days.  
FACS- sorted total ILC (CD45+lineage-CD127+CD161+) from aHC PBMC (n=4) were 
cultured for 7 days in the presence of IL-2 alone or IL-2 plus 50% SF from a pool made 
by combining SF from 10 JIA patients. (A) Multiplex cytokine analysis of cytokines in 
the SF pool used for culture by Luminex. (B) Representative plots showing scatter 
profiles (top row) and viability staining (bottom row) of ILC after culture under with IL-2 
medium alone (left panels) or 50% SF (right panels). (C) Summary plot showing live 
cells as % of total cultured cells on day 7 of culture. (D) Representative histogram 
showing Ki67 expression on ILC before and after culture. (E) Ki67+ cells as a % of total 
live ILC ex vivo and after 7 days culture. Representative plots showing (F) CRTH2 
expression and (G) expression of cKit and NKp44 on ex vivo ILC and ILC after 7 days 
culture with 50% SF. Summary plots showing (H) cKit+NKp44- ILC and (I) 
cKit+NKp44+ ILC before and after culture.   
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5.2.3 Myeloid DC are enriched at the inflamed site and correlate with 
NCR+ILC3 
 
During routine analyses of SFMC cellular composition, an enrichment of 
myeloid dendritic cells (mDC) was noted, relative to DC frequency in PBMC 
(Chapter 3, Figure 3.2). These observations raised a new hypothesis that mDC 
at the inflamed site may produce cytokines or other inflammatory mediators, 
which could contribute to ILC phenotype or mediate ILC switching from one 
subpopulation to another in the joint. In order to investigate this hypothesis, the 
phenotype of synovial mDC was examined and compared to patient and adult a 
child control healthy mDC from the PBMC compartment. Cells were gated on 
CD14 and CD11c and analysis performed by flow cytometry (after exclusion of 
dead cells) (Figure 5.10A). 
 
A significant enrichment of mDC (defined as CD14-CD11c+ cells) was 
confirmed in the SFMC from JIA patients (n=34) compared to patient PBMC 
(n=13) or adult (n=12) or child (n=3) healthy controls (p<0.0001) (Figure 5.10A 
and 5.10B). When synovial mDC were analysed against the relative frequency 
of SFMC ILC3 cells in the same patient, significant correlations were observed. 
mDC showed a strong negative correlation with NCR-ILC3 at the inflamed site 
(r=-0.73, p= <0.0001) (Figure 5.10C). Conversely, mDC were strongly positively 
associated with NCR+ILC3 (r=0.67, p=0.0005) (Figure 5.10D). Interestingly, the 
correlation between mDC and ILC3 was not maintained in the PBMC from JIA 
patients (Figure 5.10E), supporting a possible shared mechanism or 
interactions between mDC and ILC3 populations at the inflamed site.  
 
Additionally, the number of synovial mDC within the SFMC showed weak 
negative correlations with measures of disease severity at the time of synovial 
fluid sampling, including ESR (r=-0.47, p=0.067) and Physician’s VAS (r=-0.33, 
p=0.13) (Figure 5.11B and 5.11C). No associations were seen between synovial 
mDC and active joint count, or JADAS3 scores at the time of sample (Figures 
5.11A and 5.11D). 
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Figure 5.10 mDC are enriched at the inflamed site and correlate with ILC3 
populations.  
(A) Representative plots showing the gating strategy for the enumeration of mDC 
(CD14-CD11c+) in the PBMC from aHC and cHC and PBMC and SFMC from JIA 
patients. (B) Summary plot showing mDC in PBMC of aHC (n=12) and cHC (n=3) and 
PBMC (n=13) and SFMC (n=34) of JIA patients.  (C-D) Correlations between mDC in 
the SFMC of JIA patients analysed against (C) NCR-ILC3 (n=23, r=-0.73, p<0.0001) 
and (D) NCR+ILC3 (n=23, r=0.67, p=0.0005). (E) Correlation between mDC and NCR-
ILC3 from within the PBMC of JIA patients (n= 14, r=-0.015, p=0.96). Statistical 
analysis carried out by Kruskal -Wallis. Bars represent median values. * p<0.05. 
Correlations by Spearman correlation. 
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Figure 5.11 mDC are associated with less severe disease as estimated by 
ESR and Physician’s VAS.  
(A-D) Correlations in the SFMC of JIA patients showing mDC subpopulations as a % of 
total live cells analysed against clinical measures of disease severity: (A) Analysed 
against number of active joints at the time of sample (n=25, r=-0.15, p=0.47); (B) 
Analysed against ESR at time of sample (n=16, r=-0.47, p=0.067); (C) Analysed 
against physician’s VAS (n=22, r=-0.33, p=0.13) and (D) Analysed against JADAS3 
(n=18, r=-0.17, p=0.50). Correlations by Spearman correlation.  
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5.2.4 Synovial mDC express low cytokine mRNA transcript levels  
 
In order to investigate the putative interaction of mDC with ILC populations at 
the inflamed site, the synovial mDC phenotype and functional capacity was 
investigated by qPCR. Magnetic bead sorting and FACS sorting protocols were 
tested in order to ascertain the optimal sorting strategy for mDC (Chapter 2). 
Magnetic bead sorting (StemCell) using negative selection resulted in relatively 
impure mDC isolations (40-80% purity) and was therefore deemed unsuitable 
for further use (Figure 5.12A and 5.12B). In contrast, highly pure mDC samples 
(>95% purity) could be isolated by FACS sorting based on expression CD11c 
and CD14 (Figure 5.12C and 5.12C). mDC were FACS sorted from 3 aHC 
PBMC and 3 JIA SFMC samples and RNA was extracted for subsequent qPCR 
experiments.  
Figure 5.12 Flow cytometric sorting is more efficient than magnetic bead 
isolation for the isolation of mDC from blood and SFMC.  
Magnetic bead sorting and flow cytometric sorting techniques were tested and 
compared in order to ascertain the optimal sorting strategy for mDC from aHC PBMC. 
(A) Representative plots showing mDC proportions before and after sorting by 
EasySep magnetic bead separation. (B) Summary plot showing mDC purity after 
magnetic bead separation from PBMC (n=4). (C) Representative plots showing mDC 
gating strategy (CD14-CD11c+) and purity after flow cytometric sorting. (D) Summary 
plot showing mDC purity after flow cytometric sorting from PBMC (n= 3). 
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In order to test the hypothesis that mDC at the inflamed site may contribute to 
the cytokine signature seen at the inflamed site, and may influence the ILC 
phenotype in the joint by the production of skewing cytokines, the cytokine 
profiles of mDC (CD11c+CD14-) were assessed by qPCR for the gene 
expression of IL1β, IL23 and IL6 mRNA transcripts. As a positive control 
healthy sorted mDC from healthy adult donor was stimulated with LPS 
(100ng/ml for 15 hours) prior to RNA extraction. Data were analysed using a 
standard curve generated from the LPS stimulated mDC cDNA and samples 
were normalized using housekeeping gene ACTB.  
 
Surprisingly, relative expression of IL1β, IL23 and IL6 genes were all lower in 
mDC isolated from JIA SFMC compared to aHC PBMC (Figure 5.13). However, 
the difference did not reach significance and sample numbers were small 
meaning that these data should be interpreted with caution. When compared to 
gene expression in LPS-stimulated mDC from a healthy control, gene 
expression from both PBMC and SFMC was low for all cytokines measured.  
 
 
 
Figure 5.13 mDC in SFMC express low levels mRNA transcripts for 
cytokine genes. 
qPCR was performed to amplify specific transcripts from cDNA generated from mDC 
sorted by flow cytometry from JIA SFMC (n=3) and aHC PBMC (n=3), and from aHC 
sorted mDC subsequently stimulated with LPS (n=1) (100ng/ml for 15 hours). Relative 
expression of (A) IL1β (B) IL6 and (C) IL23. Bars represent the mean value of the 3 
mDC samples, error bars represent SEM.  
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5.2.5 Synovial mDC express higher CD103 and produce retinoic acid 
 
More detailed phenotyping of the DC populations at the inflamed site was then 
conducted. For the purposes of this analysis, four populations were considered 
namely total mDC (CD11c+CD14-), BDCA1+(CD1c) mDC, BDCA3+ (CD141) 
mDC and pDC (CD123+BDCA2+).  In these experiments, a ‘lineage dump’ 
channel was used, which included antibodies to CD3, CD34, CD19 and CD56 to 
exclude T cells, stem cells, B cells and NK cells.  
 
BDCA1+, BDCA3+ and pDC subpopulations were enumerated in healthy 
control PBMC of adults and children, PBMC and SFMC from JIA patients 
(Figure 5.14A and B).  BDCA1+ and BDCA3+ cells as a % of total live cells 
were enriched in the SFMC of patients compared to paired JIA, or healthy, 
PBMC (p<0.0001) (Figures 5.14C and 5.14D). pDC were also enriched in the 
SFMC compared to PBMC of patients (p=0.041) (Figure 5.14E).   
 
Since mDC in the SFMC appeared to express relatively low levels of cytokines 
IL-1β, IL-6 and IL-23 at mRNA level it is possible that they were in a 
‘tolerogenic’ state and may play a role in promoting regulation at the inflamed 
site. To test this hypothesis, mDC from both PBMC and SFMC were analysed 
for expression of CD103 (also known as αE integrin), a surface protein 
associated with a population of tolerogenic DC which are able to produce 
retinoic acid, RA, which has recently been shown to promote ILC switching 
towards NCR+ILC3 (Coombes et al., 2007, Bernink et al., 2015) (Figure 5.15A).  
Synovial mDC contained a significantly higher proportion of CD103 positive 
cells compared to mDC from patient or control PBMC in total mDC 
(CD11c+CD14-), BDCA1+ and BDCA3+ DC populations (p<0.0001, p<0.0001 
and p=0.0004 respectively) (Figures 5.15B-D).  
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Figure 5.14 BDCA1+ and BDCA3+ mDC and pDC are enriched at the 
inflamed site in JIA.  
BDCA1+, BDCA3+ and pDC were enumerated in the PBMC from aHC (n=5) and cHC 
(n=3) and PBMC (n=11) and SFMC (n=21) from JIA patients by flow cytometry. 
Representative plots showing the gating strategy for the identification of DC subsets in 
(A) PBMC and (B) SFMC of JIA patients. Summary plots showing DC subsets at a % of 
total live cells for (C) BDCA1+ mDC; (D) BDCA3+mDC and (E) pDC. Statistical 
analysis carried out by Kruskal -Wallis. Bars represent median values. *p<0.05 
****p<0.0001 
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Figure 5.15 CD103+mDC are enriched at the inflamed site in JIA.  
CD103+ mDC were enumerated in the PBMC from aHC (n=12) and cHC (n=3) and the 
PBMC (n=12) and SFMC (n=25) from JIA patients by flow cytometry. (A) 
Representative plots showing the gating strategy for the identification of CD103+ cells 
in the PBMC and SFMC of JIA patients. Previously gated on mDC (CD14-CD11c+) as 
shown in Figure 5.10.  Summary plots showing CD103+ cells at a % of mDC subsets 
for (B) total mDC  (CD14-CD11c+) (C) BDCA1+ mDC; (D) BDCA3+mDC. Statistical 
analysis carried out by Kruskal -Wallis. Bars represent median values. 
***p<0.001****p<0.0001. 
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The ability of mDC from the joint to produce RA was then tested in vitro, using 
the Aldefluor assay (Hurst and Else, 2013) as described in Chapter 2 . This is a 
flow cytometry-based assay that measures the amount of active aldehyde 
dehydrogenase (ALDH) enzymes in each cell, as a surrogate of RA production. 
A control reaction was run for each sample including the DAEB inhibitor, which 
prevents the active aldefluor substrate from binding to the ALDH enzyme. When 
aldefluor binds the ALDH enzyme fluorescence is detected in the FITC channel. 
The negative gate was set according to the DAEB control and was specific for 
each sample. Positive events were detected within this gate (Figure 5.16A). 
Interestingly among control PBMC samples there was an apparent age 
difference in that adult mDC contained on average more cells that have active 
ALDH enzyme than mDC from healthy children.  
 
Significantly higher proportions of ALDH+ mDC were identified in SFMC 
compared to PBMC samples of either healthy children or JIA patients (Figure 
5.16B). Given the strong enrichment for CD103+ mDC in the SFMC population, 
the relative difference in cells with ALDH activity was assessed between 
CD103+ and CD103- mDC from the SFMC of JIA patients (Figure 5.17A). A 
small but significantly higher ALDH activity, expressed as % of cells positive for 
RALDH in the Aldefluor assay, was detected in CD103+ mDC compared to the 
CD103- mDC within SFMC samples (p=0.016) (Figure 5.17B).  
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Figure 5.16 RALDH+ mDC are enriched in the joints of JIA patients.  
RALDH expression was analysed within mDC (CD14-CD11c+) by flow cytometry in the 
PBMC from aHC (n=6) and cHC (n=3) and the PBMC (n=4) and SFMC (n=18) from JIA 
patients. (A) Representative plots showing the gating strategy. The positive gate was 
set according to DEAB negative control (top row). Positive events were detected within 
this gate (bottom row). Previously gated on CD14-CD11c+mDC. (B) Summary plots 
showing RALDH+ cells as a % of total mDC. Statistical analysis carried out by Kruskal -
Wallis. Bars represent median values. ***p<0.001  
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Figure 5.17 RALDH expression is higher in CD103+mDC at the inflamed 
site.   
RALDH expression was analysed by flow cytometry on CD103+ and CD103- mDC 
populations from the SFMC of JIA patients (n=14). (A) Representative plots showing 
the gating strategy for identification of RALDH+ cells. Previously gated on CD14-
CD11c+mDC. (B) Summary plot showing the relative RALDH expression in CD103- 
and CD103+mDC. Statistical analysis carried out by paired T test. Bars represent 
median values. * p<0.05 
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To investigate RALDH mRNA expression in PBMC and SFMC mDC, ALDH1A1 
and ALDH1A2, qPCR was performed on FACS-sorted mDC from aHC (n=3) 
and JIA SFMC (n=3). While a trend towards higher ALDH1A1 gene expression 
was seen in aHC mDC compared to SFMC mDC, the opposite was true for 
ALDH1A2, which was more highly expressed in SFMC mDC (Figures 5.18A 
and 5.18B).  
 
 
 
Figure 5.18 mDC in SFMC show differential expression of ALDH1A1 and 
ALDH1A2 gene transcripts compared to mDC from aHC.  
qPCR was performed to amplify specific transcripts from cDNA generated from mDC 
(CD14-CD11c+) FACS sorted from JIA SFMC (n=3) and aHC PBMC (n=3). Relative 
expression of (A) ALDH1A1 and (B) ALDH1A2. Bars represent the mean value of the 3 
mDC samples, error bars represent SEM.  
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5.2.6 Synovial ILC have increased expression of retinoic acid receptor 
gene RARA 
 
The ability of synovial fluid ILC to respond to RA was next investigated to 
support the hypothesis that RA production from mDC at the inflamed site may 
be involved in ILC phenotype switching towards the NCR+ILC3 population seen 
in the SFMC. 
 
The chemokine receptor CCR9 gene is a direct target of RA signalling (Ohoka 
et al., 2011). In order to investigate the response of ILC to RA, the expression of 
a RA-responsive gene product, CCR9 on ILC from PBMC from aHC and PBMC 
and SFMC from JIA patients, was examined ex vivo by flow cytometry. 
Surprisingly, CCR9 expression on ILC was relatively low on all samples 
analysed and was not significantly higher on synovial ILC compared to ILC from 
healthy or JIA PBMC (Figure 5.19).  
 
 
 
 
Figure 5.19 Synovial ILC do not express higher CCR9 compared to ILC 
from PBMC 
Expression of chemokine receptor CCR9 measured on total ILC (CD45+lineage-
CD127+CD161+) from aHC PBMC (n=4), and PBMC (n=4) and SFMC (n=6) from JIA 
patients. (A) Representative plots showing the gating strategy for the identification of 
CCR9 positive cells as a % of total ILC (B) Summary plot showing CCR9 positive cells 
as % total ILC.   
 197 
 
Finally, gene expression of RA receptors RARA, RARB and RARG were 
analysed in FACS sorted ILC from aHC and JIA SFMC (n=3). A qPCR standard 
curve was generated from the sorted ILC with the highest gene expression 
during initial testing and all samples were normalized using housekeeping gene 
ACTB expression. Of the 3 RA receptor genes, only RARA was satisfactorily 
amplified in all the isolated ILC samples and was therefore the only gene that 
could be analysed (RARB and RARG data not shown). There was a trend 
towards higher RARA mRNA expression in ILC isolated from SFMC compared 
to aHC although this did not reach significance (Figure 5.20).  
 
 
 
Figure 5.20 Synovial ILC show increased expression of retinoic acid 
receptor gene RARA.  
qPCR was performed to amplify specific transcripts from cDNA generated from ILC 
(CD45+lineage-CD127+CD161+) FACS sorted from JIA SFMC (n=3) and aHC PBMC 
(n=3) and from CD161+ T cells sorted from aHC PBMC (n=1). Relative expression of 
RARA. Bars represent the mean value of the 3 ILC samples, error bars represent SEM.  
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5.3 Discussion 
 
The data in Chapter 4 clearly demonstrated an altered ILC phenotype in the 
joint compared to the blood from JIA patients or healthy controls. This Chapter 
aimed to elucidate the mechanisms by which the SFMC ILC phenotype is 
achieved at the inflamed site, by investigating mechanisms of ILC recruitment 
and factors that may drive potential ILC phenotype switching within the inflamed 
site.   
 
Multiplex analysis of chemokines in the blood and SF from JIA patients showed 
significantly higher concentrations of CCL2, CCL20, CXCL8, CXCL9 and 
CXCL10 at the inflamed site in this patient cohort. These findings are supported 
by previously published data, which have reported an abundance of these 
migratory ligands in JIA (Pharoah et al., 2006, de Jager et al., 2007).  
 
Differential expression of chemokine receptors was detected on synovial ILC 
compared to paired blood with a significant increase of CXCR3 and CCR5 
positive ILC at the inflamed site. Furthermore, ILC subpopulation-specific 
expression patterns were observed. Expression of both of these receptors was 
largely restricted to the ILC1 population. Both CXCR3 and CCR5 are often 
associated with Th1 cells and so the expression of these receptors on the ILC1 
subpopulation was unsurprising (Odum et al., 1999). Additionally, the data 
obtained mirrors the enrichment of CCR5/CXCR3+ Th1 cells previous described 
in JIA (Wedderburn et al., 2000a). These findings are also supported by 
recently published data, which has described increased CXCR3 and CCR5 
expression on the ILC1 subpopulations in systemic sclerosis (Roan et al., 
2016a). Together these findings support a role for selective migration of ILC1 
subpopulations to the inflamed site in JIA, possibly migrating to a chemokine 
gradient. 
 
As previous studies have described an enrichment of CCR4+ T cells at the 
inflamed site in JIA (de Kleer et al., 2004, Nistala et al., 2008a), it was surprising 
to find reduced expression of this receptor on synovial ILC compared to paired 
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blood (Issekutz et al., 2011). However, this study and others have demonstrated 
that the ILC2 population is the dominant CCR4+ population within ILC, and 
therefore given the ablation of ILC2 in the inflamed joint (described in Chapter 
4), the reduction of CCR4+ ILC in the joint is perhaps less surprising (Roan et 
al., 2016b).  Furthermore, the reduced expression of CCR4 on ILC1 and NCR-
ILC3 populations in the SFMC mirrors previously published data describing 
reduced CCR4 expression on Th17 cells from the inflamed site (Nistala et al., 
2008b). CCR6 has been previously shown to be expressed on synovial Th17 in 
JIA, where it is thought to play an important role in recruitment of these cells 
(NIstala 2008), (Nistala and Wedderburn, 2009, Cosmi et al., 2011). A trend 
towards higher CCR6 expression was seen in all synovial ILC subpopulations, 
suggesting that migration towards CCL20 could play a role in ILC recruitment to 
the joint. However, there was significant heterogeneity in CCL20 concentration 
in the SF. Therefore, a larger set of samples needs to be analysed to 
understand the heterogeneity of chemokine receptor expression on the ILC 
populations found in the JIA synovial fluid cells and how this relates to synovial 
fluid concentrations of specific chemokine ligands. It is possible that the 
concentration of ligands measure in aspirated synovial fluid may not reflect the 
microenvironment and local concentrations of chemokines or cytokines at the 
site of cell entry to the inflamed site across the endothelium  
 
Taken together, these data support the hypothesis that chemokines at the 
inflamed site may contribute to ILC recruitment of ILC1 and ILC2. The high 
CCR4 and the increased CCR6 expression on ILC2 in the SFMC are 
particularly interesting since these results raise questions as to why the ILC2 
subpopulation is reduced in SFMC.  It is now well established that there is 
considerable plasticity among ILC subpopulations (Bernink et al., 2015, Silver et 
al., 2016b). Evidence of selective recruitment of ILC3 subpopulations is still 
weak and it is unclear whether the ILC3 population in the SFMC has migrated to 
the joint via CCR6 and other interactions, or whether this population has arisen 
from other ILC subpopulations, perhaps ILC2, at the inflamed site.  
 
This plasticity hypothesis was subsequently investigated. Multiplex cytokine 
analysis of SF highlighted high levels of IL-1β, IL-6 and IL-
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fluid compared to paired blood and the influences of IL-1β and IL-6 were 
investigated further. Although IL-15 was not studied in this project, its effect on 
ILC activation and plasticity at the inflamed site would be interesting to 
investigate. It is known that ILC express the IL-2 receptor and respond to IL-2 
stimulation, since IL-15 shares structural similarities to IL-2 and signals through 
a shared beta and gamma receptor chains. It is likely that ILC may also respond 
to IL-15 stimulation (Spits et al., 2013, Mishra et al., 2014). In fact, a recent 
study has shown that NK cells and ILC1 rely on IL-15 for their development, and 
proliferate and produce inflammatory mediators in response to stimulation (Dadi 
et al., 2016). Additionally, mouse studies have shown that IL-15 causes down 
regulation of RORγt and up regulation of Tbet in ILC3 (Vonarbourg et al., 2010, 
Klose et al., 2013). IL-15 could, therefore, be a significant influence on the ILC1 
population within the inflamed joint in JIA. 
 
It is interesting that IL-17A and associated cytokines, IL-22, IL-23 and GMCSF, 
were not elevated in synovial fluid samples, since previous studies have 
demonstrated high IL-17 levels in JIA patients (de Jager et al., 2007, Agarwal et 
al., 2008a).  It is important to consider the limitations of the multiplex cytokine 
analysis used during this project, and associated issues with cytokine 
degradation after long-term storage. Previous studies have shown that while 
cytokines are broadly stable at -80°C for up to 2 years, after this time some 
cytokines are susceptible to degradation. Additionally, it has been shown that 
cytokines are susceptible to instability after freeze thawing (de Jager et al., 
2009). It is therefore possible that the results obtained may represent an 
underestimation of the true cytokine abundance.  
 
ILC plasticity was not conclusively demonstrated during the course of this 
project. One significant difficulty was the down regulation of ILC2 specific 
CRTH2 after in vitro culture. While it is possible that all ILC2 died during the 
cultures, or underwent phenotype switching, I cannot be sure that this was the 
case. This meant that I was unable to accurately assess the degree of 
phenotype switching, which may have occurred. The cell number after 7 days 
were too low to perform qPCR on the cultured ILC, which would help to clarify 
whether the ILC were still ILC2 or has switched to another ILC phenotype. In the 
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future, analysis of ILC subpopulation transcription factors before and after 
culture by PrimeFlow RNA assays could provide a more practical alternative. 
 
The effects elicited by IL-1β and IL-23 alone or in combination with IL-6 remain 
unclear. Previous studies have shown that culture with IL-1β and IL-23 results 
in ILC switching from an ILC1 to an ILC3 phenotype (Bernink et al., 2015). An 
increase in cKit expression after culture with IL-6 was observed in the present 
study. The up regulation of cKit without induction of NKp44 could suggest that 
IL-6 promotes NCR-ILC3 survival, however, since ILC2 could not be identified 
after culture, there is insufficient evidence to definitively support this hypothesis. 
IL-6 is important for the differentiation of murine Th17 cells, although there are 
conflicting opinions regarding its influence on human T cells(Bettelli et al., 
2006). Unfortunately, due to poor viability it was not possible to assess ILC 
cytokine production after culture, however one study in mouse and human IBD 
has suggested that IL-6 induces IL-17 production from human colonic ILC, 
which supports my hypothesis that IL-6 induces NCR-ILC3 and may be 
influencing this ILC subpopulation at the inflamed site(Powell et al., 2015). 
Further investigation of the role of IL-6 on ILC in the synovia is warranted. 
 
Further optimization of the culture technique for ILC would be required to fully 
evaluate their plasticity in response to synovial cytokines. One major limitation 
of the assay stems from the small population size. Starting from 1x108 aHC 
PBMC the average ILC yield after sorting was only approximately 20,000 ILC 
and cultures were set up with only 2000 ILC/ well. Therefore, a relatively small 
amount of death in some cultures meant that it was impossible to generate 
meaningful results at the end of culture due to insufficient cell numbers and data 
events collected during analysis. Other studies have cultured ILC with irradiated 
feeder cells to boost survival (Bernink et al., 2015, Lim et al., 2016). This 
method would definitely be worth exploring. Additionally, no other studies have 
attempted to culture bulk ILC, but instead work has focused on individually 
isolated ILC populations. I did not have sufficiently large samples available for 
this kind of analysis, however, isolating the individual ILC subpopulations would 
have allowed for more stringent analysis.  
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It is clear that there are cytokines enriched in the JIA synovia, which could 
promote ILC switching towards the ILC3 populations, however the source of 
these cytokines are still unknown (Bernink et al., 2015). Next, I focused on the 
presence of other immune cells in the SFMC that could be contributing to the 
cytokine milieu. A significant enrichment of mDC was characterized in the 
SFMC from JIA patients, confirming previously published data (Varsani et al., 
2003). Although BDCA1+mDC, known to produce IL-6 and IL-23 following TLR-
stimulation, were the predominant population, it is interesting that BDCA3+mDC 
were also dramatically enriched at the inflamed site. These cells are known to 
be efficient at cross presentation to CD8 T cells, and may identify one 
mechanism by which CD8 T cells are activated within the synovia(Dzionek et 
al., 2000, Jongbloed et al., 2010).  
 
mDC correlated strongly with NCR+ILC3 within the SFMC, suggesting 
interaction between these two groups. Further interrogation of the mDC 
functionality by qPCR showed low gene expression of inflammatory cytokines, 
IL-1β, IL-23 and IL-6, cytokines implicated in ILC switching. Interestingly, 
synovial mDC had lower expression of these cytokine genes compared to aHC 
mDC. One explanation maybe that SFMC mDC exhibit an ‘exhausted’ 
phenotype.  Previous studies have shown increased IL-10 at the inflamed site 
(Bending et al.,2015). It is possible that the mDC in the joint have succumbed to 
IL-10 mediated exhaustion (Kajino et al., 2007).  However, it is more likely that 
synovial mDC may have entered a tolerogenic state and may be involved in 
promoting regulation at the inflamed site. In Chapter 4, I proposed a role for 
NCR+ILC3 in regulation at the inflamed site. The strong association of 
NCR+ILC3 with mDC at the SFMC may further support a tolerogenic role for 
synovial mDC. This hypothesis is strengthened by the association between 
mDC at the inflamed site and less severe disease according to Physician’s VAS 
and ESR.  
 
Further evidence in support of a tolerogenic nature for synovial mDC was the 
significantly greater CD103 expression seen on all DC subpopulations in the 
SFMC (compared to PBMC mDC). CD103 is associated with a population of 
mDC better able to produce RA, which has been established to promote Treg 
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differentiation and, more recently, with ILC phenotype switching towards 
NCR+ILC3(Coombes et al., 2007, Bernink et al., 2015). Additionally, RA has 
been shown attenuate intestinal inflammation by promoting binding of the 
retinoic acid receptor to the IL-22 promoter in γδ T cells. Indeed, RA mediates 
increased IL-22 and reduced IL-17 production from both γδ T cells and 
ILC3(Mielke et al., 2013). RA synthesis generally occurs in the gut, however it 
may also be induced in inflammatory conditions (Aoyama et al., 2013, Wang et 
al., 2014). Further functional investigation showed that synovial mDC expressed 
higher RALDH2 gene expression and higher ALDH activity compared to healthy 
mDC, suggesting an enhanced ability to make RA.   
 
Finally, increased gene expression of RA receptor RARα on synovial ILC was 
also analysed by PCR.  Expression was greater than that observed in CD161+ 
T cells, which are known to respond to RA(Duurland et al., 2017a).  Collectively 
these data suggest that ILC may be able to respond to RA produced by mDC at 
the inflamed site. This hypothesis is supported by published data that 
demonstrated the ability of RA–producing DC to skew ILC towards NCR+ILC3, 
which are enriched in the JIA synovia, and which correlated with the mDC at the 
inflamed site (Bernink et al., 2015) Given the expression of RARα in synovial 
ILC, it was surprising that CCR9 expression was not also elevated on synovial 
ILC, since CCR9 is a direct target of RA signalling (Ohoka et al., 2011). 
Although RA-dependent CCR9 expression has been shown previously in mouse 
ILC, the current data are in keeping with published studies showing that CCR9 
is down regulated on synovial T cells (Ohoka et al., 2011, Kim et al., 2015, 
Duurland et al., 2017a). In T cells, RA induced CCR9 expression is depended 
on transient TCR signalling, but inhibited by aberrant stimulation. It may be the 
case that RA signalling in human ILC is insufficient to induce CCR9 expression. 
Alternatively, the synovial ILC may be highly activated and therefore unable to 
respond to RA signalling. Analyses in this Chapter were conducted on ex vivo 
ILC without stimulation. Short-term culture with RA could help to elucidate 
synovial ILC responses to RA and may show induction of CCR9. Additionally, 
further analysis of retinoid X receptor expression, and other targets downstream 
of RA signalling, such as integrin α4β7, could provide further insights into RA 
signalling in ILC at the inflamed site. 
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Taken together with previously published data, the results presented in this 
Chapter support a contribution of selective migration in ILC recruitment to the 
joint, and additionally provide evidence that cytokines in the synovial fluid 
including IL-6 may influence ILC phenotype. Finally, this Chapter suggests a 
role for mDC-derived RA in ILC phenotype switching at the inflamed site.  
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6 :  Final Discussion 
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This thesis presents novel data describing the IL-17 signature in JIA, and more 
specifically ERA JIA. Analysis of paired PBMC and SFMC patient samples has 
enabled valuable insight into immune pathology at the site of inflammation. In 
addition to exploring T cell derived IL-17 this thesis explores the putative role of 
a newly described immune cell population, ILC, in pathogenesis of JIA. Finally, 
steps have been taken to elucidate the mechanisms that underpin a 
subpopulation-specific ILC expansion within the inflamed synovia.     
 
6.1 IL-17 – a marker for stratified treatment in JIA? 
 
There is a universal drive towards stratified medicine in decision making to 
ensure optimal and efficient treatment of disease (Arron et al., 2015). There are 
a number of biological therapies available for the treatment of JIA, targeting key 
cytokines believed to be fundamental in driving and maintaining disease 
pathogenesis. Current treatments are predominantly aimed at targeting TNFα 
and more recently IL-6: however these new medications are useful only in a 
proportion of patients (Lovell et al., 2006, Klein and Horneff, 2009). There 
remains a group of patients who are unresponsive to these treatments and 
therefore there is a continued need for improved, specific therapies. New 
treatments targeting the IL-23/IL-17 axis are now gaining momentum for the 
treatment of JIA after proving effective for the treatment of adult arthropathies 
(Chiricozzi and Krueger, 2013, McInnes et al., 2014, Sofen et al., 2014, 
Poddubnyy et al., 2014, Baeten et al., 2015). 
 
IL-17 has long been implicated in the pathogenesis of murine and human 
arthropathies. IL-17 mediates disease by promoting neutrophil influx by inducing 
secretion of chemo-attractants and by inducing cartilage and bone destruction 
in combination with TNFα and IL-1β (Chabaud et al., 2001, Ye et al., 2001, 
Murphy et al., 2003). It also induces production of further proinflammatory 
molecules including both cytokines (TNF, IL-1, IL-6, GM-CSF) and chemokines 
(CXCL2, CXCL8, CCL20)(Chabaud et al., 2001, Hwang et al., 2004, Liang et 
al., 2006). It is well established that there is a predominance of Th17 cells in the 
inflamed joints of patients with oligo- and poly-JIA, however little has been 
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previously described of this signature in ERA JIA (Nistala et al., 2008a, Agarwal 
et al., 2008b). The IL-23/IL-17 axis is implicated, in part, due to the close 
association of ERA JIA with the HLA-B27 allele commonly associated with IL-17 
mediated disease (Edmonds et al., 1974). Further hypotheses are based on the 
genetic and clinical similarities between ERA-JIA and adult AS, in which Th17 
cells are reported to drive disease. Both ERA JIA and AS also share a genetic 
association with the locus ERAP1 which codes for endoplasmic reticulum 
aminopeptidase 1, which is important for the optimization of peptides for MHC 
presentation (Saric et al., 2002, Hinks et al., 2011, Evans et al., 2011). Finally, 
GWAS studies have identified disease associated SNP in the IL23R gene in JIA 
(Emami et al., 2016)(Hinks et al., 2011). However, cellular analysis in ERA JIA 
to date has been predominately focused on innate immune cells including 
monocytes, and has been largely restricted to Indian cohorts (Saxena et al., 
2005, Newport et al., 2007, Zhou et al., 2007, McGeachy et al., 2009, Mahendra 
et al., 2009, Myles and Aggarwal, 2011, Cortes et al., 2013, Rahman et al., 
2014).  
 
This thesis presents data demonstrating a Th17 enrichment in the joints of ERA 
patients from a UK cohort, above what has been previously reported in other 
subtypes of JIA (Nistala et al., 2008a). Additionally, these data demonstrate that 
the IL-17 signature extends beyond the CD4 T cell compartment as it is also 
observed in CD8 and γδ T cells. Importantly, IL-17+ T cells demonstrate a 
positive association with measures of disease severity supporting a role for 
these cells in promoting pathogenesis. It is interesting to note that the results 
described in this thesis echo what has been described in other HLA-B27-
associated adult arthropathies including AS (Shen et al., 2009, Bowness et al., 
2011, Jansen et al., 2015) (Gracey et al., 2016). These immunological parallels 
suggest that the similarities between ERA JIA and AS extend beyond clinical 
symptoms or genetics, but to potential pathological mechanism(s) at the 
inflamed site.  
 
When assessing the contribution of IL-17 to disease pathogenesis it is important 
to consider IL-17 production by immune cells other than T cells. In parallel to 
the T cell data described, this thesis shows a significant enrichment of NCR-
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ILC3 within the synovial fluid from JIA patients compared to paired blood. These 
cells are known to be potent producers of IL-17 (Gladiator et al., 2013, 
Hazenberg and Spits, 2014a) and are shown here to be correlate with more 
severe disease. These results mirror what has previously been reported in other 
human studies of inflammatory diseases including adult psoriasis, psoriatic 
arthritis, IBD and AS (Geremia et al., 2011, Teunissen et al., 2014a, Ciccia et 
al., 2014b, Leijten et al., 2015, Yeremenko et al., 2015). The analyses 
presented here do not show a significant difference in ILC subpopulation 
proportions between JIA subtypes. These observations need confirmation. One 
potential explanation of the current data may be the limited number of patient 
samples investigated in this study and it is likely that significant differences may 
emerge with an extended study. Indeed, when the proportion of synovial Th17 
cells within the CD4+ T cell population were analysed in relation to NCR-ILC3 
frequency, a strong positive correlation was seen. Since it has been shown that 
Th17 cells are highest in the ERA subtype of JIA, it is likely that the NCR-ILC3 
are also most prevalent in this clinical subtype. That said, there is a minority of 
patients of other JIA subtypes who also present a strong IL-17 signature. It is 
important to consider that the ILAR JIA subtypes do not represent strict 
diagnoses. There are significant clinical overlaps between subtypes. It is 
possible that some patients with other JIA subtypes may even carry the HLA-
B27 allele. 
 
Together, my findings identify a subgroup of ERA JIA/ JIA patients with an IL-17 
predominance. In these patients IL-17-producing cells are associated with more 
severe disease, supporting a role for IL-17 in disease pathogenesis. This 
subgroup of patients should be ideal candidates for therapies targeting the IL-
23/IL-17 pathway. Future work should focus on the development of a minimally 
invasive and robust strategy for the identification of these patients in the clinic. It 
would be very valuable to identify a specific biomarker for those patients with a 
strong synovial IL-17 signature so that a stratified approach to treatment could 
be adopted. There is recently increased interest in the search for biomarkers for 
the stratification of JIA patients to ensure optimal treatment. The ideal 
biomarker should be detectible in biological media, ideally which can be 
obtained with minimal discomfort to the patient, such as blood or urine. 
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Additionally, it is important for a biomarker for clinical use to be stable 
molecules which will not degrade rapidly at room temperature. Finally, it is 
crucial for the tests utilised for the detection of biomarkers to be affordable, 
reliable and simple to carry out in the clinic.  
 
The T cell and ILC analyses presented did not consistently find significant 
enrichments of IL-17 producing cells in the peripheral blood of those patients 
who demonstrated expanded IL-17+ populations within the synovial fluid. 
Interestingly, a recent study in JIA has suggested that a ‘pathogenic’ CD4 T cell 
phenotype can be identified in the peripheral blood of patients with JIA with the 
same TCRβ-chain CDR3 clones identified in the joint. In this study, these so 
called “circulating pathogenic-like lymphocytes”, CPLs, made more 
proinflammatory cytokines in an in vitro assay including IL-17, compared to 
other CD4 T cells from the same patient (Spreafico et al., 2016). This suggests 
that analysis of T cell clones may identify pathogenic T cells in the peripheral 
blood of patients; this emerging information should be confirmed in future 
studies.  
 
ILC3 cells can be divided into two distinct populations, depending on their 
expression of the NCR receptor (Hazenberg and Spits, 2014b). Adding 
complexity to the data reported here, I observed increased frequency of 
NCR+ILC3 at the inflamed site in JIA. These cells produce IL-22 and other 
cytokines, (Cella et al., 2009, Ren et al., 2011). The data presented here 
suggest that in the context of JIA these cells appear to be present in a 
reciprocal relationship to their IL-17-producing counterparts, NCR-ILC3 cells. 
While NCR-ILC3 are associated with more severe disease, NCR+ILC correlate 
with improved patient outcomes. This is surprising since IL-22-producing ILC3 
have been shown to exacerbate inflammation in adult rheumatoid arthritis. In 
the context of rheumatoid arthritis, ILC-derived IL-22 and TNFα induce 
proliferation of synovial fibroblasts (Ren et al., 2011). However, the identification 
strategy employed during this study diverges from the strategy utilized in this 
thesis making a direct comparison difficult, highlighting that these conclusions 
should be treated with caution(Spits et al., 2013). More recently, it has been 
reported that IL-22-producing ILC3 can inhibit inflammatory IL-17+ T cell 
 210 
responses via AHR signalling in murine models of IBD, supporting a protective 
role for NCR+ILC3 (Qiu et al., 2013).  
 
Since both NCR-ILC3 and NCR+ILC3 require IL-23 signalling for their 
development and function, it is important to take into account the putative 
protective role for NCR+ILC3 when considering treatment options(Geremia et 
al., 2011, Hazenberg and Spits, 2014a). Treatments targeting IL-23, such as 
Ustekinumab or Guselkumab, may not yield optimal outcomes, as their effects 
are likely to cause blockade of the NCR+ILC3 population. In this context direct 
targeting of downstream inflammatory IL-17 may prove more prudent.  
 
 Since the precise contribution of these ILC subpopulations to JIA pathogenesis 
(or resolution of disease) still remains elusive, humanised animal models of 
arthritis could provide useful insights and a unique prospect to answer these 
questions.  
 
6.2 Does the JIA synovial environment drive ILC phenotype 
switching?  
 
Data presented in Chapter 5 shows increased expression of chemokine 
receptors, CXCR3, CCR4, CCR5 and CCR6, on synovial ILC supporting a 
contribution of chemokine-mediated migration of ILC to the joint in JIA. 
However, selective migration does not completely explain the skewed ILC 
phenotype reported in the SFMC of patients with JIA. Understanding how 
immune cells function and change within the inflamed site is crucial to 
understanding the mechanisms that underpin disease. A good example of this 
in the context of JIA is the reported plasticity between Th1 and Th17 cells within 
the joints of patients. In this context, T cell plasticity likely results in more severe 
disease. It is suggested that Th1-derived IFNγ may induce secretion of CCL20 
from APC (Kryczek et al., 2008). This CCL20 subsequently recruits Th17 cells 
to the inflamed site where they perform their functions. In a positive feedback 
loop, synovial IL-12 may then promote phenotype switching of the recruited 
Th17 cells to IFNγ-producing T cells, maintaining pathology(Nistala et al., 
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2010a). These switched “ex-Th17” Th1 cells still produce cytokines, not only 
IFNγ but also for example GM-CSF (Piper et al., 2014b)  
 
ILC mirror T cell subsets in their cytokine profiles and rely on similar 
differentiation signals to their T cell counterparts(Hazenberg and Spits, 2014a). 
There is now evidence for considerable plasticity between ILC subpopulations. 
Most of this work has been conducted in mouse models and has predominantly 
focused on plasticity between ILC1 and ILC3 populations. In parallel to T cells, 
IL-12 is significant for maintaining an ILC1 phenotype, while IL-23 and IL-1β 
play a role in promoting ILC3 populations (Nistala et al., 2010b, Cella et al., 
2010, Piper et al., 2014b, Bernink et al., 2015, Lim et al., 2016).  
 
This thesis presents evidence for the first time that ILC phenotype switching 
may occur at the inflamed site in JIA, although at this stage only tentative 
conclusions can be drawn.  Multiplex cytokine analysis revealed an abundance 
of inflammatory cytokines within the synovial fluid, which may play a role in 
promoting ILC phenotype plasticity. Of particular interest is the high 
concentration of IL-6 within the inflamed synovia. IL-6 has previously been 
implicated in both Th17 development and activation of IL-17-producing ILC3 
(Bettelli et al., 2006) (Powell et al., 2015). Future work should be aimed at 
dissecting the pleiotropic effects of IL-6 on ILC3 biology ex-vivo and in vivo.  
 
During this study, total ILC were sorted by flow cytometry from healthy PBMC 
and cultured. Unfortunately, the ability to draw firm conclusions from these 
experiments, presented in Chapter 5, was hampered by the fact that ILCs 
rapidly down-regulated some of the subpopulation-specific surface markers, 
including CRTH2, crucial for the identification of ILC subpopulations. It is 
suggested that IL-4 is required for the maintenance of CRTH2 and ILC2 function 
in vitro (Bal et al., 2016, Silver et al., 2016b). However, without further analysis 
it is still unclear whether ILC, which have down regulated CRTH2, have 
undergone phenotype switching, or remain functionally active. Previously 
published studies have cultured purified ILC subpopulations isolated from 
human and mouse tissues in order to assess mechanisms of plasticity (Bernink 
et al., 2015, Bal et al., 2016). Due to the small size of the ILC population in 
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human blood, this was not possible in the present study.  Other studies have 
utilized ILC cloning techniques to follow ILC phenotype changes (Bernink et al., 
2015). Although technically very challenging, I believe this represents the best 
option to reveal the effects of synovial cytokines on ILC plasticity. 
 
In addition to IL-23 and IL-1β, a recent study has identified an important role for 
retinoic acid (RA) in augmenting an ILC3 phenotype (Bernink et al., 2015). In 
data presented in Chapter 5, an enrichment of mDC within the SFMC from JIA 
patients capable of producing RA was recorded, in addition increased 
expression of RA receptor gene RARA on synovial ILC was also observed. This 
clear enrichment of RALDH-producing mDC was demonstrated across many 
subtypes of JIA although due to small numbers of patients analysed in some 
subtypes these were not analysed separately. Together, my findings support a 
role for synovial RA in ILC skewing in JIA. However, further validation is 
required. It is interesting that CCR9 expression was not elevated on synovial 
ILC since the CCR9 gene is directly downstream of RA signalling (Ohoka et al., 
2011). This observation aligns with recently published data from the 
Wedderburn group showing reduced CCR9 expression on synovial T cells 
(Duurland et al., 2017a). Whether this CCR9 down regulation is indicative of 
impaired RA signalling remains unclear. Further analysis of RA-responsive 
genes may shed light on this.  
 
 A recent study has highlighted a pivotal role for IL-15 in the maintenance of 
pathogenic Th17 cells in autoimmunity (Chen et al., 2017). I have demonstrated 
significant amounts of IL-15 in the synovial fluid from JIA patients, although the 
role of this cytokine in ILC plasticity was not investigated. ILC are known to 
express the IL-2 receptor, which shares beta and gamma chains with the IL-15 
receptor (Hazenberg and Spits, 2014b, Mishra et al., 2014). Interestingly, recent 
murine studies have identified a role for IL-15 in the development and activation 
of ILC1, further the cytokine causes down regulation of RORγt in ILC3 
(Vonarbourg et al., 2010, Klose et al., 2013, Dadi et al., 2016). I hypothesize 
that this mechanism translates to the human setting, and IL-15 drives ILC3/ILC1 
plasticity within the inflamed joints of JIA patients. 
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6.3 Future directions  
 
This thesis and previous research by the Wedderburn group has identified an 
expansion of GM-SCF+ T cells at the inflamed site in JIA (Piper et al., 2014b). 
ILC-derived GM-CSF was not examined during the course of this study. 
However, given the parallels seen between T cells and ILC within the synovial 
fluid, it is tempting to speculate that synovial ILC produce significant GM-CSF. 
The potential effect and role of GM-CSF warrants further investigation for 
several reasons:  
 
Firstly, GM-CSF is a significant player driving inflammation in mouse models of 
disease and is also implicated in pathogenesis of adult forms of arthritis (Cook 
et al., 2011, Codarri et al., 2011). GM-CSF has been shown to maintain disease 
in mouse models of MS. This is the case even in the absence of IL-17, where 
GM-CSF activates other immune cells causing aberrant inflammation and tissue 
damage. Furthermore, GM-CSF-producing T cells are heavily implicated in the 
pathogenesis of adult rheumatoid arthritis and new clinical trials targeting GM-
CSF and its receptor have shown efficacy and safety in phase two trials 
(Behrens et al. 2014; Burmester et al. 2013). A putative role for GM-CSF in 
driving pathogenesis of JIA opens the door for novel therapeutics and further 
stratification of patients.  
 
Secondly, in contrast to its inflammatory role, GM-CSF, and in particular IL-
22+ILC3-derived GM-CSF has recently been shown to promote RA production 
from mDC (Magri et al., 2014). The work presented in this thesis in addition to 
previous publications describes a potential role for RA in skewing ILC towards 
potentially protective NCR+ILC3 (Bernink et al., 2015). Considering these 
findings together, raises a hypothesis that a positive feedback loop in the 
inflamed joint in which NCR+ILC3 produce GM-CSF, which then induces mDC 
to produce RA, which in turn supports the differentiation of NCR+ILC3 (Magri et 
al., 2014). If this is the case and NCR+ILC3 are shown to be protective in JIA, 
treatment decisions should take into account the constructive role of GM-CSF, 
particularly in those patients in which the NCR+ILC3 population is highly 
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enriched. In these cases, targeting molecules further down-stream such as IL-
17 may make more effective targets.  
 
The developmental and functional similarities between NK cells and CD127+ILC 
highlights areas for further investigation, both in the context of ILC biology and 
in terms of HLA-B27-mediated disease. One hypothesis for the pathogenesis of 
HLA-B27 is its ability to form heavy chain homodimers (Allen et al., 1999, 
Kollnberger et al., 2004, Colbert et al., 2014). These homodimers may be 
expressed on the surface of cells or within the cytoplasm and can be detected 
by NK cell KIRs(Kollnberger et al., 2002, Kollnberger et al., 2007, Cauli et al., 
2013). Ligation of HLA-B27 dimers with KIRs is shown to induce an IL-17 
phenotype in NK cells and T cells (Bowness et al., 2011, Ridley et al., 2016). It 
is known that CD127+ILC may express markers typically associated with NK 
cells. Indeed ILC3 populations are defined by expression of NK triggering 
receptor NKp44(Hazenberg and Spits, 2014b). The expression of KIRs has not 
been investigated in CD127+ILC populations to date. However since ILC, NK 
cells and T cells arise from a common progenitor cell it is possible that ILC may 
also express KIRs. This may represent one mechanism by which IL-17-
producing ILC are activated in ERA JIA. Previous studies have investigated the 
expression of KIR-3DL1 and KIR-3DL2 on T cells and NK cells. Analysis of 
these receptors on CD127+ILC should be conducted and, if expressed, the 
impact of ILC KIR binding to B27 homodimers could be assessed by culture 
techniques. 
 
This thesis confirms that the T cells populating the synovial fluid are 
predominantly of a memory phenotype and thus functionally different to their 
peripheral counterparts(Silverman et al., 1993, Wedderburn et al., 2000a, 
Chiesa et al., 2004). Recently, the concept of ‘trained immunity’ in innate cells 
has been coined and alludes to a memory type function in prototypic innate 
immune cells(Netea et al., 2011). This idea was initially described in NK cells 
(Cooper et al., 2009, Berrien-Elliott et al., 2015). Several studies have now 
identified populations of long-lived NK cells in vaccinated individuals with 
heightened cytokine responses (Sun et al., 2009a, White et al., 2014). These 
‘memory’ NK cells respond quickly after re-stimulation to produce increased 
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levels of IFNγ and are implicated in pathogenesis of allergic disease(O'Leary et 
al., 2006). Various mechanisms for the development of trained immunity have 
been postulated, although a lot remains to be uncovered. It is known that the 
interaction of innate immune cells with their target PAMPS results in profound 
changes in expression patterns of surface receptors on these cells (Bowdish et 
al., 2007, Sun et al., 2009b). In addition, chromatin modulation and accessibility, 
modulated by histone methylation and acetylation are important for inducing 
memory in innate immune cells (Foster et al., 2007, Carson et al., 2011). 
Although technically very challenging, analysis of PRR expression and 
epigenetics of ILC from inflamed sites could provide exciting insight into 
functionality of these cells and further clarify their role in promoting 
pathogenesis of inflammatory disease. 
 
6.4  Concluding remarks 
 
Despite rapid advancements in treatment strategies for childhood arthritis, there 
are still a proportion of patients who fail to achieve clinical remission. While the 
pathogenesis of several subtypes of JIA has been well examined, there is little 
known about the pathogenesis of ERA JIA. Previous studies into pathogenesis 
of JIA have typically focused on the cytokine contribution of CD4 T cells. This 
thesis marks the first report of ILC in childhood arthritis, and takes steps to 
elucidate the mechanisms by which these cells populate the inflamed synovia. 
The present study clearly demonstrated a heightened IL-17 signature across T 
cell subtypes and ILC in the synovial fluid from ERA patients. Additionally, I 
have identified a subgroup of JIA patients who make ideal candidates for novel 
treatments targeting the IL-23/IL-17 axis. Further analysis of synovial ILC 
populations has highlighted the importance of careful consideration when 
making treatment decisions targeting the IL-23/IL-17 pathway to ensure that 
only pathogenic cells are targeted. In addition, several cytokines and immune 
mediators within the synovial fluid, including IL-6, IL-15 and RA, identified may 
be significant for ILC plasticity and function at the inflamed site. Finally, several 
novel hypotheses are presented for future investigation into ILC memory and 
the pathogenic roles for ILC in JIA. 
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Appendices 
 
 
 
Appendix 1. Polyfunctional T cells are expanded in SFMC from ERA JIA 
patients.  
Summary Venn diagrams showing mean cytokine positive cells and coproduction for 
IFNγ, IL-17A, IL-22 and GM-CSF from PBMC from aHC (n=4), and PBMC (n=6) and 
SFMC (n=6) from ERA JIA patients. (A-C) aHC (A) CD4 T cells; (B) CD8 T cells and 
(C) CD4-CD8- T cells. (D-F) ERA JIA PBMC (D) CD4 T cells; (E) CD8 T cells and (F) 
CD4-CD8- T cells. (G-I) ERA JIA SFMC (G) CD4 T cells; (H) CD8 T cells and (I) CD4-
CD8- T cells. 
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